Page last updated: 2024-12-05

nitroglycerin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nitroglycerin is a highly explosive organic compound that is used primarily as a vasodilator to treat angina. It is synthesized by the nitration of glycerol with a mixture of concentrated nitric acid and sulfuric acid. Nitroglycerin's vasodilating effects are mediated by its conversion to nitric oxide (NO), a potent vasodilator. NO relaxes smooth muscle cells in blood vessels, leading to dilation and increased blood flow. This dilation helps to reduce the workload on the heart, which can improve symptoms of angina. Nitroglycerin is also used to prevent and treat acute coronary syndromes, such as heart attacks. Nitroglycerin is a potent drug with a narrow therapeutic window. It is essential to titrate the dose carefully to minimize the risk of side effects, such as hypotension, headache, and dizziness. Nitroglycerin has been extensively studied for its cardiovascular effects. It has been shown to be effective in treating angina and preventing heart attacks. Research on nitroglycerin continues to focus on understanding its mechanism of action and developing new and improved formulations.'

Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4510
CHEMBL ID730
CHEBI ID28787
SCHEMBL ID15421
MeSH IDM0009426

Synonyms (362)

Synonym
BIDD:GT0142
1,2,3-propanetriol, trinitrate
glycerol nitric acid triester
1,2,3-propanetriol trinatrate
nitroject
nitroglyn
buccal
tridil sublin
C0061
nitroglycerin (ng)
nitrocine
nitrong parenteral
trinitrate 1,2,3-propanetriol
nitrocap
niong
nitronet
nitrospan
transderm-nitro tts
niglycon
nitro-dur 10
minitram
herzer
vasolator
nk-843
nitrocine 5
niong retard
aldonitrin
lentonitrina
trinipatch
nitrong retard
glycerintrinitrate [czech]
nitro retard
nirmin
nitrocerin
nitrobaat
nitrocontin
nitrovis
nitro-time
nitrolingual pumpspray
sustonit
vernies
angibid
un0143
buccard
plastranit
nitroderm tts ext
nitro-par
dauxona
glonoin
willong
nitro rorer
nitrek
nitradisc
colenitral
nitroglicerina [spanish]
nitro-dur 5
cardabid
trinitroglicerina fabra
mionitrat
angiolingual
nitropatch
cardiodisco
nitroclyn
nitrocot
transiderm-nitro
nitrong-sr
trinitron
coro-nitro
nitrogard-sr
polnitrin
NTG ,
nitrozell retard
nitropront
nitro-bid
hsdb 30
nitroglin
deponit tts 10
klavikordal
trinitrol
triniplas
nitrolin
nitroprontan
nitric acid triester of gylcerol
deponit-5
suscard
trinitrina erba
deponit tts 5
susadrin
nitrodyl tts
sk-106n
vasoglyn
glyceroltrinitraat [dutch]
corditrine
discotrine
blasting gelatin
nitrolowe
nitrogliceryna [polish]
nitrolingual spray
nitrine-tdc
gilucor nitro
nysconitrine
nitrostabilin
glycerol(trinitrate de) [french]
sustak
cordipatch
trinalgon
sdm no. 17
sustac
nitro-pflaster
nitroglycerin, liquid, not desensitized [forbidden]
diafusor
trinitrolong
perganit
angorin
nitroglicerina [italian]
nitrorex
nitrobukal
nitora
niglin
glycerylnitrat
aquo-trimitrosan
gilustenon
nitroprol
temponitrin
nitrolan
anglix
nitro-span
nitroretard
nitrol ointment
propanetriol trinitrate
nitrodyl
nitroglycerin-acc
brn 1802063
percutol
herwicard
soup
un1204
perlinganit
nitrorectal
cardamist
trinitrine simple laleuf
rcra waste no. p081
un3319
glytrin
nitroard
adesitrin
nitriderm tts
nitrocontin continus
nitropercuten
nitrodisc
nitrol (pharmaceutical)
rcra waste number p081
myoglycerin
nitrogard
corangin nitrokapseln
myocon
cardinit
gtn-pohl
trinitrin
nitro-m-bid
turicard
deponit
chitamite
perglottal
glycerol (trinitrate de) [french]
nitro mack retard
gepan nitroglicerin
glyceryl nitrate
nitradisc tts
nitromint aerosol
nitrong
un3064
nitro dur tts
nitro-lent
top-nitro
nitrobid oint
mi-trates
nitropen
nitromint retard
einecs 200-240-8
nitromex
nitroletten
ccris 4089
myovin
nitroderm tts-5
nitroperlinit
angonist
nitro-mack retard
nitro-gesanit retard
nitrobid
transderm-n tts
trinitrosan
nitromack retard
nitromel
ratiopharm
tridil
nitroglycerine [french]
un0144
angiplex
nitradisc pad
nitro iv
neos nitro opt
nit-ret
nitroglycerin in dextrose 5%
deponit 5
nitronal aqueous
nitronal
CHEBI:28787 ,
glycerin trinitrate
nitrolingual
trinitroglycerol
propane-1,2,3-triyl trinitrate
natispray
glyceryl
ng
nitroglycerol
nitro-dur
1,2,3-propanetrioltrinitrate
1,2,3-trinitrooxypropane
nitrostat
nitroglycerine
trinitroglycerin
1,2,3-propanetriyl nitrate
minitran
glycerol, nitric acid triester
nitromist
glycerol trinitrate
transderm nitro
rectogesic
trinitrate, glyceryl
sk-866
rectiv
anogesic
vascana
nitroglycerin injection
millisrol
epinitril
nitroderm
sk-878
imx-150
minitro
lenitral
nitroderm tts
mqx-503
nitroplast
nitromint
med-2002
nitrocor
nitriderm
myocor
transderm-nitro
cellegesic
glyceryl trinitrate
nitroglycerin
C07455
55-63-0
GTN ,
DB00727
nitroglicerina
nitromed
nitro-bid (tn)
transderm-nitro (tn)
D00515
minitran (tn)
nitroglycerin (jp17/usp)
nitromist (tn)
nitro-dur (tn)
HMS2094M15
trinitrin tablets
glonoinum
diluted nitroglycerin
nitroglycerin tablets
CHEMBL730
c01da02
trinitrine
1,3-dinitrooxypropan-2-yl nitrate
1,2,3-propanetriol trinitrate
4-01-00-02762 (beilstein handbook reference)
glycerine trinitrate
gonitro
nitroglycerin [usp:jan]
nitrocapt.d.
glycerintrinitrate
glycerol(trinitrate de)
unii-g59m7s0ws3
1,2,3-propanetriol, 1,2,3-trinitrate
nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass [un0143] [explosive 1.1d, poison]
nitrogliceryna
ec 200-240-8
g59m7s0ws3 ,
glyceroltrinitraat
nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass
nitroquik
glycerol (trinitrate de)
percutol oint.
nitroglycerin, liquid, not desensitized
nitroquick
TNG ,
nitroglycerin ointment
2,3-bis(nitrooxy)propyl nitrate
nitroglycerin [hsdb]
nitroglycerin tablets [jan]
diluted nitroglycerin [usp-rs]
nitroglycerin [mi]
nitroglycerin [usp impurity]
glonoinum [hpus]
glyceryl trinitrate [mart.]
glyceryl trinitrate [who-dd]
diluted nitroglycerin [usp monograph]
nitroglycerin [vandf]
9010-02-0
nitroglycerin [orange book]
gtpl7053
SCHEMBL15421
2,3-dinitrooxypropyl nitrate
nitro-prn
solinitrina
s.n.g.
nitrosigma
nitric acid triester of glycerol
un 0143 (salt/mix)
un 0144 (salt/mix)
nitrolande
nitrolar
sutonit
un 1204 (salt/mix)
nitrofortin
corangil
nitro mack
sdm no. 27 (salt/mix)
aquo-trinitrosan
reminitrol
sdm no. 17 (salt/mix)
DTXSID1021407 ,
SR-01000944510-1
sr-01000944510
AKOS030254238
Q162867
FT-0752897
trans-nitro
1,2,3-tris-nitryloxy-propane
EN300-7352804
1,3-bis(nitrooxy)propan-2-yl nitrate
glonoinum kit refill
diluted nitroglycerin (usp monograph)
diluted nitroglycerin (usp-rs)
nitroglycerin, dextrose
(component of) sdm no 17
nitroglycerin sustained-release capsules
nitroglycerin slocaps
glyceroli trinitratis
nitroglycerin transdermal system
nitroglycerin (usp impurity)
nitroglycerin in dextrose
nitroglycerin lingual
nk 843
(component of) sdm no 37
nitroglycerin transdermal delivery system
glyceroltrinitrat
nitroglycerin transdermal infusion system
glyceryl trinitrate (mart.)
s.n.g

Research Excerpts

Overview

Nitroglycerin (NTG) is a prodrug that has long been used in clinical practice for the treatment of angina pectoris. It is a potent vasodilator and facilitates radial artery cannulation by increasing the internal diameter and preventing the vasospasm in adult patients.

ExcerptReferenceRelevance
"Nitroglycerin (NTG) is a prodrug that has long been used in clinical practice for the treatment of angina pectoris. "( Nitroglycerin: a comprehensive review in cancer therapy.
Bettaieb, A; Meunier, M; Plenchette, S; Yammine, A, 2023
)
3.8
"Nitroglycerin seemed to be an ideal agent to increase the chance of flap survival in mastectomy flaps. "( Topical nitroglycerin is associated with a reduced mastectomy skin flap necrosis-systematic review and meta-analysis.
Irwansyah, D; Pranata, R; Vania, R, 2020
)
2.44
"Nitroglycerin is a potent, reliable and reproducible migraine trigger of the entirety of the migraine attack, making its use experimentally attractive."( Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study.
Bose, PR; Goadsby, PJ; Karsan, N; Newman, J; Thompson, C, 2020
)
1.54
"Nitroglycerin is a potent vasodilator and facilitates radial artery cannulation by increasing the internal diameter and preventing the vasospasm in adult patients."( Subcutaneous Nitroglycerin for Radial Arterial Catheterization in Pediatric Patients: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kim, EH; Kim, HS; Kim, JT; Lee, JH; Mossad, EB, 2020
)
1.65
"Nitroglycerin (NTG) is a vasodilator used in the prehospital setting with chest pain patients. "( Adverse events after prehospital nitroglycerin administration in a nationwide registry analysis.
Ashburn, NP; Lowell, LM; Popp, LM; Stopyra, JP, 2021
)
2.35
"Nitroglycerin is a prototypic NO-donor, and triggers migraine in humans."( Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
Ben Aissa, M; Bennett, BM; Bertels, Z; Gaisina, IN; Gandhi, R; Lee, SH; Litosh, V; Moye, LS; Novack, M; Pradhan, AA; Thatcher, GR; Tipton, AF; Wang, Y, 2018
)
1.2
"Nitroglycerin (NG) is a toxic explosive found as a contaminant of soil and groundwater. "( Biodegradation of nitroglycerin in porous media and potential for bioaugmentation with Arthrobacter sp. strain JBH1.
Hughes, JB; Husserl, J, 2013
)
2.17
"Nitroglycerin (NTG) is an organic nitrate rapidly denitrated by enzymes to release free radical nitric oxide and shows improved wound healing and tissue protection from oxidative damage. "( Preliminary investigation of topical nitroglycerin formulations containing natural wound healing agent in diabetes-induced foot ulcer.
Avachat, AM; Bhosale, SS; Hotkar, MS; Oswal, YM, 2015
)
2.13
"Nitroglycerin ointment is a topical vasodilator that has been shown to improve skin flap survival in an animal model."( Effects of nitroglycerin ointment on mastectomy flap necrosis in immediate breast reconstruction: a randomized controlled trial.
Bahng, S; Bovill, E; Brasher, P; Gdalevitch, P; Ho, A; Lennox, P; Macadam, S; Van Laeken, N, 2015
)
1.53
"Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. "( [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
Boellaard, R; de Jong, EE; Dingemans, AC; Groen, HJ; Hoekstra, OS; Lambin, P; Leijenaar, RT; Smit, EF; Troost, EG; van der Noort, V; van Elmpt, W, 2017
)
2.1
"Trinitroglycerin (TNG) is an industrial chemical mostly known for its clinical use in treating angina and manufacturing dynamite. "( Degradation of trinitroglycerin (TNG) using zero-valent iron nanoparticles/nanosilica SBA-15 composite (ZVINs/SBA-15).
Ampleman, G; Dashan, W; Hawari, J; Saad, R; Thiboutot, S, 2010
)
1.32
"Nitroglycerin tolerance is a result of inactivation of aldehyde dehydrogenase 2 (ALDH2), an enzyme essential for cardioprotection in animals subjected to myocardial infarction."( ALDH2 activator inhibits increased myocardial infarction injury by nitroglycerin tolerance.
Ferreira, JC; Mochly-Rosen, D; Sun, L, 2011
)
1.33
"Nitroglycerin is a nitric oxide (NO) donor which activates nuclei involved in nociceptive transmission following systemic administration. "( Nitroglycerin induces hyperalgesia in rats--a time-course study.
Greco, R; Nappi, G; Sandrini, G; Sandrini, M; Tassorelli, C; Wang, D, 2003
)
3.2
"Nitroglycerin is a nitric oxide donor that exerts potent effects on the cardiovascular system. "( Potent antifibrillatory effects of intrapericardial nitroglycerin in the ischemic porcine heart.
Kumar, K; Nearing, BD; Nguyen, K; Verrier, RL; Waxman, S; Wellenius, GA; Zhao, SX, 2003
)
2.01
"Nitroglycerin is a nitric oxide donor and induces a hyperalgesic state, partially mediated by central mechanisms."( Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia.
Greco, R; Nappi, G; Sandrini, G; Tassorelli, C, 2003
)
1.04
"Nitroglycerin is a NO donor, which easily crosses the blood brain barrier."( Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain.
Blandini, F; Greco, R; Nappi, G; Tassorelli, C, 2004
)
2.49
"Nitroglycerin (NG) is a nitrate ester used in dynamites, propellants, and medicines and is therefore a common constituent in propellant-manufacturing and pharmaceutical wastewaters. "( Reduction of nitroglycerin with elemental iron: pathway, kinetics, and mechanisms.
Cha, DK; Chiu, PC; Kim, BJ; Oh, SY, 2004
)
2.14
"0.4% Nitroglycerin ointment is an intra-anal formulation of nitroglycerin (glyceryl trinitrate) indicated for the treatment of chronic anal fissure pain.black triangle Nitroglycerin is a nitric oxide (NO) donor, which reduces the increased anal canal pressure caused by a hypertonic internal anal sphincter, improving anodermal blood flow. "( 0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.
Easthope, SE; Fenton, C; Wellington, K, 2006
)
1.36
"Nitroglycerine (GTN) is an organic nitrate that has been used for more than 100 years. "( Nitroglycerine causes mitochondrial reactive oxygen species production: in vitro mechanistic insights.
Daiber, A; Di Stolfo, G; Dragoni, S; Forconi, S; Gori, T; Lisi, M; Münzel, T; Parker, JD; Sicuro, S, 2007
)
3.23
"Nitroglycerin (NGL) is a nitrogen oxide (NO) donor, which relaxes the sphincter of Oddi."( Pharmacological approach to acute pancreatitis.
Bang, UC; Bendtsen, F; Nojgaard, C; Semb, S, 2008
)
1.07
"Nitroglycerin (Ng) is a potent and short-acting coronary and systemic vasodilator, widely used in anginal pain treatment. "( Arterial hypoxemia following the administration of sublingual nitroglycerin in patients with ischemic heart disease and pneumonia.
Kuhnreich, E; Naschitz, JE; Yeshurun, D, 1981
)
1.95
"Nitroglycerin is a vasodilator which induces vascular relaxation by releasing nitric oxide in the wall of blood vessels. "( Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat.
Joseph, SA; Tassorelli, C, 1995
)
2.15
"Nitroglycerin spray is a newly developed nitroglycerin (TNG) form, which delivers 0.3 mg of TNG with each spray emission. "( [Intranasal administration of nitroglycerin solution and nitroglycerin spray during general anesthesia].
Honda, N; Iwasaka, H; Kinoshita, R; Kitano, T; Kunisaki, Y; Taniguchi, K; Yamamoto, H, 1993
)
2.02
"Nitroglycerin seems to be a relatively safe advanced life support drug; however, a few patients experience serious adverse effects. "( Safety of prehospital nitroglycerin.
Holliman, CJ; Meador, S; Roth, GS; Swope, G; Wuerz, R, 1994
)
2.05
"Nitroglycerin is a commonly employed pharmacological agent which produces vasodilatation by release of nitric oxide (NO.). "( Nitroglycerin metabolism in vascular tissue: role of glutathione S-transferases and relationship between NO. and NO2- formation.
Boyer, TD; Harrison, DG; Kurz, MA; Peterson, TE; Whalen, R, 1993
)
3.17
"Nitroglycerin is an organic nitrate which possesses peculiar activities mediated, to some extent, by the central nervous system via the noradrenergic system."( NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration.
Joseph, SA; Tassorelli, C, 1995
)
1.25
"Nitroglycerin is a nitric oxide donor which induces sustained expression of Fos protein, a marker of neuronal activation, in specific neuronal groups in the central nervous system. "( Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: a pharmacological investigation.
Joseph, SA; Nappi, G; Tassorelli, C, 1997
)
2.03
"Nitroglycerin ointment is a newly described treatment for several painful anal conditions. "( Treatment of proctalgia fugax with topical nitroglycerin: report of a case.
Cataldo, PA; Lowenstein, B, 1998
)
2.01
"Nitroglycerin is a superior conduit vasodilator and is more effective in preventing graft spasm than diltiazem. "( Nitroglycerin is superior to diltiazem as a coronary bypass conduit vasodilator.
Aldea, GS; Keaney, JF; Shah, N; Shapira, OM; Shemin, RJ; Vita, JA; Xu, A, 1999
)
3.19
"Nitroglycerin is an organic nitrate that has been used as a vasodilator in the treatment of cardiac diseases for over a century. "( The effects on the central nervous system of nitroglycerin--putative mechanisms and mediators.
Buzzi, MG; Joseph, SA; Nappi, G; Tassorelli, C, 1999
)
2.01
"Nitroglycerin (NTG) is an important cardiovascular agent, but tolerance during continuous administration limits its clinical utility. "( Vascular peroxynitrite formation during organic nitrate tolerance.
Bauer, JA; Coyle, CM; Jing, L; Mihm, MJ, 1999
)
1.75
"Nitroglycerine is a valuable additive to colloid-free University of Wisconsin solution, extending effective preservation of the rat heart to 16 hours and significantly improving left ventricular function after 12 and 16 hours preservation. "( Improved cardiac preservation by the addition of nitroglycerine to colloid-free University of Wisconsin solution (MUW).
Baxter, K; Howden, B; Jablonski, P; Saunder, A, 1999
)
2
"Nitroglycerin is a safe and less invasive alternative to control blood pressure and, in contrast to the methods mentioned, can also be used during stent-grafting performed under local anesthesia."( Nitroglycerin to control blood pressure during endovascular stent-grafting of descending thoracic aortic aneurysms.
Bernard, EO; Germann, RC; Lachat, ML; Schmid, ER, 2000
)
2.47
"Nitroglycerin is a vasodilator that has been reported to improve cutaneous flap and graft survival. "( A single postoperative application of nitroglycerin ointment does not increase survival of cutaneous flaps and grafts.
Brodland, DG; Dunn, CL; Fazio, MJ; Griego, RD; Huether, MJ; Zitelli, JA, 2000
)
2.02
"Nitroglycerin is an effective antianginal medication but its use is limited by the development of tolerance and rebound. "( Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity.
Hébert, D; Lam, JY, 2000
)
3.19
"Nitroglycerin is a vasodilating agent by virtue of its actions on vascular smooth muscle fibers. "( [Pharmacology of nitroglycerin (author's transl)].
Chelly, J; Passelecq, J; Schmitt, H; Tannières, ML,
)
1.91
"Nitroglycerin is an allergen, and the transdermal drug delivery systems for nitroglycerin recently used to treat angina pectoris have sensitized."( Occupational allergic contact dermatitis caused by nitroglycerin.
Estlander, T; Helander, I; Jolanki, R; Kanerva, L; Laine, R; Tarvainen, K, 1991
)
1.25
"Nitroglycerin (NTG) is a potent vascular smooth muscle relaxant. "( Responsiveness of peripheral veins to transdermal and sublingual nitroglycerin in healthy male volunteers.
Blaschke, TF; Hiremath, AN; Hoffman, BB, 1989
)
1.96
"Nitroglycerin is an effective agent for reducing preload and afterload in acute myocardial infarction. "( Nitroglycerin in acute myocardial infarction.
Jugdutt, BI, 1989
)
3.16
"Nitroglycerin is a potent venous dilator and a mild arterial vasodilator that has been shown to improve the hemodynamic response to vasopressin in portal hypertensive patients and to decrease portal pressure in experimental animals. "( Portal hemodynamics during nitroglycerin administration in cirrhotic patients.
Garcia-Tsao, G; Groszmann, RJ,
)
1.87
"Nitroglycerin is a volatile substance which evaporates from tablets if strict precautions are not taken. "( Instability of nitroglycerin tablets.
Mayer, GA, 1974
)
2.05

Effects

Nitroglycerin only has a limited late preconditioning protective effect in conscious animals submitted to a reversible prolonged ischemia since it protects against arrhythmias but not against stunning. Nitroglycerine has a direct vasodilating action on both the heart and lungs.

Nitroglycerin exerts a direct effect on the pulmonary circulation in doses that do not affect systemic resistance vessels or the myocardium. It has been shown to inhibit platelet function in vitro by stimulating prostacyclin or inhibiting thromboxane A2 production.

ExcerptReferenceRelevance
"Nitroglycerin has a class 1C indication by the ACCF/AHA guidelines for patients with ST-segment elevation or depression that accompanies ischemic chest discomfort in the setting of cocaine use."( Peripheral Administration of Nitroglycerin in Pulseless Ventricular Tachycardia due to Cocaine-Induced Coronary Vasospasm.
Babapoor-Farrokhran, S; Banka, S; Gill, D; Gulab, A; Kalla, A; Kalra, S, 2021
)
1.63
"Nitroglycerin ointment has a rapid onset of action and time to full clinical effect with high efficacy and relatively low adverse event rate for patients with SCI experiencing AD."( Pharmacodynamics and effectiveness of topical nitroglycerin at lowering blood pressure during autonomic dysreflexia.
Bunnell, AE; Burns, SP; Engle, A; Linsenmeyer, TA; Solinsky, R; Svircev, JN, 2017
)
2.16
"Nitroglycerin has a favourable haemodynamic profile which promotes forward blood flow."( The effects of nitroglycerin during cardiopulmonary resuscitation.
Stefaniotou, A; Varvarousi, G; Varvarousis, DP; Xanthos, T, 2014
)
1.48
"Nitroglycerin has a rapid onset of action and short half-life and there is a clear dose-response curve on both global hemodynamics and peripheral circulation."( Impact of intravenous nitroglycerin in the management of acute decompensated heart failure.
Brugts, JJ; den Uil, CA, 2015
)
1.45
"Nitroglycerin only has a limited late preconditioning protective effect in conscious animals submitted to a reversible prolonged ischemia since it protects against arrhythmias but not against stunning."( Nitroglycerin induces late preconditioning against arrhythmias but not stunning in conscious sheep.
Lascano, EC; Negroni, JA; Valle, HF, 2007
)
3.23
"Nitroglycerin has a reducing influence on these changes, but not down to the initial level."( [The treatment of acute myocardial infarctions with beta-receptor-blockers. II. Hemodynamic effects of propranolol with and without combination therapy with nitroglycerin (author's transl)].
Hochrein, H; Lehmann, HU; Oeff, M; Witt, E, 1981
)
1.18
"Nitroglycerin has an effect to dilate vessels."( [Usefulness of enhanced MR angiography by nitroglycerin].
Fujita, M; Hashimoto, N; Ishihara, K; Katsumori, T; Kutsumi, H; Ohno, K; Sato, O; Soga, T; Takahashi, T; Ueguchi, T, 1993
)
1.27
"Nitroglycerine has a direct vasodilating action on both venous and arterial smooth muscle fibers. "( [Clinical use of nitroglycerin as an hypotensive agent during general anesthesia (author's transl)].
Chelly, J; Derome, P; Tannières, ML; Visot, A; Vourc'h, P,
)
1.91
"Nitroglycerin has a class 1C indication by the ACCF/AHA guidelines for patients with ST-segment elevation or depression that accompanies ischemic chest discomfort in the setting of cocaine use."( Peripheral Administration of Nitroglycerin in Pulseless Ventricular Tachycardia due to Cocaine-Induced Coronary Vasospasm.
Babapoor-Farrokhran, S; Banka, S; Gill, D; Gulab, A; Kalla, A; Kalra, S, 2021
)
1.63
"Nitroglycerin ointment has a rapid onset of action and time to full clinical effect with high efficacy and relatively low adverse event rate for patients with SCI experiencing AD."( Pharmacodynamics and effectiveness of topical nitroglycerin at lowering blood pressure during autonomic dysreflexia.
Bunnell, AE; Burns, SP; Engle, A; Linsenmeyer, TA; Solinsky, R; Svircev, JN, 2017
)
2.16
"Nitroglycerin ointment has been shown to reduce the incidence of mastectomy flap necrosis in a randomized controlled study, using 45 g per breast and treating one side only in bilateral cases."( Nitroglycerin Ointment for Reducing the Rate of Mastectomy Flap Necrosis in Immediate Implant-Based Breast Reconstruction.
Fine, N; Li, DD; Turin, SY; Vaca, EE, 2018
)
2.64
"Nitroglycerin has a favourable haemodynamic profile which promotes forward blood flow."( The effects of nitroglycerin during cardiopulmonary resuscitation.
Stefaniotou, A; Varvarousi, G; Varvarousis, DP; Xanthos, T, 2014
)
1.48
"Nitroglycerin has a rapid onset of action and short half-life and there is a clear dose-response curve on both global hemodynamics and peripheral circulation."( Impact of intravenous nitroglycerin in the management of acute decompensated heart failure.
Brugts, JJ; den Uil, CA, 2015
)
1.45
"Nitroglycerin (NTG) has been reported to possess preconditioning-like (PCL) protections on heart and other tissues. "( Nitroglycerin protects small intestine from ischemia-reperfusion injury via NO-cGMP pathway and upregulation of alpha-CGRP.
Dun, Y; Hao, Y; Li, J; Yang, C; Zhang, M; Zhang, Y, 2009
)
3.24
"Nitroglycerin (NTG) has been shown to be a useful adjunct for pain treatment without increasing adverse side effects. "( Transdermal nitroglycerin as an adjuvant to patient-controlled morphine analgesia after total knee arthroplasty.
Eidelman, LA; Lenchinsky, A; Orbach-Zinger, S; Paul-Kesslin, L; Salai, M; Velks, S,
)
1.95
"Nitroglycerin (GTN) has been clinically used to treat angina pectoris and acute heart episodes for over 100 years. "( Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway.
Ansenberger-Fricano, K; Bonini, MG; Fernandes, DC; Fukai, T; Laurindo, FR; Mao, M; Mason, RP; Minshall, RD; Stadler, K; Sudhahar, V; Tanaka, LY; Vasquez-Vivar, J, 2012
)
3.26
"Nitroglycerine (NTG) has analgesic properties. "( The analgesic effect of three different doses of nitroglycerine when added to lidocaine for intravenous regional anesthesia in trauma patients.
Fatemy, A; Honarmand, A; Safavi, M, 2011
)
2.07
"Nitroglycerin has been widely used as a model of experimental migraine. "( Brain blood flow in the nitroglycerin (GTN) model of migraine: measurement using positron emission tomography and transcranial Doppler.
Bednarczyk, EM; Burch, K; Gona, J; Haka, M; Kassab, MY; Trinidad, K; Wack, DS, 2002
)
2.06
"Nitroglycerin (NTG) has been found efficacious in acute pain, but has not been tested for chronic pain with neuropathic characteristics."( Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial.
Eidelman, LA; Glantz, L; Godovic, G; Kramer, M; Lekar, M, 2004
)
1.35
"Nitroglycerine has been used clinically in the treatment of angina for 130 years, yet important details on the mechanism of action, biotransformation, and the associated phenomenon of nitrate tolerance remain unanswered. "( Nitrates and NO release: contemporary aspects in biological and medicinal chemistry.
Bennett, BM; Nicolescu, AC; Thatcher, GR; Toader, V, 2004
)
1.77
"Nitroglycerin has been used successfully as an acute tocolytic during Caesarean sections and manual removal of placenta."( Acute tocolysis.
Arulkumaran, S; Chandraharan, E, 2005
)
1.05
"Nitroglycerin only has a limited late preconditioning protective effect in conscious animals submitted to a reversible prolonged ischemia since it protects against arrhythmias but not against stunning."( Nitroglycerin induces late preconditioning against arrhythmias but not stunning in conscious sheep.
Lascano, EC; Negroni, JA; Valle, HF, 2007
)
3.23
"Nitroglycerine has beneficial effects in multiple systems, especially the cardiovascular system."( Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans.
Wimalawansa, SJ, 2007
)
1.06
"Nitroglycerin (GTN) has been shown, in both human and animal studies, to induce a protective phenotype that limits tissue damage after ischemia and reperfusion. "( The mechanism of nitrate-induced preconditioning.
Di Stolfo, G; Dragoni, S; Forconi, S; Gori, T; Leone, MC; Lisi, M; Parker, JD, 2008
)
1.79
"Nitroglycerin has been the mainstay of the medical management of angina pectoris for over 100 years. "( The transdermal administration of nitrates: an overview.
Demma, FJ; Wilson, RR, 1983
)
1.71
"Nitroglycerin has been shown to be a potent large-vessel coronary dilator, but the effects of nitroprusside on coronary artery size are unclear."( Comparison of the effects of nitroprusside and nitroglycerin on coronary size.
Conti, CR; Day, RM; Feldman, RL; Hill, JA; Pepine, CJ, 1983
)
1.24
"Nitroglycerin has theoretic appeal as a vasodilator drug in patients with pulmonary hypertension because it exerts a direct effect on the pulmonary circulation in doses that do not affect systemic resistance vessels or the myocardium and do not activate neurohumoral reflexes."( Nitroglycerin therapy in the management of pulmonary hypertensive disorders.
Brooks, KM; Halperin, JL; Lee, WH; Packer, M; Rothlauf, EB, 1984
)
2.43
"Nitroglycerin has been found to exercise its action in two phases: first decreasing and then increasing cardiac output."( [Effect of nitrates on cardiodynamics in patients with atrioventricular block treated by electrocardiostimulation].
Giliarovskii, AK; Kapralova, TA; Kuz'mishin, LE; Mikhaĭlov, AA; Zhelnov, VV, 1984
)
0.99
"Nitroglycerin has little effect on cerebral blood flow even when used in combination with dopamine."( Cerebral blood flow and intracranial pressure in the dog during intravenous infusion of nitroglycerin alone and in combination with dopamine.
Kistler, JP; Lees, RS; von Essen, C; Zervas, NT,
)
1.07
"Nitroglycerin has a reducing influence on these changes, but not down to the initial level."( [The treatment of acute myocardial infarctions with beta-receptor-blockers. II. Hemodynamic effects of propranolol with and without combination therapy with nitroglycerin (author's transl)].
Hochrein, H; Lehmann, HU; Oeff, M; Witt, E, 1981
)
1.18
"Nitroglycerin (NTG) has been demonstrated to provide uterine relaxation in the management of various obstetric complications. "( Alternating nitroglycerin and syntocinon to facilitate uterine exploration and removal of an adherent placenta.
Ananthanarayan, C; Chan, AS; Rolbin, SH, 1995
)
2.11
"Nitroglycerin has been shown to inhibit platelet function in vitro by stimulating prostacyclin or inhibiting thromboxane A2 production, or both. "( Methylene blue inhibits the antithrombotic effect of nitroglycerin.
Baribeau, J; Johnstone, MT; Lacoste, L; Lam, JY; Théroux, P; Waters, D, 1993
)
1.98
"Nitroglycerin has an effect to dilate vessels."( [Usefulness of enhanced MR angiography by nitroglycerin].
Fujita, M; Hashimoto, N; Ishihara, K; Katsumori, T; Kutsumi, H; Ohno, K; Sato, O; Soga, T; Takahashi, T; Ueguchi, T, 1993
)
1.27
"Nitroglycerin has been reported to reduce activated partial thromboplastin time (aPTT) values in patients treated with concurrent heparin and nitroglycerin. "( Lack of in vitro interaction between heparin and nitroglycerin.
Barnes, AD; Horn, JR; Wittkowsky, AK, 1996
)
1.99
"Nitroglycerin (GTN) has been used as the drug of choice in the treatment of angina pectoris. "( Variable glyceryl dinitrate formation as a function of glutathione S-transferase.
Adachi, T; Fujii, T; Hirano, K; Tatematsu, M; Usami, Y, 1996
)
1.74
"Nitroglycerin has been shown to possess antiplatelet properties in both animals and humans. "( Persistent inhibition of platelets during continuous nitroglycerin therapy despite hemodynamic tolerance.
Hébert, D; Lam, JY; Xiang, JX, 1997
)
1.99
"Nitroglycerin (GTN) has been used to treat heart disease for many years. "( Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo.
Benet, LZ; Sumi, M; Yuan, R, 1997
)
2
"Nitroglycerin has been the drug of choice for relieving myocardial ischemia for more than a hundred years. "( Nitroglycerin-induced hypoxemia does not produce myocardial ischemia.
Bilgen, F; Calişirişçi, U; Canik, S; Demirtaş, M; Kopman, EA; Ozler, A; Toraman, F; Yiğiter, B, 1997
)
3.18
"Nitroglycerin (TNG) has recently gained popularity in obstetric anesthesia for facilitating acute uterine relaxation in the treatment of obstetric emergencies such as retained placenta. "( Placental tissue enhances uterine relaxation by nitroglycerin.
Csavoy, AN; Datta, S; Segal, S, 1998
)
2
"Nitroglycerine has a direct vasodilating action on both venous and arterial smooth muscle fibers. "( [Clinical use of nitroglycerin as an hypotensive agent during general anesthesia (author's transl)].
Chelly, J; Derome, P; Tannières, ML; Visot, A; Vourc'h, P,
)
1.91
"Nitroglycerin (NTG) has recently been suggested to decrease myocardial ischemia and enhance cardiac pump function during acute myocardial infarction (AMI). "( Hemodynamic effects of nitroglycerin in acute myocardial infarction.
Amsterdam, EA; Mason, DT; Williams, DO, 1975
)
2.01
"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension. "( Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.
Baird, MG; Becker, L; Come, PC; Flaherty, JT; Greene, HL; Pitt, B; Rouleau, JR; Weisfeldt, ML, 1975
)
1.93
"Nitroglycerin has no effect on the electron transport and oxidative phosphorylation of isolated rabbit heart mitochondria at 5 X 10(-4) M and lower concentrations. "( Possible mode of action of nitroglycerin on heart mitochondria.
Bor, P; Csete, K; Szekeres, L; Vághy, P,
)
1.87
"Nitroglycerin has been reported to reduce mortality in patients with acute myocardial infarction. "( Dose-dependent effect of intravenous nitroglycerin on platelet aggregation, and correlation with plasma glyceryl dinitrate concentration in healthy men.
Ahlner, J; Karlberg, KE; Sylvén, C; Torfgård, K, 1992
)
2
"Nitroglycerin has dependable, short-lived veno- and arterial vasodilatory effects ameliorating ischemia through both preload reduction and coronary vasodilation. "( Interpretation of cardiac pathophysiology from pressure waveform analysis: effects of nitroglycerin.
Aguirre, FV; Hilton, TC; Kern, MJ, 1992
)
1.95
"Nitroglycerin (NTG) has the potential to reduce myocardial ischemia during percutaneous transluminal coronary angioplasty (PTCA). "( Buccal nitroglycerin decreases ischemic pain during coronary angioplasty: a double-blind, randomized, placebo-controlled study.
Ekström, L; Emanuelsson, H; Johansson, SR, 1990
)
2.18
"Nitroglycerin, however, has little effect on ischemia-induced regional dysfunction and on ST-segment elevation in the intracoronary ECG."( The effects of pretreatment with nitroglycerin on ischemic left ventricular dysfunction during coronary angioplasty.
Amende, I; Herrmann, G; Hood, WP; Lichtlen, PR; Simon, R; Wenzlaff, P, 1991
)
1.28
"Nitroglycerin has multiple mechanisms of action in angina pectoris."( Transdermal nitroglycerin in angina pectoris.
Abrams, J, 1989
)
1.38
"Nitroglycerin has been shown to cause a downward shift in the left ventricular (LV) pressure-volume relation in patients. "( A mechanism for the nitroglycerin-induced downward shift of the left ventricular diastolic pressure-diameter relation.
Belenkie, I; Kingma, I; Knudtson, ML; MacDonald, RP; Smiseth, OA; Smith, ER; Tyberg, JV, 1986
)
2.04
"Nitroglycerin has long been a mainstay of the treatment of ischemic cardiac pain. "( The role of transdermal nitroglycerin in the treatment of coronary heart disease.
Taylor, SH, 1986
)
2.02
"Nitroglycerin (NTG) has long been used beneficially to reduce myocardial oxygen demand by its effects on the systemic and peripheral vascular resistances."( Control of perioperative hypertension during coronary artery surgery. A randomised double-blind study comparing isosorbide dinitrate and nitroglycerin.
Barash, PG; Cahalan, M; Durkin, MA; Kaplan, J; Morris, RB; Thys, D, 1988
)
1.2
"Nitroglycerin has maintained its position in the treatment of angina pectoris for more than a century. "( Efficacy of different forms of nitrates in angina pectoris.
Luomanmäki, K, 1985
)
1.71

Actions

Nitroglycerin can increase the peripheral plasma CGRP level and decrease the concentration of ET when treating CHF. The nitrogoglyin-induced increase in tissue Po2 was disproportionate to the increase in MBF, indicating enhanced O2 unloading. Nitroglycerine ointments may increase the risk of PIVC failure and are associated with adverse effects.

ExcerptReferenceRelevance
"Nitroglycerin ointments may increase the risk of PIVC failure and are associated with adverse effects."( A systematic review and meta-analysis of new interventions for peripheral intravenous cannulation of children.
Curtis, S; Fritze, Z; Heinrichs, J; Klassen, T, 2013
)
1.11
"nitroglycerin, can increase the radiotracer uptake in areas with moderate and severe hypoperfusion."( Viable myocardium scintigraphy with intravenous nitroglycerine by computed tomography with Tc-99m (MIBI).
Almeida, RS; Camargo, TN; Lima, EJ; Nascimento, MW; Ramos Filho, J; Silva, RM, 2008
)
1.32
"Nitroglycerin can increase the peripheral plasma CGRP level and decrease the concentration of ET when treating CHF. "( [Effects of nitroglycerin on plasma calcitonin gene-related peptide and endothelin in congestive heart failure].
Lü, YZ; Ou, SQ; Yu, ZX, 2003
)
2.14
"The nitroglycerin-induced increase in tissue Po2 was disproportionate to the increase in MBF, indicating enhanced O2 unloading."( Effects of nitroglycerin on erythrocyte rheology and oxygen unloading: novel role of S-nitrosohemoglobin in relieving myocardial ischemia.
Bin, JP; Christiansen, J; Doctor, A; Fisher, NG; Hendersen, EM; Kaul, S; Le, DE; Leong-Poi, H; Lindner, J, 2006
)
1.2
"Nitroglycerin can increase gastric blood flow and slow gastric emptying."( Intragastric nitroglycerin at a vasodilatory dose attenuates acidified aspirin-induced gastric mucosal injury.
Chan, CC; Leung, FW, 2007
)
1.43
"Nitroglycerin was found to increase cardiac output, initially, as a sequel of positive inotropy and chronotropy, with a subsequent decrease of cardiac output."( Analysis of oral molsidomine effects on ventricular function and dimensions in the conscious dog.
Fiedler, VB; Göbel, H; Nitz, RE, 1983
)
0.99
"Nitroglycerin did not produce marked or significant changes in oxygen tension and myocardial contractility in the central ischemic or distant areas."( [Effect of nitroglycerin on myocardial function in short-term ischemia].
Moskvitina, OA; Trubetskoĭ, AV, 1982
)
1.38
"The nitroglycerin-induced increase in the orthostatic rise in heart rate and the change in digital-pulse-wave morphology roughly paralleled the plasma concentration, whereas the reduction in systolic blood pressure in the upright position was still evident 15 mins after the infusion, i.e."( Plasma concentrations and haemodynamic effects of nitroglycerin during and after intravenous infusion in healthy volunteers.
Chu, LC; Fankhauser, P; Gérardin, A; Hodler, J; Imhof, PR; Müller, P; Ott, B; Sieber, A, 1982
)
1
"Nitroglycerin (NTG) may cause paradoxical bradycardia and occasional life-threatening hypotension. "( Hypotensive and bradycardiac responses to reflex sympathetic inhibition produced by nitroglycerin in rats with sinoaortic deafferentation.
Long, JP; Ma, S, 1993
)
1.95
"Nitroglycerin may cause paradoxical bradycardia and occasional life threatening hypotension in patients."( Noradrenergic mechanisms and the cardiovascular actions of nitroglycerin.
Long, JP; Ma, SX; Schmid, PG, 1994
)
1.25
"Nitroglycerin tended to increase blood flow only in patients not in the cluster period and in controls."( Pain induces decrease of blood flow in the common carotid arteries in cluster headache attacks.
Hannerz, J; Jogestrand, T, 1993
)
1.01
"The nitroglycerin-induced increase in systolic gradient RaSAP-AoSAP correlated to decreases in stroke volume index, mean arterial pressure, and arterial elastance, but not to decrease in pulse wave augmentation."( Aortic and radial pulse contour: different effects of nitroglycerin and prostacyclin.
Pontén, J; Sellgren, J; Söderström, S, 1999
)
1.03
"Nitroglycerin was active to enhance transduction of large tumors with trabecular or pseudoglandular histological pattern, which were impermeable to adenoviral vectors even after histamine or angiotensin treatments."( A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.
Alzuguren, P; Bilbao, R; Bustos, M; Drozdzik, M; Pajares, MJ; Prieto, J; Qian, C, 2000
)
1.03
"Nitroglycerin can increase blood flow to the underperfused endocardium in the absence of alterations in heart size, hemodynamic parameters, and total transmural flow to the ischemic region."( Effects of nitroglycerin and propranolol on the distribution of transmural myocardial blood flow during ischemia in the absence of hemodynamic changes in the unanesthetized dog.
Greenfield, JC; McHale, PA; Parker, JP; Swain, JL, 1979
)
1.37
"Nitroglycerin led to an increase in relative coronary flow comparable to that observed under nifedipine but did not antagonize the disturbances of the process of activation by ouabain and only partially inhibited ST-elevation."( Nifedipine antagonizes ouabain-induced ST-segment changes and derangement of epicardial activation pattern in isolated rabbit hearts.
Dhein, S; Klaus, W; Müller, A, 1990
)
1
"Nitroglycerin did not increase femoral artery flow or cardiac output and did not lower total peripheral vascular resistance at any dose studied."( Effects of continuous intravenous infusions of nitroglycerin on canine systemic and hind limb microcirculatory hemodynamics.
Kazmers, A; Lindenauer, SM; Stanley, JC; Whitehouse, WM, 1986
)
1.25
"Nitroglycerin and lower doses of nifedipine and prostacyclin improved coronary perfusion due to selective or preferential dilation of large coronary arteries."( Comparative effects of intracoronary vasodilators on restoring coronary perfusion during flow-reducing coronary stenosis in the dog.
Fukuzaki, H; Kashiki, M; Sakamoto, S; Yokoyama, M, 1987
)
0.99
"Nitroglycerin was used to lower mean arterial pressure during periods of potential increased blood loss."( Nitroglycerin-controlled circulation in orthognathic surgery.
Farole, A; Golia, JK; Seltzer, JL; Woo, R, 1985
)
2.43
"Nitroglycerin therapy can cause dose-related increases in intracranial pressure. "( Intravenous nitroglycerin-induced intracranial hypertension.
Fowler, AA; Glauser, FL; Ohar, JM; Selhorst, JB, 1985
)
2.09

Treatment

Nitroglycerin is used worldwide for patients with various ischemic and congestive cardiac diseases, including angina pectoris. Nitroglycerine treatment caused endothelial dysfunction in NZWR and WHHL, associated with an increase in superoxide and ONOO.

ExcerptReferenceRelevance
"The nitroglycerin-treated group showed significant increases in blood potassium during di-estrous while the piroxicam-treated group showed significant increases in blood potassium, urea and clotting time with a significant decrease in sodium levels during di-estrous compared to controls. "( Comparative study of piroxicam and nitroglycerin on prostaglandin-modulated blood and electrolyte indices during di-estrous in female Wistar Rats.
Adebayo, OO; Adele, BO; Adewoye, EO, 2023
)
1.75
"Nitroglycerin pre-treated animals did not show any rubbing behavior after locally injected saline."( Correlation between algogenic effects of calcitonin-gene-related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin-induced sensitization.
Capuano, A; Greco, MC; Navarra, P; Tringali, G, 2014
)
1.32
"In nitroglycerine-treated rabbits, experimental myocardial ischemia produced less pronounced depressor BP shifts in the pulmonary artery than those produced by ischemia in controls (prior to pharmacological treatment) or by experimental ischemia provoked after acetylcholine infusion."( Changes in pulmonary hemodynamics induced by experimental myocardial ischemia in nitroglycerin- or acetylcholine-treated rabbits.
Evlakhov, VI; Poyasov, IZ, 2014
)
1.14
"Nitroglycerin, which treats impaired cardiac function through vasodilation as it is converted to nitric oxide, is used worldwide for patients with various ischemic and congestive cardiac diseases, including angina pectoris. "( ALDH2 activator inhibits increased myocardial infarction injury by nitroglycerin tolerance.
Ferreira, JC; Mochly-Rosen, D; Sun, L, 2011
)
2.05
"Nitroglycerin treatment caused endothelial dysfunction in NZWR and WHHL, associated with an increase in superoxide and ONOO(-) production and a substantial drop in cGK-I activity. "( Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits.
Beisiegel, U; Giaid, A; Heitzer, T; Kontush, A; Lavall, D; Marklund, SL; Meinertz, T; Möller-Bertram, T; Mollnau, H; Munzel, T; Walter, U; Warnholtz, A, 2002
)
2.09
"Nitroglycerin treatment of WHHL with exogenous NO worsens rather than improves endothelial dysfunction secondary to increased formation of superoxide and/or peroxynitrite leading to decreased cGK-I activity. "( Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits.
Beisiegel, U; Giaid, A; Heitzer, T; Kontush, A; Lavall, D; Marklund, SL; Meinertz, T; Möller-Bertram, T; Mollnau, H; Munzel, T; Walter, U; Warnholtz, A, 2002
)
2.09
"Nitroglycerin treatment increased LDCL, and the inhibitory effect of uric acid and ebselen on LDCL was augmented in tolerant rings. "( Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance.
August, M; Bachschmid, M; Baldus, S; Daiber, A; Hink, U; Kolb, P; Mollnau, H; Münzel, T; Oelze, M; Tsilimingas, N; Ullrich, V; Walter, U; Zou, MH, 2003
)
1.76
"Nitroglycerin treatment of 7 days produced a lack of hypotensive response to a single intravenous bolus of 30 microg/kg nitroglycerin, which caused a significant decrease in mean arterial blood pressure in control rabbits."( Development of insulin resistance by nitrate tolerance in conscious rabbits.
Bajza, A; Literati-Nagy, P; Nemeth, J; Peitl, B; Porszasz, R; Rabloczky, G; Szilvassy, J; Szilvassy, Z, 2004
)
1.04
"Nitroglycerin treatment may improve response to DCb in patients with lung adenocarcinoma, partly through decreasing VEGF and P-gp production via reduction of HIF-1alpha."( Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Asada, M; Fuji, H; Inoue, D; Kanda, A; Kaneta, T; Kondo, T; Nakayama, K; Okinaga, S; Sasaki, H; Sasaki, T; Suzuki, S; Suzuki, T; Takai, Y; Watanabe, M; Yamanda, S; Yamaya, M; Yanagihara, K; Yasuda, H; Yoshida, M; Zayasu, K, 2006
)
3.22
"Nitroglycerin-treated dogs showed no difference from control dogs in infarct weight (26.2 +/- 5.9 gm +/- SE vs 27.7 +/- 5.6 gm), percent risk region/LV (36.0 +/- 1.4% vs 37.9 +/- 3.1%), or present infarct/LV (23.5 +/- 5.2% vs 24.8 +/- 4.9%)."( The effects of nitroglycerin-methoxamine combination on infarct size in conscious dogs.
Bolli, R; Epstein, SE; Goldstein, RE; Sheehan, FH, 1983
)
1.34
"Nitroglycerin treatment had no effect on either beating rate recovery or release of CPK and LDH from myocytes."( In vitro protective effects of nicorandil on hypothermic injury to immature cardiac myocytes: comparison with nitroglycerin.
Fukasawa, M; Fukui, K; Hirooka, S; Kohi, M; Orita, H; Washio, M, 1994
)
1.22
"Nitroglycerin treatment markedly inhibited relaxations to nitroglycerin (maximum relaxations in untreated: 92 +/- 1 vs."( Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.
Berrington, WR; Freeman, BA; Harrison, DG; Kurz, S; Münzel, T; Rajagopalan, S; Thoenes, M; Thompson, JA, 1996
)
1.33
"nitroglycerin to treatment with nitroglycerin ointment 2% vary greatly and may affect the length of time patients remain in the ICU, nursing time, and possible recurrent angina."( Converting i.v. nitroglycerin therapy to nitroglycerin ointment therapy: a comparison of two methods.
Dunham, G; Esposito, GA; Granger, BB; Granger, CB; Tudor, GE, 1998
)
1.37
"With nitroglycerin treatment, similar to SIN-1 treatment, myocyte injury was diminished, TGF-beta1 release increased, and total TGF-beta1 expression decreased."( Protection of myocytes from hypoxia-reoxygenation injury by nitric oxide is mediated by modulation of transforming growth factor-beta1.
Chen, HJ; Li, DY; Mehta, JL, 2002
)
0.77
"Nitroglycerin treatment stimulated a dose-dependent increase in MMP-9 mRNA levels (NTG 200 pmol: 193 +/- 6% and NTG 2,000 pmol: 372 +/- 9% compared to controls, p < 0.005) and MMP-9 activity (NTG 200: 142 +/- 5.5% and NTG 2,000: 167 +/- 11% compared to controls, p < 0.005)."( Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages.
Celermajer, DS; Death, AK; Jessup, W; Martell, S; McGrath, KC; Nakhla, S; Yue, DK, 2002
)
2.48
"nitroglycerin treatment in unstable angina pectoris."( Buccal versus intravenous nitroglycerin in unstable angina pectoris.
Dellborg, M; Gustafsson, G; Swedberg, K, 1991
)
1.3
"In nitroglycerin treated animals, the flow increase with reperfusion was similar to the control group (12 +/- 10 to 65 +/- 33 ml/min per 100 g)."( Effects of nitroglycerin on regional O2 supply and O2 consumption in reperfused dog myocardium.
Acad, BA; Joselevitz-Goldman, J; Weiss, HR, 1989
)
1.18
"treatment with nitroglycerin produced an increase of CGRP levels in brainstem and trigeminal ganglia, but not in the hypothalamus and hippocampus."( Correlation between algogenic effects of calcitonin-gene-related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin-induced sensitization.
Capuano, A; Greco, MC; Navarra, P; Tringali, G, 2014
)
0.94
"Pretreatment with nitroglycerine increased median CFVR from 3.6 (range 2.8-4.3) to 5.0 (4.1-6.0), p = 0.002. "( Effects of nitroglycerine on coronary flow velocity before and during adenosine provocation.
Gan, LM; Jeppsson, A; Wittfeldt, A, 2016
)
1.16
"Pretreatment with nitroglycerine dilates coronary arteries and increases coronary flow velocity reserve indicating that adenosine alone causes a submaximal hyperemia."( Effects of nitroglycerine on coronary flow velocity before and during adenosine provocation.
Gan, LM; Jeppsson, A; Wittfeldt, A, 2016
)
1.16
"Pretreatment with nitroglycerin (120 microg/kg, i.v.) markedly reduced infarct size."( Delayed cardioprotection afforded by nitroglycerin is mediated by alpha-CGRP via activation of inducible nitric oxide synthase.
Deng, HW; Du, YH; Huang, ZZ; Jiang, DJ; Li, YJ; Peng, J, 2004
)
0.92
"Pretreatment with nitroglycerin did not significantly inhibit the maximum vasopressin contraction in either the internal thoracic artery or radial artery."( Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery.
Furnary, A; He, GW; Wei, W; Yang, CQ, 2005
)
0.65
"Pretreatment with nitroglycerin significantly decreased its vasodilation and depressor effect and the release of CGRP, which was restored in the presence of vinpocetine, an inhibitor of phosphodiesterase."( Reversal of tolerance to nitroglycerin with vinpocetine: a role of calcitonin gene-related peptide.
Chen, YR; Deng, HW; Hu, CP; Li, YJ; Nie, SD; Wang, S, 2008
)
0.97
"Treatment with nitroglycerin was continued in 3 of the 5 patients and all 3 have reported improvement in their exercise tolerance."( Partial reversibility of chronic pulmonary hypertension caused by pulmonary thromboembolic disease.
Bower, JS; Dantzker, DR, 1981
)
0.6
"Treatment with nitroglycerine is associated with a higher prevalence of ischemic episodes, thus suggesting that myocardial ischemia is unlikely to be caused by spasm of large epicardial vessels or grafts."( Early postoperative myocardial ischemia after coronary artery bypass grafting. Detrimental effects of nitroglycerine infusion.
Chiariello, L; Cirillo, F; Crea, F; De Paulis, R; Gaspardone, A; Gioffrè, PA; Iamele, M; Penta de Peppo, A; Pierri, MD; Tomai, F, 1995
)
0.85
"Pretreatment with nitroglycerin at the concentration of 3x10(-7) or 10(-6) M for 5 min produced a significant improvement of cardiac function and a decrease in the release of creatine kinase."( The cardioprotective effects of nitroglycerin-induced preconditioning are mediated by calcitonin gene-related peptide.
Deng, HW; Hu, CP; Li, YJ, 1999
)
0.91
"Pretreatment with nitroglycerin, 10(-7), 3 x 10(-7), 10(-6) M for 5 min produced a significant improvement of intestinal tissue morphology and a decrease in the release of both lactate dehydrogenase and malondialdehyde."( Protective effects of nitroglycerin-induced preconditioning mediated by calcitonin gene-related peptide in rat small intestine.
Dun, Y; Hao, YB; Wu, YX; Zhang, Y; Zhao, RR, 2001
)
0.95
"Pretreatment with nitroglycerin (60 or 120 microg/kg i.v.) reduced both the infarct size and the release of creatine kinase during reperfusion and caused a significant increase in the expression of alpha-CGRP mRNA, but not beta-CGRP mRNA, concomitantly with an increase in concentrations of NO and CGRP."( Delayed cardioprotection induced by nitroglycerin is mediated by alpha-calcitonin gene-related peptide.
Deng, HW; Li, NS; Li, YJ; Peng, J; Ye, F; Zhou, ZH, 2002
)
0.91
"Treatment with nitroglycerine and nifedipine together with phenoxybenzamine completely suppressed the symptoms."( Leiomyomatosis cutis et uteri.
Christophers, E; Engelke, H, 1979
)
0.6
"Pretreatment with nitroglycerin (100 microM), 8-Br cyclic guanosine monophosphate (cGMP) (1 microM), or diltiazem (40 microM) inhibited contractile responses produced by NE; however, these agents had no significant effect on NE-induced IP accumulation."( Effect of KT-362, a putative intracellular calcium antagonist, on norepinephrine-induced contractions and inositol monophosphate accumulation in canine femoral artery.
Eskinder, H; Gross, GJ; Hillard, CJ; Wilke, RA, 1989
)
0.6
"Treatment by nitroglycerin intravenously (i.v.) is not always efficient and an alternate possibility of treatment is essential."( Coronary vasospasm after myocardial revascularisation. Treatment by verapamil.
Capouet, V; Deuvaert, F; Massaut, J, 1986
)
0.62
"Treatment with nitroglycerin inhibited the contractions caused by PGF2 alpha and Ca2+, but did not significantly alter the contraction induced by reoxygenation."( Reoxygenation and calcium-induced cerebroarterial contractions as affected by vasodilator agents.
Bian, K; Toda, N, 1988
)
0.61
"Pretreatment with nitroglycerine also potentiated the inhibitory response to noradrenaline.6."( The potentiation of rat uterine inhibitory responses to noradrenaline by theophylline and nitroglycerine.
Levy, B; Wilkenfeld, BE, 1968
)
0.79

Toxicity

Transdermal nitroglycerin appears to be a safe therapy for the mother and fetus. Intravenous administration of urapidil was associated with better control of blood pressure and preserved cardiac function.

ExcerptReferenceRelevance
" There were no significant differences regarding nature and incidence of adverse events between the groups."( Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Pectoris (MIRSA).
Buchner-Moell, D; de Muinck, ED; Lie, KI; van de Ven, LL, 1992
)
0.28
" Adverse events on treatment, particularly those correlated to vasodilation, were less frequent in the carvedilol group."( Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina.
Derr, I; Eberhardt, R; Ehmer, B; van der Does, R, 1992
)
0.28
"In a double-blind, randomized, placebo cross-controlled trial the effectiveness and the adverse effects of two types of buccal tablets containing 5 mg nitroglycerin: Polnitrin produced by Warsaw Pharmaceutical Works POLFA and its analogue of foreign origin, were assessed."( [Evaluation of clinical effectiveness and adverse effects of Polnitrin].
Kośmicki, M; Sadowski, Z, 1992
)
0.48
" Angiotensin-converting enzyme inhibitors are responsible for a plethora of adverse effects, including renal insufficiency, hypotension, angioedema, cough, and increased insulin sensitivity."( Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors.
Arnold-Capell, P; Curry, SC, 1991
)
0.53
" Use of parenteral aminophylline to treat adverse events associated with intravenous dipyridamole brought complete relief of symptoms in 439 of 454 patients (96."( The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group.
Kempthorne-Rawson, J; Ranhosky, A, 1990
)
0.28
" There were not toxic signs in mice and rats."( [Acute toxicity test on dermal application of NT-1 tape and 10% nitroglycerin (NT-1 ointment)].
Morita, K; Shinomiya, M; Yamakita, O; Yoshida, R, 1986
)
0.51
" The LD50 value for adrenaline in control animals was 11."( Adrenaline toxicity in mice: sensitization of alpha 1 adrenoreceptors by nitroglycerin.
Axelsson, KL; Rydell, EL, 1984
)
0.5
" No adverse effects were seen in dogs given up to 1 mg/kd/day of TNG for 4 weeks, then 5 mg/kg/day for 9 more weeks."( Subacute and chronic toxicity studies of trinitroglycerin in dogs, rats, and mice.
Dacre, JC; Ellis, HV; Glennon, JP; Hong, CB; Lee, CC, 1984
)
0.53
" Eleven percent of the patients receiving diltiazem CD experienced treatment-related adverse events, which were limited to headache and abdominal pain; these adverse events did not lead to discontinuation of treatment."( Clinical efficacy and safety of once-daily diltiazem in patients with stable angina pectoris switched from twice-daily diltiazem.
Boulet, AP; Jacob, C; Juneau, M; Lenis, J; Savard, D, 1995
)
0.29
" No significant adverse events occurred."( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects.
Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995
)
0.56
"NAC in combination with NTG and streptokinase appeared to be safe for the treatment of evolving AMI and was associated with significantly less oxidative stress, a trend toward more rapid reperfusion, and better preservation of left ventricular function."( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects.
Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995
)
0.56
" No new or unusual adverse events were noted."( Antianginal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID.
Annable, L; Baird, M; Boulet, AP; Juneau, M; Klinke, WP; Lakhani, Z; Larivière, L; Warnica, W; Waters, D, 1995
)
0.29
" Relief of chest pain and/or adverse hemodynamic outcome were the primary endpoints."( Nitroglycerin in the treatment of cocaine associated chest pain--clinical safety and efficacy.
DiSano, MJ; Dyer, S; Fairweather, P; Feldman, JA; Fish, SS; Gennis, P; Hoffman, RS; Hollander, JE; Schumb, DA; Wax, P, 1994
)
1.73
" No statistically significant differences were found in vein size or adverse effects following nitroglycerin ointment application."( Evaluation of the safety and efficacy of topical nitroglycerin ointment to facilitate venous cannulation.
Cropp, A; Griffith, P; James, B,
)
0.6
" Almost 90 treatment years revealed no significant or serious adverse events, and there were no changes in haematology or biochemistry associated with intermittent nitrate patch therapy."( The long-term safety and tolerability of transdermal glyceryl trinitrate, when used with a patch-free interval in patients with stable angina.
Akhras, F; Clark, AR; Foran, JP; Jackson, G; Padaria, SF; Wainwright, RJ,
)
0.13
"3%) had adverse effects: One became asystolic and apneic for two minutes, two experienced profound bradycardia with hypotension, and one became hypotensive while tachycardic."( Safety of prehospital nitroglycerin.
Holliman, CJ; Meador, S; Roth, GS; Swope, G; Wuerz, R, 1994
)
0.6
"Nitroglycerin seems to be a relatively safe advanced life support drug; however, a few patients experience serious adverse effects."( Safety of prehospital nitroglycerin.
Holliman, CJ; Meador, S; Roth, GS; Swope, G; Wuerz, R, 1994
)
2.05
" A similar pattern of vascular damage was found in rats treated with a very toxic cyclosporin treatment (50 mg."( Regional differences in vasculotoxic effects of cyclosporin in rats.
de Ridder, L; Lameire, N; Van de Voorde, J; Verbeke, M, 1995
)
0.29
" Information was obtained about the number of examinations performed, complications related to ICUS imaging, and any adverse clinical consequences related to ICUS imaging."( Safety of intracoronary ultrasound: data from a Multicenter European Registry.
Batkoff, BW; Linker, DT, 1996
)
0.29
" No serious adverse events occurred in any patients during therapy with amlodipine as well as with nifedipine."( [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension].
Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997
)
0.3
"Isoket spray is effective and safe antianginal drug."( [Comparative efficacy, safety, cardio-hemodynamic effects of isosorbide dinitrate (ID) aerosol and sublingual tablets of nitroglycerin].
Ol'binskaia, LI; Sizova, ZhM; Ushakova, AV, 1998
)
0.51
" To overcome the shortcomings we have developed a new, safe lasing technique that consists of multiple trains of a small number of pulses each."( A new, safer lasing technique for laser-facilitated coronary angioplasty.
Topaz, O, 1993
)
0.29
" Nitrolingual-Spray is as effective and safe as NTG tablets for the treatment of symptomatic coronary heart disease."( A randomized crossover evaluation of antianginal efficacy and safety of nitrolingual-spray and nitroglycerin tablet form in coronary artery disease patients.
Chao, CL; Chen, MF; Chien, KL; Lee, YT; Su, TC; Sung, FC, 2000
)
0.53
" During the 14-day application of EPI several GTN commonly induced systemic adverse reactions were observed, particularly headache, confirming the systemic bioavailability of GTN from the patch."( Assessment of skin safety of a new glyceryl trinitrate transdermal patch. Animal and human studies.
Rovati, LC; Santoro, A; Setnikar, I, 2001
)
0.31
" Patients who did not experience any adverse side effects were instructed to use the cream at home at least three times per week, 5-10 minutes prior to sexual relations."( Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: a pilot study.
Berman, JR; Berman, LA; Vierregger, K; Walsh, KE,
)
0.42
"Topical nitroglycerin is safe and effective in providing temporary relief of introital dyspareunia and vulvar pain in women with vulvodynia."( Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: a pilot study.
Berman, JR; Berman, LA; Vierregger, K; Walsh, KE,
)
0.85
"The aim of this study was the comparative evaluation of antianginal efficacy and the adverse effects of 3 nitrates in oral doses: isosorbide dinitrate 80 mg in slow release form (ISDN-80), nitroglycerin 15 mg--slow release (NITRO-15) and pentaerythritol tetranitrate 100 mg in normal tablets (PENTA-100) in patients (pts) with stable angina pectoris."( [Comparative evaluation of the clinical effectiveness and the adverse effects of three different forms of nitrates in high oral doses in patients with stable angina pectoris].
Jedrzejczyk, B; Kośmicki, M; Kowalik, I; Sadowski, Z, 2002
)
0.51
" The headaches, the most frequent adverse effects, occurred after ingestion of ISDN-80 in 6 pts, NITRO-15 in 4 pts, PENTA-100 in 3 pts and P in 1 pt."( [Comparative evaluation of the clinical effectiveness and the adverse effects of three different forms of nitrates in high oral doses in patients with stable angina pectoris].
Jedrzejczyk, B; Kośmicki, M; Kowalik, I; Sadowski, Z, 2002
)
0.31
" Outcome parameters were (1) the effects on fetal and maternal heart frequency (FHF/MHF) and blood pressure, and (2) subjective experiences of adverse effects assessed by utilising a questionnaire."( Maternal and fetal side effects of tocolysis using transdermal nitroglycerin or intravenous fenoterol combined with magnesium sulfate.
Gross, W; Kähler, C; Möller, A; Möller, U; Richter, S; Schleussner, E; Seewald, HJ, 2003
)
0.56
"Transdermal nitroglycerin appears to be a safe therapy for the mother and fetus and is a promising new option for the treatment of preterm labour."( Maternal and fetal side effects of tocolysis using transdermal nitroglycerin or intravenous fenoterol combined with magnesium sulfate.
Gross, W; Kähler, C; Möller, A; Möller, U; Richter, S; Schleussner, E; Seewald, HJ, 2003
)
0.94
"Nesiritide is as safe as NTG in heart failure patients with acute coronary syndromes."( Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy.
Emerman, CL; Peacock, WF; Young, J, 2004
)
0.32
" All GRD doses were well tolerated, and incidence of adverse events for all GRD groups combined was less than that for placebo."( Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris.
Albert, KS; Gana, TJ; Glasser, SP; Pascual, LG, 2005
)
0.33
" GRD was safe and well tolerated."( Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris.
Albert, KS; Gana, TJ; Glasser, SP; Pascual, LG, 2005
)
0.33
" Twenty-seven patients experienced adverse events reported as drug related."( An open multicenter efficacy and safety evaluation of amlodipine in the treatment of symptomatic myocardial ischemia.
Beckerman, B, 1991
)
0.28
" Drug effects on exercise capacity (study 1 only), frequency of anginal attacks and consumption of short-acting itroderivatives, and incidence of adverse events (AEs) were evaluated."( Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies.
Cerreer-Bruhwyler, F; Dubois, C; Famaey, JP; Géczy, J; Messin, R,
)
0.13
" Headache is the most common side effect of nitrates; often dose-related and reported by up to 82% of patients in placebo-controlled trials."( Side effects of using nitrates to treat angina.
Rodgers, T; Thadani, U, 2006
)
0.33
"Treatment of RA grafts with phenoxybenzamine was associated with a reduction in perioperative myocardial injury and adverse cardiac events in this study population."( Radial artery graft treatment with phenoxybenzamine is clinically safe and may reduce perioperative myocardial injury.
Bourke, ME; Gunning, D; Kulik, A; Mesana, TG; Rubens, FD; Ruel, M, 2007
)
0.34
" Treatment-related adverse events were mostly mild/moderate hypotension, headache, and dizziness, which are often associated with NTG alone."( Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.
Bart, BA; Glue, P; Jen, F; Koren, MJ; Malhotra, B; Parker, JD; Siegel, RL; Wang, H; Webb, DJ, 2007
)
0.65
" Theophylline, a re-emerging drug for the treatment of obstructive airway disease, has a narrow therapeutic index which precludes its safe use."( Free radicals and theophylline neurotoxicity : an experimental study.
Gulati, K; Ray, A; Vijayan, VK, 2007
)
0.34
" When the animals were pretreated with either ABT-627 or A-192621, given alone or combined, the adverse effects of IAP on GFR, RPF, V, and U(Na)V were significantly augmented."( Adverse effects of pneumoperitoneum on renal function: involvement of the endothelin and nitric oxide systems.
Abassi, Z; Bishara, B; Hoffman, A; Karram, T; Khatib, S; Winaver, J, 2008
)
0.35
" Cardiotoxicity causing angina, arrhythmia and infarction are serious adverse events associated with these agents."( [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB, 2010
)
0.36
" We assessed the rates of adverse events (AEs) related to these agents."( Periprocedural safety of 64-detector row coronary computed tomographic angiography: results from the prospective multicenter ACCURACY trial.
Bell, GW; Budoff, MJ; Delago, A; Dunning, AM; Edwardes, M; Glasofer, S; Labounty, TM; Lin, FY; Min, JK,
)
0.13
"The performance of CCTA is safe with low rates of AEs."( Periprocedural safety of 64-detector row coronary computed tomographic angiography: results from the prospective multicenter ACCURACY trial.
Bell, GW; Budoff, MJ; Delago, A; Dunning, AM; Edwardes, M; Glasofer, S; Labounty, TM; Lin, FY; Min, JK,
)
0.13
" CRT-related serious adverse events (SAEs), adverse events (AEs), and follow-up MACE (death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization for heart failure) were recorded."( Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.
Anderson, RD; Azarbal, B; Handberg, E; Johnson, BD; Kar, S; Kelsey, SF; Kothawade, K; Lerman, A; Mehta, PK; Merz, CN; Pepine, CJ; Petersen, J; Samuels, B; Sharaf, B; Shaw, L; Shufelt, C; Sopko, G; Wei, J, 2012
)
0.38
" There was no hypotension and other adverse reaction of nitroglycerin in the nitroglycerin group."( Efficacy and safety of nitroglycerin for preventing venous spasm during contrast-guided axillary vein puncture for pacemaker or defibrillator leads implantation.
Duan, X; Ling, F; Shen, Y; Tong, XS; Xu, HY; Yang, J, 2013
)
0.95
"Intravenous nitroglycerin is effective and safe for preventing venous spasm during contrast-guided axillary vein puncture for pacemaker or defibrillator leads implantation."( Efficacy and safety of nitroglycerin for preventing venous spasm during contrast-guided axillary vein puncture for pacemaker or defibrillator leads implantation.
Duan, X; Ling, F; Shen, Y; Tong, XS; Xu, HY; Yang, J, 2013
)
1.08
"15), and serious adverse events, 14 (56%) versus 10 (63%; P=0."( Feasibility of an ambulance-based stroke trial, and safety of glyceryl trinitrate in ultra-acute stroke: the rapid intervention with glyceryl trinitrate in Hypertensive Stroke Trial (RIGHT, ISRCTN66434824).
Ankolekar, S; Bath, PM; Cox, P; Cross, I; Fuller, M; Renton, C; Siriwardena, AN; Sprigg, N, 2013
)
0.39
" GTN reduces SBP at 2 hours and seems to be safe in ultra-acute stroke."( Feasibility of an ambulance-based stroke trial, and safety of glyceryl trinitrate in ultra-acute stroke: the rapid intervention with glyceryl trinitrate in Hypertensive Stroke Trial (RIGHT, ISRCTN66434824).
Ankolekar, S; Bath, PM; Cox, P; Cross, I; Fuller, M; Renton, C; Siriwardena, AN; Sprigg, N, 2013
)
0.39
"To evaluate the utility of glucagon and the technique used for endoscopic removal, including the rate of success and the adverse events of the techniques."( Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction.
Haas, J; Leo, J; Vakil, N, 2016
)
0.43
" Data extracted included glucagon administration and its success rate, outcome of radiographic studies, and the endoscopic method of removal and adverse events associated with it, including 30-day mortality."( Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction.
Haas, J; Leo, J; Vakil, N, 2016
)
0.43
" Endoscopic removal regardless of technique is safe and effective."( Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction.
Haas, J; Leo, J; Vakil, N, 2016
)
0.43
" However, it increased the risk of cardiovascular adverse events."( Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials.
Gong, B; Li, Z; Wu, Z, 2016
)
0.43
"Occurrence of adverse events and relative hypotensive events during all episodes treated with the protocol, and efficacy of attaining target blood pressure for all episodes with protocol adherence and for initial episode experienced by each patient."( A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries.
Bunnell, AE; Burns, SP; James, JJ; Solinsky, R; Svircev, JN, 2016
)
0.43
" Twenty-three total adverse events occurred (5."( A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries.
Bunnell, AE; Burns, SP; James, JJ; Solinsky, R; Svircev, JN, 2016
)
0.43
"This inpatient nursing driven-protocol for treating autonomic dysreflexia utilizing conservative measures, nitroglycerin paste and oral hydralazine achieved target blood pressure with a high success rate and a low incidence of adverse events."( A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries.
Bunnell, AE; Burns, SP; James, JJ; Solinsky, R; Svircev, JN, 2016
)
0.65
" Patients given urapidil had fewer associated adverse events, specifically headache (p=0."( Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.
Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017
)
0.46
"Intravenous administration of urapidil, compared with nitroglycerin, was associated with better control of blood pressure and preserved cardiac function, as well as fewer adverse events, for elderly patients with hypertension and acute heart failure."( Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.
Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017
)
0.7
" The most commonly reported adverse events during MED2005 treatment were headache (patients, n = 18 [7."( Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study.
Eardley, I; Holland, T; Ralph, DJ; Taubel, J; Terrill, P, 2018
)
0.48
"Central adjudication of serious adverse events (SAEs) can be undertaken in clinical trials, especially for open-label studies where outcome assessment may be at risk of bias."( Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial.
Bath, PM; Bereczki, D; Berge, E; Collins, R; Díez-Tejedor, E; Godolphin, PJ; Gommans, J; Lees, KR; Montgomery, AA; Ozturk, S; Phillips, S; Pocock, S; Prasad, K; Sprigg, N; Szatmari, S; Wang, Y; Woodhouse, LJ, 2018
)
0.48
" GTN appears safe in ipsilateral or bilateral carotid stenosis, and might improve outcome in severe ipsilateral carotid stenosis."( It is safe to use transdermal glyceryl trinitrate to lower blood pressure in patients with acute ischaemic stroke with carotid stenosis.
Appleton, JP; Bath, PM; Belcher, A; Bereczki, D; Berge, E; Caso, V; Chang, HM; Christensen, HK; Collins, R; Gommans, J; Laska, AC; Ntaios, G; Ozturk, S; Sare, GM; Sprigg, N; Szatmari, S; Wang, Y; Wardlaw, JM; Woodhouse, LJ, 2019
)
0.51
" However, there was no significant difference in drug-related adverse reactions, explantation, superficial flap necrosis, infection, hematoma or seroma between the NTG and placebo groups."( Efficacy and safety of topical nitroglycerin in the prevention of mastectomy flap necrosis: a systematic review and meta-analysis.
Gu, L; Ma, J; Qin, Z; Wang, P; Wang, Q, 2020
)
0.84
"High blood pressure (BP) in acute stroke has adverse outcomes."( Benefits and safety of transdermal glyceryl trinitrate in acute stroke: a systematic review and meta-analysis of randomised trials (protocol).
Chan, WL; Lee, WF; Lim, BL; Ng, WM; Tay, WL, 2021
)
0.62
" Safety outcomes include reported adverse events."( Benefits and safety of transdermal glyceryl trinitrate in acute stroke: a systematic review and meta-analysis of randomised trials (protocol).
Chan, WL; Lee, WF; Lim, BL; Ng, WM; Tay, WL, 2021
)
0.62
" Potential adverse effects include hypotension, bradycardia or tachycardia, and mental status change."( Adverse events after prehospital nitroglycerin administration in a nationwide registry analysis.
Ashburn, NP; Lowell, LM; Popp, LM; Stopyra, JP, 2021
)
0.9
" Adverse event outcomes were defined as a new systolic blood pressure (SBP) < 90, heart rate (HR) < 50 or > 120, mean arterial pressure (MAP) < 65, or change in mental status following NTG administration."( Adverse events after prehospital nitroglycerin administration in a nationwide registry analysis.
Ashburn, NP; Lowell, LM; Popp, LM; Stopyra, JP, 2021
)
0.9
" Adverse events occurred in 7% of encounters."( Adverse events after prehospital nitroglycerin administration in a nationwide registry analysis.
Ashburn, NP; Lowell, LM; Popp, LM; Stopyra, JP, 2021
)
0.9
" Safety outcomes were adverse events."( Benefits and safety of transdermal glyceryl trinitrate in acute stroke: A systematic review and meta-analysis of randomized trials.
Chan, WL; Lee, WF; Lim, BL; Loo, KV; Man Goh, CJ; Ng, WM; Situ, W, 2022
)
0.72
"An accurate, simple and safe method was developed for simultaneous determination of nitroglycerine (NG) and nitrocellulose (NC) in double base solid propellants (DB propellants)."( A simple and safe approach for simultaneous spectrophotometric determination of nitroglycerin and nitrocellulose in double base solid propellants.
Mardi, K; Zarei, AR, 2022
)
1.17
"0) years), adverse events occurred in 68 patients (1."( Factors influencing the safety of outpatient coronary CT angiography: a clinical registry study.
Andre, F; Brado, M; Buss, SJ; Emami, M; Fortner, P; Frey, N; Görich, J; Gückel, F; Seitz, S; Sokiranski, R; Sommer, A, 2022
)
0.72
"Coronary CTA with intravenous beta-blocker administration is a safe procedure in an outpatient setting as adverse events are rare and mostly mild."( Factors influencing the safety of outpatient coronary CT angiography: a clinical registry study.
Andre, F; Brado, M; Buss, SJ; Emami, M; Fortner, P; Frey, N; Görich, J; Gückel, F; Seitz, S; Sokiranski, R; Sommer, A, 2022
)
0.72
" The secondary outcomes recorded at the same time points were healing rate, visual analogue scales for itching and burning, rate of complications and adverse events, patient quality of life and satisfaction, and cost analysis."( Efficacy and safety of Propionibacterium extract gel versus glyceryl trinitrate ointment in the treatment of chronic anal fissure: a randomized controlled trial.
Altomare, DF; Cantarella, F; Currò, G; Fulginiti, S; Gallo, G; Grossi, U; La Torre, M; Rinaldi, M; Santoro, GA; Tierno, S; Tomasicchio, G; Trompetto, M; Vanini, P, 2023
)
0.91
" Adverse events occurred more frequently in the GTN group than in the PeG group, peaking at visit 1 [37 (63."( Efficacy and safety of Propionibacterium extract gel versus glyceryl trinitrate ointment in the treatment of chronic anal fissure: a randomized controlled trial.
Altomare, DF; Cantarella, F; Currò, G; Fulginiti, S; Gallo, G; Grossi, U; La Torre, M; Rinaldi, M; Santoro, GA; Tierno, S; Tomasicchio, G; Trompetto, M; Vanini, P, 2023
)
0.91
"While there was no difference in healing rates between the two treatments, PeG was more cost-effective and associated with fewer adverse events."( Efficacy and safety of Propionibacterium extract gel versus glyceryl trinitrate ointment in the treatment of chronic anal fissure: a randomized controlled trial.
Altomare, DF; Cantarella, F; Currò, G; Fulginiti, S; Gallo, G; Grossi, U; La Torre, M; Rinaldi, M; Santoro, GA; Tierno, S; Tomasicchio, G; Trompetto, M; Vanini, P, 2023
)
0.91

Pharmacokinetics

The decline in plasma nitroglycerin concentration was biexponential with an initial half-life of 0. The pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl] (4,3-d)pyri was studied.

ExcerptReferenceRelevance
" Nitroglycerin followed essentially one-compartment kinetics after intracardial administration, showing a mean half-life of about 4 min and a mean apparent volume of distribution of about 3 liters/kg."( Pharmacokinetics of nitroglycerin in rats.
Fung, HL; Yap, PS, 1978
)
1.49
" A significant change of the pharmacokinetic parameters at the sublingual use of NG both after the long-term treatment with trinitrolong and after therapy with nitroderm was observed: in both cases the time of half-release of NG from plasma and the average time of retention increased, the area under the curve of concentration-time significantly increased and the drug clearance decreased (for trinitrolong the difference in the clearance parameter is significant)."( [Sublingual nitroglycerin: the pharmacokinetic changes following long-term treatment with trinitrolong and nitroderm-TTS].
Blagodatskikh, SV; Martsevich, SIu; Metelitsa, VI; Piotrovskiĭ, VK; Riabokon', OS,
)
0.51
" The goal of this study was to examine the pharmacokinetic properties of these metabolites in rats."( Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat.
Benet, LZ; Gumbleton, M; Labisch, C; Lau, DT, 1991
)
0.57
"Evaluation of Pharmacodynamic Equivalence of Glyceryl Trinitrate Sprays for Oral Application with or without Fluorochlorohydrocarbons."( [Evaluation of pharmacodynamic equivalence of glycerol trinitrate-containing sprays for oral administration with or without chlorofluorocarbons ].
Belz, GG; de Mey, C; Erb, KA; Kroll, M; Wolf, GK, 1991
)
0.28
" The ACVF method of cardiovascular monitoring should prove useful in human pharmacodynamic studies."( Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-Doppler device.
Silke, B; Taylor, SH; Verma, SP, 1990
)
0.28
" Additionally, for practical use of the transdermal system, a simple pharmacokinetic model to describe plasma 1,3-GDN levels after percutaneous (p."( Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis.
Iwaki, M; Kanokogi, A; Ogiso, T; Terao, Y, 1990
)
0.56
" Thus, the enhanced efficacy of GTN in advanced age seems to stem mainly from pharmacodynamic changes, which may be the consequence of dampened baroreceptor reflexes, as suggested by a lower heart rate increase per unitary fall in systolic arterial pressure observed in group B (0."( Age-related changes in the pharmacodynamics of intravenous glyceryl trinitrate.
Boncinelli, L; Bürgisser, C; Di Bari, M; Ferrucci, L; Fumagalli, S; Marchionni, N; Moschi, G; Paoletti, M; Salani, B, 1990
)
0.28
" After some remarks about the assay methods, the main pharmacokinetic data are briefly reviewed, as are the plasma concentrations obtained after different formulations."( Introductory remarks about clinically relevant pharmacokinetic properties of organic nitrates.
Bogaert, M, 1990
)
0.28
"The use of a function to fit blood concentration-time data points is equivalent, under certain assumptions, to specifying a model of the distribution of residence times of the drug molecules in the body (stochastic pharmacokinetic model)."( Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body.
Piotrovskii, VK, 1987
)
0.27
" Noninvasive measurements of peripheral blood flow can serve as a convenient and accurate tool for pharmacokinetic studies of vasoactive drugs."( Pharmacokinetic activity of nitrites evaluated by digital pulse volume recording.
Bass, A; Hirshberg, A; Schneiderman, J; Walden, R,
)
0.13
" The short duration of the bypass procedure and the continuous changes during the process hamper a rigorous pharmacokinetic evaluation."( Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.
Bogaert, MG; Buylaert, WA; Herregods, LL; Mortier, EP, 1989
)
0.28
" Because intravenous nitroglycerin is a potent, rapidly acting agent with a hemodynamic half-life measured in minutes, we evaluated its cardiovascular effects with and without volume expansion in six patients with severe pregnancy-induced hypertension."( Cardiovascular alterations in severe pregnancy-induced hypertension: effects of intravenous nitroglycerin coupled with blood volume expansion.
Cotton, DB; Dorman, KF; Jones, MM; Joyce, TH; Longmire, S; Tessem, J, 1986
)
0.81
" The terminal half-life is 2-6 minutes, and clearance about 30 l/min."( [Pharmacokinetics of glycerol trinitrate].
Menke, G; Rietbrock, N; Woodcock, BG, 1986
)
0.27
" The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets."( [Dinitrosorbilong--a new Soviet anti-angina preparation. Its comparative pharmacodynamic, pharmacokinetic and clinical study].
Blagodatskikh, SV; Martsevich, SIu; Metelitsa, VI; Piotrovskiĭ, VK; Riabokon', OS, 1986
)
0.27
"The antianginal and hypotensive activity and the pharmacokinetic properties of glyceryl 1-nitrate (G-1-N) were examined in the rat and in the dog."( [Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs].
Laufen, H; Leitold, M; Yeates, RA, 1986
)
0.27
" The plasma half-life is about 2 to 3 minutes; plasma clearance values reported vary from 216 to 3270 L/h, indicating extensive non-hepatic metabolism."( Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations.
Bogaert, MG, 1987
)
0.27
" Inter-subject variances of pharmacokinetic parameters were low compared to variances reported for glyceryl trinitrate."( Glyceryl-1-nitrate pharmacokinetics in healthy volunteers.
Laufen, H; Leitold, M, 1987
)
0.27
" The half-life of elimination of G-2-N in the rat came to 2 h, and the substance was 100% bioavailable."( [The pharmacology and pharmacokinetics of glycerol-2-nitrate].
Laufen, H; Leitold, M; Yeates, RA, 1987
)
0.27
"The pharmacokinetic and pharmacodynamic aspects of organic nitrates are discussed, with particular emphasis on the 3 major organic nitrates currently in use, nitroglycerin (NTG), isosorbide dinitrate and isosorbide-5-mononitrate."( Pharmacokinetics and pharmacodynamics of organic nitrates.
Fung, HL, 1987
)
0.47
" The purpose for this present study was to determine the pharmacokinetic parameters of nitroglycerin and the dinitrate metabolites after multiple intravenous infusions of nitroglycerin in healthy volunteers."( Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers.
Benet, LZ; Noonan, PK; Williams, RL, 1985
)
0.77
"3-1 liter/min/kg), (b) a large volume of distribution (approximately 3 liters/kg), and (c) a rapid plasma half-life (approximately 3 min)."( Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects.
Fung, HL; Golden, LH; Goldfarb, A; McNiff, EF; Yacobi, A; Young-Chang, FM, 1981
)
1.71
" Pharmacokinetic calculations based on plasma concentrations should be viewed with caution, as the data on which these calculations are based are often very limited, and the very rapid disappearance of for example glyceryl trinitrate from plasma makes the choice of an appropriate kinetic model and exact calculations difficult."( Clinical pharmacokinetics of organic nitrates.
Bogaert, MG,
)
0.13
" A terminal half-life of approximately 15 min was observed after high intravenous bolus doses of nitroglycerin."( Pharmacokinetics of nitroglycerin after parenteral and oral dosing in the rat.
Fung, HL; Kamiya, A; Maier, GA; Ogata, H, 1984
)
0.81
"A comparative pharmacokinetic study was performed for three different nitroglycerin application forms."( [Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation (author's transl)].
Maier-Lenz, H; Ringwelski, L; Windorfer, A, 1980
)
0.75
" Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied."( Clinical pharmacokinetics of nitrates.
Bogaert, MG, 1994
)
0.29
" We have obtained pharmacodynamic data on NTG-induced hemodynamic tolerance in a rat model of congestive heart failure (CHF), which we have shown to mimic human behavior toward NTG in vivo."( Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure.
Bauer, JA; Fung, HL, 1994
)
0.59
"The pharmacodynamic equivalence of a fluorohydrocarbons-(FCH)-free glyceryl trinitrate (GTN, CAS 55-63-0)-containing pump spray with low ethanol content (Nitrolingual-Spray N; TL) versus a conventional FCH-containing GTN spray (Nitrolingual-Spray, R) as reference and a FCH-free GTN pump spray with high ethanol content (TH) was investigated by digital plethysmography (DPG) in a double-blinded, placebo-controlled (TL-matched placebo spray), randomized, period-balanced, 4-way cross-over design."( [Pharmacodynamic equivalence and clinical trial of a new fluorocarbon-free glycerol trinitrate pump spray with low ethanol content in comparison to a fluorocarbon-containing reference spray and a fluorocarbon-free pump spray with high ethanol content].
Belz, GG; de Mey, C; Erb, K; Mutschler, H; Roll, S; Zimmermann, T, 1994
)
0.29
" For each subject parametric pharmacodynamic modeling was performed with simultaneous analysis utilizing the DBP vs."( Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glyceryl dinitrate upon blood pressure in healthy volunteers.
Benet, LZ; Gumbleton, M, 1993
)
0.29
"To construct a pharmacokinetic (PK) model and to determine population PK parameters of nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN)."( Novel pharmacokinetic modelling of transdermal nitroglycerin.
Auclair, B; Ducharme, MP; Ngoc, AH; Sirois, G, 1998
)
0.78
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3
"The purpose of this study was to assess the ability of our previously constructed pharmacokinetic (PK) model to describe nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN) plasma concentrations after a single-dose application of a GTN transdermal matrix delivery system."( Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system.
Auclair, B; Ducharme, MP; Ngoc, AH; Sirois, G, 1998
)
0.79
" Many novel antimigraine compounds are in clinical development, yet full characterization of each one's pharmacodynamic behavior is a formidable task due to the difficulty in studying a migraineur during an attack."( The pharmacodynamics of sumatriptan in nitroglycerin-induced headache.
Forrest, A; Fullerton, T; Gengo, FM; Komorowski-Swiatek, D, 1999
)
0.57
" The ratios of the Cmax were within said limits for the signal metabolite 1,2-GDN and only slightly below (0."( Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch.
Caplain, H; Gualano, V; Rovati, LC; Santoro, A; Setnikar, I, 2000
)
0.31
" Since GDNs have an effect on haemodynamic function, pharmacokinetic analyses that include the parent drug as well as the metabolites are important."( Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites.
Hashimoto, S; Kobayashi, A, 2003
)
0.32
"The pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d)pyrimidine-7-one (DA-8159), a new erectogenic, and nitroglycerin has been evaluated in rats."( Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats.
Bae, SK; Kwon, JW; Lee, DC; Lee, MG; Lee, SJ; You, M, 2005
)
0.71
"In the present study, we aimed to elucidate the pharmacodynamic action of DL and its mechanism in an animal model of migraines induced by glyceryl trinitrate (GTN)."( Pharmacodynamic action and mechanism of Du Liang soft capsule, a traditional Chinese medicine capsule, on treating nitroglycerin-induced migraine.
Chen, L; Hou, M; Liu, Y; Tang, Q; Xu, X; Xue, Q; Yang, S; Zhang, X, 2017
)
0.67
"In the pharmacodynamic action assay, DL (1."( Pharmacodynamic action and mechanism of Du Liang soft capsule, a traditional Chinese medicine capsule, on treating nitroglycerin-induced migraine.
Chen, L; Hou, M; Liu, Y; Tang, Q; Xu, X; Xue, Q; Yang, S; Zhang, X, 2017
)
0.67
" Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for a pharmacodynamic drug interaction affecting blood pressure."( Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Ayalasomayajula, S; Buchbjerg, J; Golor, G; Hinder, M; Langenickel, TH; Pal, P; Prescott, MF; Schuehly, U; Sunkara, G, 2018
)
0.74
"The results from this study demonstrate no pharmacodynamic drug interaction between nitroglycerin and sacubitril/valsartan in healthy subjects, suggesting that no change of dose selection and escalation recommendations or clinical monitoring during nitroglycerin administration is required."( Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Ayalasomayajula, S; Buchbjerg, J; Golor, G; Hinder, M; Langenickel, TH; Pal, P; Prescott, MF; Schuehly, U; Sunkara, G, 2018
)
0.96

Compound-Compound Interactions

The effects of intravenous nitroglycerin (NTG) combined with dopamine on intracranial pressure (ICP) and cerebral arteriovenous oxygen difference (AVDO2) were studied in 11 patients with acute subarachnoid haemorrhage.

ExcerptReferenceRelevance
" The aim of this study was to examine the systemic and splanchnic hemodynamic responses to terlipressin administered alone or combined with nitroglycerin in patients with cirrhosis."( [Hemodynamic effects of the administration of terlipressin alone or combined with nitroglycerin in patients with cirrhosis].
Gaudin, C; Hadengue, A; Kleber, G; Lebrec, D; Moreau, R; Sogni, P; Soubrane, O, 1992
)
0.71
" These data suggest improvements in cardiac function from the combination of celiprolol and nitrate therapy which were not achieved by either agent when used as monotherapy; they afford an interesting insight into the manner in which such widely utilised therapeutic modalities interact in coronary artery disease."( A rest and exercise haemodynamic evaluation of a new cardio-selective beta-adrenoceptor blocker celiprolol alone and in combination with nitroglycerine in ischaemic heart disease.
Frais, MA; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1986
)
0.47
" This potentially beneficial drug combination warrants further trial in patients with myocardial ischemia."( Hemodynamic effects of nitroglycerin combined with diltiazem in patients with coronary artery disease.
Cremer, KF; Feldman, RL; Gelman, JS; Hill, JA; Joyal, M; Pepine, CJ, 1984
)
0.58
" Nitroglycerin has little effect on cerebral blood flow even when used in combination with dopamine."( Cerebral blood flow and intracranial pressure in the dog during intravenous infusion of nitroglycerin alone and in combination with dopamine.
Kistler, JP; Lees, RS; von Essen, C; Zervas, NT,
)
1.26
"Patients with AMI received either 15 g NAC infused over 24 hours (n = 20) or no NAC (n = 7), combined with intravenous NTG and streptokinase."( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects.
Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995
)
0.56
"NAC in combination with NTG and streptokinase appeared to be safe for the treatment of evolving AMI and was associated with significantly less oxidative stress, a trend toward more rapid reperfusion, and better preservation of left ventricular function."( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects.
Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995
)
0.56
"The effects of intravenous nitroglycerin (NTG) combined with dopamine on intracranial pressure (ICP) and cerebral arteriovenous oxygen difference (AVDO2) were studied in 11 patients with acute subarachnoid haemorrhage (SAH)."( Effects of intravenous nitroglycerin combined with dopamine on intracranial pressure and cerebral arteriovenous oxygen difference in patients with acute subarachnoid haemorrhage.
Aoki, H; Boku, E; Goda, K; Imanishi, M; Iwanaga, H; Koshimae, N; Okuchi, K; Sakaki, T; Tokunaga, H, 1995
)
0.9
"The cardiovascular effects of NT-1, a new patch form of nitroglycerin, alone and in combination with nifedipine in conscious dogs were examined."( Cardiovascular effects of NT-1, a new patch form of nitroglycerin, alone and in combination with nifedipine in conscious dogs.
Kanda, A; Kanou, M; Kyuki, K; Yamaguchi, K; Yoshida, M, 1995
)
0.79
"min-1) (NTG group, n = 5), combined with dopamine (3-5 mg."( [Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation].
Hagihira, S; Inagaki, Y; Mashimo, T; Mori, T; Okuno, Y; Takashina, M; Yoshiya, I, 1997
)
0.3
"9 years; 11/30 patients aged <6 months) underwent open heart procedures on the beating heart for simple and complex cardiac malformations using a self designed perfusion system with pressure- and volume-controlled continuous hypothermic coronary perfusion (PVC-CONTHY-CAP) in combination with ultra-short beta1-receptor blockade (Esmolol) and nitroglycerine for myocardial protection."( Myocardial protection by pressure- and volume-controlled continuous hypothermic coronary perfusion in combination with Esmolol and nitroglycerine for correction of congenital heart defects in pediatric risk patients.
Borowski, A; Eichstaedt, HC; Korb, H; Raji, MR; Schickendantz, S, 1998
)
0.68
"4 U/kg vasopressin combined with 5 microg/kg nitroglycerin (n = 7)."( Vasopressin combined with nitroglycerin increases endocardial perfusion during cardiopulmonary resuscitation in pigs.
Lindner, KH; Lurie, KG; Mayer, H; Prengel, AW; Wenzel, V, 1998
)
0.86
"To compare the maternal and fetal side effects of transdermal nitroglycerin and intravenous fenoterol combined with magnesium sulfate in a prospective randomised study."( Maternal and fetal side effects of tocolysis using transdermal nitroglycerin or intravenous fenoterol combined with magnesium sulfate.
Gross, W; Kähler, C; Möller, A; Möller, U; Richter, S; Schleussner, E; Seewald, HJ, 2003
)
0.8
" The present study investigated the efficacy of NTG combined with the nonsteroidal anti-inflammatory drug etodolac for the treatment of CPP."( Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial.
Eidelman, LA; Glantz, L; Godovic, G; Kramer, M; Lekar, M, 2004
)
0.63
" Although kynurenic acid does not cross the BBB, its precursor, kynurenine, if combined with probenecid, crosses it readily."( Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.
Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Mihály, A; Németh, H; Toldi, J; Vécsei, L, 2007
)
0.34
" The present investigation tested the hypothesis of whether kynurenine in combination with systemically administered probenecid protects second-order trigeminal neurons against stimulation arriving via central processes of trigeminal ganglion cells."( Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid.
Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Németh, H; Toldi, J; Vécsei, L, 2007
)
0.34
" Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of L-kynurenine (L-KYN) combined with probenecid (PROB) or with 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC."( l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus.
Bohár, Z; Fülöp, F; Párdutz, A; Tajti, J; Toldi, J; Vámos, E; Varga, H; Vécsei, L, 2009
)
0.57
" The aim of this study is to compare the acute hemodynamic effects of inhaled nitroglycerine (iNTG), intravenous nitroglycerine (IV NTG) alone and their combination with intravenous dobutamine (IV DOB) during the early postoperative period, in patients with PAH undergoing mitral valve or double valve replacement surgery."( Acute hemodynamic effects of inhaled nitroglycerine, intravenous nitroglycerine, and their combination with intravenous dobutamine in patients with secondary pulmonary hypertension.
Choudhury, M; Chowdhury, U; Kapoor, PM; Kiran, U; Mandal, B,
)
0.63
" Only iNTG produced selective pulmonary vasodilatation, while IV NTG and its combination with IV dobutamine had a significant concomitant systemic vasodilatory effect."( Acute hemodynamic effects of inhaled nitroglycerine, intravenous nitroglycerine, and their combination with intravenous dobutamine in patients with secondary pulmonary hypertension.
Choudhury, M; Chowdhury, U; Kapoor, PM; Kiran, U; Mandal, B,
)
0.4
"The diagnostic and prognostic role of nitroglycerin-induced dilation (NID) combined with ergonovine provocation test in patients with suspected VSA patients is not clear."( Diagnostic and prognostic role of nitroglycerin-induced dilation in patients with suspected vasospastic angina, combined with ergonovine provocation test.
Ahn, T; Han, SH; Jang, AY; Kang, WC; Kim, M; Lee, K; Oh, PC; Suh, SY, 2021
)
1.17
"This study aimed to assess the efficacy and safety of Tongxinluo capsule (TXLC) in combination with conventional therapies for treating stable angina pectoris (SAP) through a comprehensive meta-analysis and systematic review."( Tongxinluo capsule in combination with conventional therapies for stable angina pectoris: A meta-analysis and systematic review.
Feng, R; Gao, Q; Ji, X; Jiang, K; Li, Y; Lin, Q; Liu, J; Pan, Y; Qu, X; Wang, W; Wei, D; Xia, J; Xie, L; Zhang, R; Zheng, P, 2023
)
0.91

Bioavailability

The pharmacokinetics and bioavailability of nitroglycerin (GTN) and its metabolites were compared after a single 14-hour application of Transderm-Nitro, Nitrodisc, and Nitro-Dur II. It is concluded that alteredBioavailability of tetrahydrobiopterin is involved in the pathophysiology of endothelial dysfunction seen in nitrog Glycerin tolerance.

ExcerptReferenceRelevance
" Bioavailability and physical tests were conducted on the compressed tablet and two leading brands of molded tablets."( Stabilized compressed nitroglycerin tablets.
Chafetz, L; Daly, RE; Goodhart, FW; Gucluyildiz, H; Ninger, FC, 1976
)
0.57
" The results demonstrate that changes in skin temperature may cause extensive short-term changes in the bioavailability of nitroglycerin."( Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin.
Bredesen, JE; Gjesdal, K; Klemsdal, TO, 1992
)
0.79
" The relative bioavailability of the tablets in comparison with the oral solution was 70 per cent based on metabolite concentrations."( Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets.
Curry, SH; Green, P; Kwon, HR, 1992
)
0.61
" The lack of pharmacokinetic data is related to the difficulty in assaying nitrates and there are at present no definitive data describing the effect of aging on their bioavailability or elimination."( Nitrates in the elderly. Pharmacological considerations.
Kelly, JG; O'Malley, K,
)
0.13
" This ratio may thus be indicative of the bioavailability of nitroglycerin following transdermal application."( Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.
Benet, LZ; John, V; Liang-Gee, W; Lin, ET; Thakker, KM; Williams, RL, 1991
)
1.97
" Changes of bioavailability as well as of systemic clearance might be involved in the exercise-induced increase in plasma nitroglycerin concentrations."( Influence of exercise on nitroglycerin plasma concentrations after transdermal application.
Bogaert, MG; Dubois, JP; Lefebvre, RA; Sioufi, A; Teirlynck, O, 1990
)
0.79
" Bioavailability of oral GTN (0."( Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs.
Benet, LZ; Lee, FW; Metzler, CH; Salmonson, T, 1990
)
0.28
" Experimental examinations revealed that Nitrogranulong showed the same bioavailability as Nitro-Mack-Retard and sustac, produced a prolonged coronarolytic effect, and caused the hemodynamic and ECG changes typical of trinitroglycerol."( [Pharmacodynamics and results of a clinical trial of nitrogranulong, a new Soviet long-acting preparation of nitroglycerin].
Alibekov, SD; Belova, LF; Belozerova, OP; Ivanov, AA; Rusakova, KA; Sakovich, GS; Sokolov, SIa; Trumpe, TE, 1990
)
0.49
" The bioavailability of 1,3-GDN after gel base systems with and without a membrane was relatively high."( Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis.
Iwaki, M; Kanokogi, A; Ogiso, T; Terao, Y, 1990
)
0.56
" Preparation B exhibits a superior bioavailability and a more rapid onset of haemodynamic efficacy."( Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system.
Harder, S; Huber, T; Merz, PG; Rietbrock, N, 1990
)
0.28
" The plasma levels varied considerably from one patient to another, confirming that the bioavailability of transdermal nitroglycerin is extremely variable in children."( [Transcutaneous transport of trinitrin in children after application of nitroglycerin patches].
Dupuis, C; Francart, C; Olive, G; Rey, E; Vaksmann, G, 1990
)
0.72
"The relative bioavailability of a glyceryl trinitrate (GTN) spray (Nitro-Corangin Spray) compared to that of another GTN Spray was evaluated in 12 healthy male volunteers using an open, randomized cross-over design with two treatment phases."( [Biological availability of glycerol trinitrate after sublingual administration].
Herling, C; Muck, B; Rietbrock, N, 1989
)
0.28
"5 mg nitroglycerin proved to possess better bioavailability than Sustac (6."( [Evaluation of biological equivalency of Sustonit (Polfa) and Sustac by plethysmography].
Filczewski, M; Kobylińska, M; Sadowski, Z, 1989
)
0.79
" In the present investigation, the bioavailability of oral nitroglycerin when administered in a capsule dosage form and as a solution was determined."( The bioavailability of oral nitroglycerin.
Benet, LZ; Noonan, PK, 1986
)
0.81
"The purpose of this study was to measure the bioavailability of nitroglycerin from a new transdermal delivery system, Nitro-Dur II, relative to that of Nitro-Dur."( Relative bioavailability of a new transdermal nitroglycerin delivery system.
Babcock-Atkinson, E; Cohen, A; Golub, A; Gonzalez, MA; Noonan, PK; Ray, M; Ruggirello, D; Tomlinson, J, 1986
)
0.77
"5 to 50 mg) was administered in randomized fashion to three skin sites, arm, chest, or thigh, to compare the hemodynamic effects and bioavailability in nine patients with severe congestive heart failure."( Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure.
Armstrong, PW; Moe, G, 1986
)
0.53
" The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets."( [Dinitrosorbilong--a new Soviet anti-angina preparation. Its comparative pharmacodynamic, pharmacokinetic and clinical study].
Blagodatskikh, SV; Martsevich, SIu; Metelitsa, VI; Piotrovskiĭ, VK; Riabokon', OS, 1986
)
0.27
" The bioavailability of the 20 mg tablet relative to the 20 mg drops was 98."( Pharmacokinetics of oral glycerol-1-nitrate.
Laufen, H; Leitold, M; Yeates, RA, 1986
)
0.27
"Ten patients with chronic congestive heart failure were studied to assess the hemodynamic effects and bioavailability of a transdermal nitroglycerin delivery system."( Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure.
Armstrong, PW, 1987
)
0.73
" The bioavailability of G-1-N in the rat and in the dog is practically 100%."( [Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs].
Laufen, H; Leitold, M; Yeates, RA, 1986
)
0.27
" The oral bioavailability on the basis of areas under the curve amounted to 88."( Glyceryl-1-nitrate pharmacokinetics in healthy volunteers.
Laufen, H; Leitold, M, 1987
)
0.27
" The relative bioavailability of Nitroderm and Trinitrolong according to the pharmacokinetic data was 29% and 256%, respectively, of sublingual NG tablets."( New transdermal and transmucosal nitroglycerin delivery systems in patients with ischaemic heart disease.
Blagodatskikh, SV; Metelitsa, VI; Piotrovskii, VK; Ryabokon, OS, 1987
)
0.55
" This preliminary model suggests that transdermal bioavailability for a drug metabolized in the skin can be reasonably estimated."( Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.
Benet, LZ; Nakashima, E; Noonan, PK, 1987
)
0.49
" Compared to the oral route, losses in bioavailability due to first-pass liver metabolism are reduced."( Transdermal delivery of drugs.
Brown, L; Langer, R, 1988
)
0.27
" We conclude that the metabolism of ISDN and GTN by the GIT may contribute to the high clearance of these organic nitrates, and the low oral bioavailability of ISDN."( Patterns of isosorbide dinitrate and glyceryl trinitrate metabolites formed by selected segments of the rabbit gastrointestinal tract.
Bennett, BM; Brien, JF; MacMillan, H; Marks, GS; Nakatsu, K; Tam, GS, 1988
)
0.27
" Each subject also received intravenous infusions of nitroglycerin so that the absolute bioavailability could be evaluated."( Incomplete and delayed bioavailability of sublingual nitroglycerin.
Benet, LZ; Noonan, PK, 1985
)
0.77
"Several recent studies have shown that hydralazine and nitroglycerin may increase the apparent oral bioavailability of high-clearance drugs."( Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow.
Cumella, JC; Lalka, D; Middleton, E; Svensson, CK; Tronolone, M, 1985
)
0.82
" The marked reduction in skin blood flow by vasopressin did not decrease the steady-state plasma concentration of NTG nor the estimated cutaneous absorption rate of NTG ointment, indicating that cutaneous blood flow is not an important determinant in the absorption of NTG ointment."( Pharmacokinetic-hemodynamic interactions between vasopressin and nitroglycerin: comparison between intravenous and cutaneous routes of nitrate delivery.
Blei, AT; Friedman, S; Fung, HL; Gottstein, J; Robertson, G,
)
0.37
" Trinitrin and its derivatives occupy an intermediate position because of their relatively low bioavailability after oral administration: long-term administration is not always easy and may require special modes of administration (i."( [Classification and principles of the use of vasodilators in the treatment of left ventricular insufficiency].
Cattan, S; Degeorges, M; Guérin, F; Pailleret, JJ; Weber, S, 1985
)
0.27
"The absolute bioavailability of glyceryl trinitrate from a transdermal therapeutic system (Nitroderm TTS, 20 cm2) was assessed with a new method in 6 healthy volunteers."( Absolute bioavailability of glyceryl trinitrate from a transdermal system, assessed by digital plethysmography.
Bircher, J; Bührer, M; Isenschmid, M; Müller, M; Vorkauf, H, 1985
)
0.27
" The bioavailability buccally is 47%."( Disposition of nitroglycerin in the beagle dog after intravenous and buccal administration.
Ritschel, WA; Shaaya, AN; Tan, HS, 1985
)
0.62
" Significant advances in nitrate formulations and delivery systems have been made in providing better bioavailability and sustained plasma concentrations of these drugs."( Nitrate formulations and drug delivery systems--an overview.
Fung, HL, 1985
)
0.27
" When GTN is infused through PVC tubing, the dosage cannot be controlled and any assessment of pharmacokinetics or absolute bioavailability becomes invalid."( [The effect on biologic availability of the choice of infusion material in nitroglycerin therapy].
Bonn, R; Cawello, W, 1983
)
0.5
" The absolute bioavailability of topical nitroglycerin was 56."( Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism.
Kosobud, L; Noonan, PK; Smeach, S; Wester, RC, 1983
)
0.77
" After oral administration, plasma concentrations are very low; with sublingual or cutaneous administration, higher plasma concentrations can be obtained, suggesting a high first-pass extraction after oral administration, but quantitative data on bioavailability are lacking."( Clinical pharmacokinetics of organic nitrates.
Bogaert, MG,
)
0.13
" The specific and sensitive HPLC-TEA method developed in this study provides a reliable and rapid assay for the routine analysis for metabolism or bioavailability studies of nitrate esters and their metabolites in plasma of blood, with a detection limit as low as 1 ng ml-1."( Measurement of plasma concentrations of vasodilators and metabolites by the TEA Analyzer.
Goff, EU; Yu, WC,
)
0.13
"After application of an ointment of glycerol trinitrate (nitroglycerin, Nitrofortin; in the following briefly called GTN) the bioavailability of the unchanged GTN was evaluated."( [Bioavailability of glycerol trinitrate (nitroglycerin) from an ointment preparation].
Fink, E; Gielsdorf, W; Jaeger, H; Schlegel, E; Settlage, JA, 1983
)
0.78
" The different peripheric vascular effect found in the two groups was considered as a consequence of the increased drug bioavailability in cirrhotics, caused by portosystemic shunts."( [Strain-gauge plethysmographic measurement of the systemic bioavailability of oral nitroglycerin in liver cirrhosis].
Albano, O; Altomare, E; Buonamico, P; Carbone, P; D'Ercole, M; Palasciano, G; Portincasa, P; Pugliese, D; Sabba', C; Stufano, N, 1983
)
0.49
" The bioavailability of intraportal and intrajejunal nitroglycerin is influenced by the extent of portal systemic collaterals."( Portal-systemic shunting and the hemodynamic effects of nitroglycerin in the rat.
Blei, AT; Gottstein, J; O'Reilly, DJ, 1984
)
0.76
" The bioavailability of oral nitroglycerin (F) showed an apparent Michaelis-Menten dependency on dose."( Pharmacokinetics of nitroglycerin after parenteral and oral dosing in the rat.
Fung, HL; Kamiya, A; Maier, GA; Ogata, H, 1984
)
0.88
"The rate of percutaneous absorption of nitroglycerin from different ointment preparations was studied in the rabbit using an indirect method which suffices bioavailability requirements."( Evaluation of nitroglycerin ointments in the rabbit.
Grummich, K; Ritschel, WA; Ritschel-Beurlin, G, 1980
)
0.89
"The relative importance of the effect of absorption and first-pass extraction in bioavailability and clinical effectiveness of oraldihydroergotamine (DHE) was examined in six subjects with orthostatic hypotension."( Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension.
Bobik, A; Esler, M; Jennings, G; McLean, A; Skews, H, 1981
)
0.26
"5-mg/kg dose) gave a mean +/-SD bioavailability of 26."( Rectal absorption of nitroglycerin in the rat: avoidance of first-pass metabolism as a function of rectal length exposure.
Fung, HL; Kamiya, A; Ogata, H, 1982
)
0.58
"The pharmacokinetics and bioavailability of nitroglycerin (GTN) and its metabolites, 1,2-glyceryl dinitrate (1,2-GDN) and 1,3-glyceryl dinitrate (1,3-GDN), were compared after a single 14-hour application of Transderm-Nitro (Ciba-Geigy, Summit, NJ), Nitrodisc (GD Searle, Chicago, IL), and Nitro-Dur II (Key Pharmaceuticals, Kenilworth, NJ) systems to 18 healthy male subjects on 3 separate occasions."( Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique.
Chan, K; Cipriano, A; Joshi, JC; Morgan, JM; Piraino, AJ; Redalieu, E; Sun, JX, 1995
)
0.8
"8 mg GTN showed somewhat lower bioavailability of GTN and its metabolites than to the reference."( Clinical pharmacological equivalence of a novel FCH-free GTN spray with low ethanol content vs a FCH-containing GTN spray.
Belz, GG; Blume, H; de Mey, C; Erb, K; Mutschler, H; Zimmermann, T, 1995
)
0.29
"The study objective was to determine the bioavailability and main pharmacokinetic parameters of glyceryl trinitrate (GTN, CAS 55-63-0) following cutaneous application of two different glyceryl trinitrate patches using a randomized cross-over design."( Bioequivalence evaluation of two glyceryl trinitrate patches after 12-h usage in healthy volunteers.
Bonn, R; Fritschi, E; Hutt, V; Pabst, G; Sauter, K, 1994
)
0.29
"In the course of this study both the bioavailability and main pharmacokinetic parameters of the glyceryl trinitrate (GTN, CAS 55-63-0) metabolites 1,2 and 1,3-glyceryl dinitrate (1,2-GDN and 1,3-GDN) were to be determined following transdermal application of a glyceryl trinitrate test patch (Deponit 5) and an already marketed reference patch."( Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers.
Bonn, R; Fritschi, E; Hutt, V; Pabst, G; Sauter, K, 1994
)
0.29
" The data were obtained in a bioavailability study of two sprays of glyceryl trinitrate, which differed in their galenical characteristics and in the dose of GTN (0."( Comparison of the effects of two different galenical preparations of glyceryl trinitrate on pulmonary artery pressure and on the finger pulse curve.
Bonn, R; Buschmann, M; Jähnchen, E; Rehe, A; Roskamm, H; Schnellbacher, K; Trenk, D; Wiegand, A, 1993
)
0.29
"These data indicate that hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans and suggest that the bioavailability of nitric oxide is decreased in hyperhomocyst(e)inemic humans."( Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.
Creager, MA; Gerhard, M; Omland, T; Tawakol, A; Wu, JT, 1997
)
0.3
" Vascular NO bioavailability as assessed with ESR spectroscopy using iron-thiocarbamate as a trap for NO was significantly reduced in tolerant vessels."( Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability.
Duncker, L; Förstermann, U; Hartmann, M; Hink, U; Li, H; Matheis, E; Meinertz, T; Mollnau, H; Münzel, T; Oelze, M; Skatchkov, M; Warnholtz, A, 2000
)
0.63
"The pharmacokinetic characteristics and the bioavailability of glyceryl trinitrate (GTN, CAS 55-63-0) and of its main metabolities 1,2-glyceryl dinitrate (1,2-GDN, CAS 621-65-8) and 1,3-glyceryl dinitrate (1,3-GDN, CAS 623-87-0) during a single 24-h application of three strengths of a newly developed GTN transdermal patch (Epinitril) were investigated."( Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch.
Caplain, H; Follet, M; Gualano, V; Rovati, LC; Santoro, A; Setnikar, I, 2000
)
0.31
" These data suggest that 1 cm(2)/kg transdermal doses of NTG may have a limited bioavailability or a higher clearance and minimal hemodynamic effects in children with congestive heart failure already receiving other medications, implying that higher doses should be used."( Effects of transdermal nitroglycerin in children with congestive heart failure: a Doppler echocardiographic study.
D'Athis, P; Francart, C; Godart, F; Pariente-Khayat, A; Pons, G; Rey, C; Rey, E; Vaksmann, G,
)
0.44
" Mechanisms responsible for endothelial dysfunction in hyperhomocyst(e)inaemia are poorly understood, but may involve impaired bioavailability of endothelium-derived nitric oxide (NO)."( Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans.
Bode-Böger, SM; Böger, RH; Haynes, WG; Knapp, HR; Lentz, SR, 2001
)
0.31
" During the 14-day application of EPI several GTN commonly induced systemic adverse reactions were observed, particularly headache, confirming the systemic bioavailability of GTN from the patch."( Assessment of skin safety of a new glyceryl trinitrate transdermal patch. Animal and human studies.
Rovati, LC; Santoro, A; Setnikar, I, 2001
)
0.31
" It is concluded that altered bioavailability of tetrahydrobiopterin is involved in the pathophysiology of endothelial dysfunction seen in nitroglycerin tolerance."( Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats.
Aldershvile, J; Boesgaard, S; Gruhn, N, 2001
)
0.75
" We previously identified increased vascular superoxide formation and reduced NO bioavailability as one causal mechanism."( Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta.
Hink, U; Klöss, S; Meinertz, T; Mollnau, H; Mülsch, A; Münzel, T; Oelze, M; Smolenski, A; Stasch, JP; Töpfer, A; Walter, U; Warnholtz, A, 2001
)
0.64
"In healthy humans, continuous treatment with nitroglycerin (GTN) causes nitric oxide synthase dysfunction, probably through the reduced bioavailability of tetrahydrobiopterin."( Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study.
Ahmed, S; Al-Hesayen, A; Burstein, JM; Gori, T; Kelly, S; Miner, SE; Parker, JD, 2001
)
0.89
" We hypothesize that the reduced bioavailability of tetrahydrobiopterin is involved in the pathogenesis of both phenomena."( Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study.
Ahmed, S; Al-Hesayen, A; Burstein, JM; Gori, T; Kelly, S; Miner, SE; Parker, JD, 2001
)
0.63
" Conclusively, nipradilol, beta-blocker with nitric oxide-releasing action, in contrast to the other beta-blockers and nitric oxide donors, showed a successful anti-atherosclerotic effect through the restoration of nitric oxide bioavailability and possible interaction with oxygen radicals."( Anti-atherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis.
Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Sumi, D; Thakur, NK; Tsunekawa, T, 2002
)
0.31
"Intracoronary infusion of BH4 restores coronary endothelial function by improving the bioavailability of endothelium derived nitric oxide in hypercholesterolaemic patients."( Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia.
Chayama, K; Fukuda, Y; Matsuda, K; Matsuura, H; Teragawa, H; Yamagata, T, 2002
)
0.31
" Nitrate tolerance increased bioavailability of NO in the heart without increasing formation of reactive oxygen species."( Nitrate tolerance does not increase production of peroxynitrite in the heart.
Baxter, GF; CsonkA, C; Csont, T; Dux, L; Ferdinandy, P; Görbe, A; Onody, A; Schulz, R, 2002
)
0.31
" Altered superoxide production and NO bioavailability have been implicated in contributing to the development of tolerance, an effect that may be ameliorated by the administration of antioxidants."( Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate.
Devine, AB; Dixon, LJ; Hamilton, P; Hanratty, CG; Leahey, WJ; McGrath, LT; McVeigh, GE; Morgan, DG; Wilson, M, 2002
)
0.31
" L-arginine has been used to improve endothelial function by increasing nitric oxide (NO) bioavailability and in animal models this in turn has attenuated the progression of atherosclerosis."( Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure.
Bennett-Richards, KJ; Bruckdorfer, KR; Deanfield, JE; Donald, AE; Kattenhorn, M; Oakley, GR; Rees, L; Varghese, Z, 2002
)
0.31
" Glyceryl trinitrate (GTN) that is normally subject to first pass elimination, may exhibit higher bioavailability in these patients."( Noninvasive evaluation of portal-systemic shunting by glyceryl trinitrate.
Aubrecht, J; Perlík, F; Slanar, O, 2002
)
0.31
" Under these conditions, enhanced expression of cyclooxygenase-2 might lead to increased production of vasoconstrictor prostanoids and reactive oxygen species that reduce the bioavailability of endothelium-derived nitric oxide."( Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
Duffy, SJ; Eberhardt, RT; Gokce, N; Holbrook, M; Keaney, JF; Maxwell, C; Morrow, JD; Palmisano, J; Price, DT; Vita, JA; Widlansky, ME, 2003
)
0.32
" The mechanistic relationship between impaired systemic nitric oxide (NO) bioavailability and platelet activation in vivo remains unclear."( Rapid regulation of platelet activation in vivo by nitric oxide.
Bauersachs, J; Channon, KM; Eigenthaler, M; Neubauer, S; Schäfer, A; Wiesmann, F, 2004
)
0.32
"In vitro and animal studies demonstrate that myeloperoxidase catalytically consumes nitric oxide as a substrate, limiting its bioavailability and function."( Serum myeloperoxidase levels independently predict endothelial dysfunction in humans.
Brennan, ML; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Mann, SA; Penn, MS; Shishehbor, MH; Vita, JA, 2004
)
0.32
" Basal and stimulated endothelial nitric oxide (NO) bioavailability was assessed by measurement of the responses to intra-arterial N(G)-monomethyl-l-arginine (l-NMMA) and bradykinin, respectively."( Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress.
Clapp, BR; Hingorani, AD; Kharbanda, RK; MacAllister, RJ; Mohamed-Ali, V; Stephens, JW; Vallance, P, 2004
)
0.32
"Inflammation causes widespread endothelial dysfunction, reduces vascular NO bioavailability and increases oxidative stress."( Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress.
Clapp, BR; Hingorani, AD; Kharbanda, RK; MacAllister, RJ; Mohamed-Ali, V; Stephens, JW; Vallance, P, 2004
)
0.32
" We conclude that in NTG-treated rabbits, endothelial nitric oxide production in mesenteric resistance arteries is reduced, possibly through a reduction in the bioavailability of L-arginine via an action mediated by superoxide."( Chronic nitroglycerine administration reduces endothelial nitric oxide production in rabbit mesenteric resistance artery.
Itoh, T; Kajikuri, J; Suzuki, Y; Suzumori, K; Watanabe, Y; Yamamoto, T, 2005
)
0.76
" Superoxide decreases the bioavailability of nitric oxide (NO) via its reaction that yields peroxynitrite."( Endothelial dysfunction in trauma patients: a preliminary communication.
Lang, JD; Mathru, M, 2005
)
0.33
"5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0."( 0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.
Easthope, SE; Fenton, C; Wellington, K, 2006
)
0.85
"Investigations from basic biology suggest that activation of the Rho/Rho kinase pathway reduces the bioavailability of nitric oxide (NO) and thereby promotes atherosclerosis and its clinical complications."( Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease.
Creager, MA; Ganz, P; Grunert, ME; Liao, JK; Nohria, A; Noma, K; Prsic, A; Rikitake, Y, 2006
)
0.33
"These findings demonstrate that NO bioavailability is reduced in hypertensive subjects with familial history of stroke."( Nitric oxide release is impaired in hypertensive individuals with familial history of stroke.
Balla, C; Cosentino, F; De Luca, N; De Sensi, F; De Siati, L; Francia, P; Musumeci, B; Rao, MA; Volpe, M, 2006
)
0.33
" Additional mechanisms involving blockade of Ca2+ entry in the vascular smooth muscle and increase in NO bioavailability contributes to beneficial effects of long-term propranolol treatment."( Vascular effects of long-term propranolol administration after chronic nitric oxide blockade.
Antunes, E; Claudino, MA; De Nucci, G; Priviero, FB; Teixeira, CE; Zanesco, A, 2007
)
0.34
"The present study aimed to elucidate the effect of long-term treatment with nitroglycerin (NTG) on the bioavailability of nitric oxide (NO) examined by a catheter-type NO sensor."( Evaluation of pharmacological modulation of nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor.
Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kuroi, A; Mochizuki, S, 2007
)
0.83
"We examined whether nitroglycerin (NTG)-induced impairment of nitric oxide (NO) bioavailability could be modified by a peroxisome proliferator-activated receptor (PPAR) gammaagonist."( Effect of pioglitazone on nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor.
Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kuroi, A; Mochizuki, S; Muragaki, Y; Tsujioka, H; Yoshida, K, 2008
)
0.97
" The failure of synthesis and/or the lost of nitric oxide bioavailability is the major feature of endothelial dysfunction and key factor initiating progression of atherosclerosis."( [Endothelium and nitric oxide].
Garaliene, V, 2008
)
0.35
" GTN bioactivation measured as activation of purified soluble guanylate cyclase or release of NO in the presence of WT- or E268Q-ALDH2 was markedly potentiated by superoxide dismutase, suggesting that bioavailability of GTN-derived NO is limited by co-generation of superoxide."( Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2.
Baral, PK; Beretta, M; Gorren, AC; Gruber, K; Koesling, D; Mayer, B; Russwurm, M; Schmidt, K; Wenzl, MV; Zeller, A, 2009
)
0.63
" According to a widely held view, oxidation of tetrahydrobiopterin (BH(4)) by peroxynitrite causes uncoupling of endothelial NO synthase (eNOS), resulting in reduced NO bioavailability and endothelial dysfunction under conditions of oxidative stress."( Evidence against tetrahydrobiopterin depletion of vascular tissue exposed to nitric oxide/superoxide or nitroglycerin.
Mayer, B; Rehn, M; Schmidt, K; Stessel, H; Wölkart, G, 2010
)
0.58
" However, it did not ameliorate intraplatelet NO bioavailability and endothelial function during the period studied."( Exercise training in doxorubicin-induced heart failure: effects on the L-arginine-NO pathway and vascular reactivity.
Brunini, TM; Carvalho, JJ; Carvalho, LC; de Castro, JP; Matsuura, C; Mendes-Ribeiro, AC; Resende, AC,
)
0.13
" One of the earliest events in the development of atherosclerosis is endothelial dysfunction, namely, a reduction in nitric oxide (NO) synthesis or its bioavailability within the peri-endothelial environment, where it is responsible for maintenance of vascular tissue integrity."( Endothelial dysfunction in type 2 diabetes.
Ferrannini, E; Natali, A, 2012
)
0.38
" Although not causal, endothelial dysfunction and reduced nitric oxide bioavailability are likely to play an important role in the maternal and fetal pathophysiology of this condition."( The nitric oxide pathway and possible therapeutic options in pre-eclampsia.
Everett, TR; Johal, T; Lees, CC; Wilkinson, IB, 2014
)
0.4
" We suggest that oxidative stress, MnSOD inhibition and depletion of glutathione pool in response to GTN treatment lead to decreased bioavailability of NO after GTN biotransformation in rat reticulocytes."( Biotransformation and nitroglycerin-induced effects on antioxidative defense system in rat erythrocytes and reticulocytes.
Curčić, MG; Dorđević, NZ; Marković, SD; Spasić, MB; Stajn, AS, 2014
)
0.72
" In the case of acute decompensated heart failure, there is a typical decreased bioavailability of nitric oxide (NO), which needs to be supplemented by exogenous nitrates."( Impact of intravenous nitroglycerin in the management of acute decompensated heart failure.
Brugts, JJ; den Uil, CA, 2015
)
0.73
" The present data suggest that the oxidative stress and reduced bioavailability of nitric oxide may contribute to attenuation of vasodilator responses to ACh and Ang II, and hyperreactivity to Ang II in the mesentery of preeclamptic rat, which may contribute to the increased peripheral vascular resistance and BP, as well as intrauterine growth restriction in L-NAME-induced PE."( Differential responses of mesenteric arterial bed to vasoactive substances in L-NAME-induced preeclampsia: Role of oxidative stress and endothelial dysfunction.
Amaral, TAS; Carvalho, LCRM; Costa, CA; Moura, RS; Ognibene, DT; Resende, AC; Rocha, APM, 2018
)
0.48
"Individual effects of nitrogen-based energetic materials (EMs) 2,4-dinitrotoluene (2,4-DNT), 2-amino-4,6-dinitrotoluene (2-ADNT), 4-amino-2,6-dinitrotoluene (4-ADNT), nitroglycerin (NG), and 2,4,6,8,10,12-hexanitrohexaazaisowurtzitane (CL-20) on litter decomposition, an essential biologically-mediated soil process, were assessed using Orchard grass (Dactylis glomerata) straw in Sassafras sandy loam (SSL) soil, which has physicochemical characteristics that support "very high" qualitative relative bioavailability for organic chemicals."( Energetic contaminants inhibit plant litter decomposition in soil.
Checkai, RT; Hawari, J; Kuperman, RG; Simini, M; Sunahara, GI, 2018
)
0.68
" Correlation analysis showed in the overall population that the less NO and EETs bioavailability increases during heating, the more flow-mediated dilatation is reduced."( Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients.
Bellien, J; Cailleux, AF; Duflot, T; Iacob, M; Joannidès, R; Lamoureux, F; Leuillier, M; Li, D; Moreau-Grangé, L; Morisseau, C; Prévost, G; Rémy-Jouet, I; Renet, S; Richard, V; Roche, C; Wils, J, 2019
)
0.51
"These results demonstrate that an increased EETs degradation by sEH and altered NO bioavailability are associated with conduit artery endothelial dysfunction in type 2 diabetic patients independently from their hypertensive status."( Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients.
Bellien, J; Cailleux, AF; Duflot, T; Iacob, M; Joannidès, R; Lamoureux, F; Leuillier, M; Li, D; Moreau-Grangé, L; Morisseau, C; Prévost, G; Rémy-Jouet, I; Renet, S; Richard, V; Roche, C; Wils, J, 2019
)
0.51
"Reduced bioavailability of the nitric oxide (NO) signaling molecule has been associated with the onset of cardiovascular disease."( The Generation of Nitric Oxide from Aldehyde Dehydrogenase-2: The Role of Dietary Nitrates and Their Implication in Cardiovascular Disease Management.
Bosco, F; Cardamone, A; Carresi, C; Coppoletta, A; Gliozzi, M; Macrì, R; Maiuolo, J; Mollace, R; Mollace, V; Muscoli, C; Musolino, V; Oppedisano, F; Palma, E; Scarano, F, 2022
)
0.72
" In vivo pharmacokinetic study demonstrated improved brain bioavailability of SUT-NEsG as compared to orally administered sumatriptan solution (SUT-SL)."( Quality by design for sumatriptan loaded nano-ethosomal mucoadhesive gel for the therapeutic management of nitroglycerin induced migraine.
Alharbi, HM; Almari, AH; Batool, S; Din, FU; Fatease, AA; Lahiq, AA; Shafique, U; Sohail, S, 2023
)
1.12

Dosage Studied

A moderate hypotension was induced by CV-1808, nifedipine, and nitroglycerin. A significant reduction in cardiac function was seen after dosing with propranolol. None of the K+ channel blockers had an effect on the dose-response curve to NO.

ExcerptRelevanceReference
" There is increasing evidence that certain orally administered nitrates at larger than usual dosage can further increase the tolerance to effort."( Pharmacotherapy of myocardial ischemia.
Gorlin, R, 1976
)
0.26
" Optimal daily dosage for nadolol was 100 mg, and 112 mg for propranolol."( Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris.
Dahlqvist, A; Furberg, B; Raak, A; Wrege, U, 1978
)
0.26
" The dosage was 3 x 80 mg/die during 4 weeks."( [Exertion-electrocardiographic and hemodynamic studies with oral verapamil in chronic ischemic heart disease].
Assmann, I; Fiehring, H; Oltmanns, G; Schwela, H, 1978
)
0.26
" Thus, the dosage of nitroglycerin may be critical in respect to infarct size, despite the beneficial hemodynamic effects of the drug."( Effects of intravenous nitroglycerin on hemodynamics and ischemic injury in patients with acute myocardial infarction.
Bussmann, WD; Kaltenbach, M; Schöfer, H, 1978
)
0.89
"A specific assay for nitroglycerin dosage forms using high-performance liquid chromatography was developed."( Specific high-performance liquid chromatographic assay for nitroglycerin in dosage forms.
Crouthamel, WG; Dorsch, B, 1979
)
0.82
" With a dosage of 3-10 mg/h the pressure lowering of the right circulation could be sustained."( [Treatment of decompensated valvular disease with nitroglycerin (author's transl)].
Himmler, FC; Klein, G; Volger, E; Wirtzfeld, A, 1979
)
0.51
"A rapid high-pressure liquid chromatographic method for determining the nitroglycerin concentration in liquid dosage forms and intravenous admixture solutions is presented."( Rapid and accurate stability-indicating assay for nitroglycerin.
Amann, AH; Baaske, DM; Carter, JE, 1979
)
0.75
" Advanced age modifies the approach to treatment; the choice of drugs and the dosage must be adjusted accordingly."( Drug therapy for cardiovascular disease in the aged.
Kennedy, RD, 1975
)
0.25
" All three agents diminished vascular resistance and lowered blood pressure, although they differed in the intensity of their effects (NP greater than PH = GTN) and in the steepness of their dose-response curves (NP greater than PH greater than GTN)."( Comparison of the cardiovascular effects of phentolamine, sodium nitroprusside and nitroglycerin in anaesthetized cats (comparison of vasodilators).
Hoffmann, A; Meier, M,
)
0.36
" A heart rate in the 50s does not preclude an increase in the dosage of propranolol when necessary."( Pathophysiology and medical management of angina pectoris.
Brest, AN; Duca, PR; Gottlieb, RS, 1977
)
0.26
" Quantitative comparisons were made from dose-response curves established for nitroglycerin (ng), PE nitrates, and other common organic nitrates after intrajugular administration."( Comparative vasodilator effects of nitroglycerin, pentaerythritol trinitrate and biometabolites, and other organic nitrates.
Davidson, IW; Di Carlo, FJ; Parker, JC, 1975
)
0.76
" The study indicated that this brand of nitroglycerin tablets might be handled like any other solid dosage form in hospital distribution systems without endangering patient care."( Stability of stabilized nitroglycerin tablets in typical distribution and administration systems.
Dorsch, B; Shangraw, R, 1975
)
0.83
" Its antianginal effectivess was investigated in 20 patients with documented coronary heart disease in a 44-wk study incorporating a prolonged 12-wk lead-in period, individualization of P dosage in a 6-wk dose-finding period, and a 24-wk doule-blind crossover phase."( Efficacy of beta adrenergic blockade in coronary heart disease: propranolol in angina pectoris.
Amsterdam, EZ; Mason, DT; Miller, RR; Olson, HG; Pratt, CM, 1975
)
0.25
"The influence of body position change on the arterial pressure and heart rate responses produced by acute short-acting and sustained-release dosage forms of nitroglycerin was evaluated in a series of chronically prepared, conscious beagle dogs."( Orthostatic influences on cardiovascular responses to nitroglycerin in conscious dogs.
Korol, B; McLaughlin, LJ; Miller, LD, 1976
)
0.7
"Increments in heart rate during the TNG test (sublingual nitroglycerin with assumption of upright posture), passive head-up tilt, and postrecumbency standing were compared to the effects of intravenous isoproterenol in 15 mild hypertensives during administration of placebo and two dosage levels of propranolol."( Heart rate responses during treatment of hypertension with propranolol. The clinical usefulness of the nitroglycerin test.
Hansson, L; Zweifler, AJ, 1976
)
0.72
" When keeping the heart rate constant by means of a pace maker, carbocromen even at higher dosage caused a clear-cut improvement."( [The effect of carbocromen on the ST segment of the epicardial electrocardiogram in a model of intermitting myocardial ischemia (author's transl)].
Kunath, B; Nitz, RE; Scholtholt, J; Sirbulescu, R, 1976
)
0.26
" Dose-response curves to nitroglycerin were constructed for 11 normotensive volunteers before and during treatment with a sustained-release formulation of isosorbide dinitrate, 80 mg, three times daily for 7 days and followed by concurrent treatment with NAC at a mean dose of 150 mg/kg/day, in divided doses, for 2 days."( Desensitization of nitrate-induced venodilation: reversal with oral N-acetylcysteine in humans.
Blaschke, TF; Hoffman, BB; Kongpatanakul, S; Vincent, J, 1992
)
0.59
"5 mM nitroglycerin shifted the dose-response curve to nitroglycerin to the right by a factor of 90, reflecting the development of tolerance."( In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Lappe, RW; Merkel, LA; Perrone, MH; Rivera, LM, 1992
)
0.8
" NOHb has not been identified previously in human subjects given nitroglycerin, and a significant dose-response relationship was observed between nitroglycerin and NOHb."( Nitric oxide hemoglobin in patients receiving nitroglycerin as detected by electron paramagnetic resonance spectroscopy.
Cantilena, LR; Frasur, S; Kruszyna, H; Kruszyna, R; Smith, RP; Wilcox, DE, 1992
)
0.78
" In nontolerant and tolerant dogs, however, L-methionine did not alter the dose-response of large epicardial artery dilation to intravenous GTN challenges and did not modify nitrate tolerance of the low pressure system of the dog."( Mechanisms of interaction between the sulfhydryl precursor L-methionine and glyceryl trinitrate.
Bassenge, E; Harrison, DG; Holtz, J; Just, H; Mülsch, A; Münzel, T, 1992
)
0.28
" A dosage of 4 mm nitroglycerin ointment per kilogram of body weight was applied to two patients with ischemia caused by vasospasm from indwelling radial artery catheterization and to two patients with ischemia resulting from dopamine extravasation."( Treatment of peripheral tissue ischemia with topical nitroglycerin ointment in neonates.
McCulloch, LM; Sola, A; Wong, AF, 1992
)
0.87
" Additional clinical research is therefore needed to determine the optimal intermittent dosing strategy."( Tolerance, rebound, and time-zero effect of nitrate therapy.
Frishman, WH, 1992
)
0.28
" The patients were studied without any pretreatment (n = 14) or after 1 week of treatment with the oral ACE inhibitor quinapril at a dosage of 10 mg/day (n = 11)."( Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure.
deCampora, P; DeLuca, N; Enea, I; Lembo, G; Mele, AF; Rendina, V; Romano, M; Rubattu, S; Tritto, C; Volpe, M, 1992
)
0.28
" To compare the venodilatory potency of nitroglycerin and of 1,2-GDN and 1,3-GDN in vivo, cumulative dose-response curves were established in nine healthy volunteers by use of the dorsal hand vein compliance technique."( Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins.
Benet, LZ; Blaschke, TF; Gumbleton, M; Haefeli, WE; Hoffman, BB, 1992
)
0.82
" Norepinephrine caused a parallel shift of the dose-response curve for CA(ven) in the presence of a lower baseline value."( Blockade of endothelium-derived relaxing factor synthesis with NG-nitro-L-arginine methyl ester leads to enhanced venous reactivity in vivo.
Raberger, G; Schemper, M; Schwarzacher, S; Weidinger, F, 1992
)
0.28
" Another suggested that no tolerance develops to intermittent dosing (18 mg/16 hr out of 24 hr) during exercise testing but no effect is seen on daily life ischemia."( Daily life ischemia and nitrate therapy.
Pepine, CJ, 1992
)
0.28
" The co-prescription of intravenous N-acetylcysteine at a dosage of 10 g/24 hours in 10 of the 19 patients did not affect the blood pressure or the response to the GTN bolus compared with the 9 other patients who had received placebo after double-blind randomisation."( [Evaluation of tolerance during intravenous administration of low dose of isosorbide dinitrate in the treatment of unstable angina].
Auclert, L; Blin, P; Guérin, C; Guérin, F; Pellois, A; Touiza, K; Weber, S, 1992
)
0.28
" Nitroglycerin itself was virtually undetectable after the solution and tablet preparations; the metabolites were consistently detectable from a few minutes after dosing to 24 h later."( Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets.
Curry, SH; Green, P; Kwon, HR, 1992
)
1.52
" Dose-response relationships to acetylcholine were not different between groups, except at the lowest concentration (-8 log M) where young dogs had enhanced relaxation responses."( Effects of increasing age on vascular responses of the in vivo femoral artery of adult beagles.
Kaiser, L; Ptu, S, 1992
)
0.28
" Tailoring the dosing and choice of medication to prevent or reduce ischemia may be important if potential disease-activity triggering mechanisms are to be attenuated."( Therapeutic implications of circadian variations in myocardial ischemia and related physiologic functions.
Pepine, CJ, 1991
)
0.28
"The efficacy of a controlled-release topical dosage form of glyceryl trinitrate (Nitroglycerin Transdermal Therapeutic System, Nitroderm TTS, NTG-TTS; CAS 55-63-0) was studied in the experimental model of congestive heart failure in beagles."( Efficacy of the glyceryl trinitrate transdermal therapeutic system in a dog model of heart failure.
Inukai, T; Katahira, J; Nakao, K; Tanaka, M, 1991
)
0.51
" Preincubation of contracted artery rings with GTP (100 microM) or guanosine (100 microM) before eliciting relaxations with nitrovasodilators significantly shifted the dose-response curves of nitrocompounds to the left and augmented the increases in cyclic GMP."( Modification of nitrovasodilator effects on vascular smooth muscle by exogenous GTP and guanosine.
Laustiola, KE; Manninen, V; Metsä-Ketelä, T; Pörsti, I; Vapaatalo, H; Vuorinen, P, 1991
)
0.28
" Three and 24 hr after the end of the infusion, each rabbit was anesthetized with pentobarbital and instrumented to monitor blood pressure, and dose-response curves were performed using SNAP or GTN."( Lack of tolerance to a 24-hour infusion of S-nitroso N-acetylpenicillamine (SNAP) in conscious rabbits.
Chern, WH; Han, BJ; Lee, FW; Shaffer, JE, 1992
)
0.28
" In comparison to placebo captopril 25 mg and 50 mg dosage increased time to 1 mm ST depression from 188."( The role of captopril as single therapy in hypertension and angina pectoris.
Akhras, F; Jackson, G, 1991
)
0.28
" IV TNG in low dosage is safe in the setting of acute myocardial infarction and modestly effective in relieving chest pain."( Intravenous nitroglycerin for acute myocardial infarction.
Borzak, S, 1991
)
0.66
" In conclusion, whereas nicorandil possesses a dilatory action on both large and small coronary arteries, in a clinical setting, with a daily dosage of 15-30 mg, part of the beneficial effects of nicorandil may be the result of a dilation of the large coronary arteries and may be due to the fact that a coronary steal phenomenon does not occur after nicorandil administration."( Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.
Hashimoto, K; Kinoshita, M; Ohbayashi, Y, 1991
)
0.53
"Sixty patients (31 male, 29 female) were studied in a 4-week double-blind parallel dose-response study."( A double-blind dose-response study of amlodipine in patients with stable angina pectoris.
Alfiero, R; Cocco, G, 1991
)
0.28
" nitrate tolerance--was observed in approximately one fourth of the patients, and was not prevented by a twelve-hour dosing interval on isosorbide dinitrate nor a six hour transdermal nitroglycerin-free interval."( [Prolonged action nitrates in stable angina pectoris].
Eidsaunet, W; Erikssen, J; Myhre, E; Røde, R; Thaulow, E, 1991
)
0.47
" Dose-response relations to norepinephrine, endothelium-dependent dilators (acetylcholine, histamine, and A23187), and nitroglycerin were done."( Depression of endothelium-dependent relaxation in aorta from rats with Brugia pahangi lymphatic filariasis.
Kaiser, L; Lamb, VL; Tithof, PK; Williams, JF, 1991
)
0.49
"Using an in vivo model of nitroglycerin tolerance in the CHF rat, we examined the effects of hydralazine bolus dosing during continuous nitroglycerin infusion."( Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure.
Bauer, JA; Fung, HL, 1991
)
0.84
" Numerous dosage formulas for the continuous administration of nitrates are currently used, although several studies have demonstrated the rapid development of tolerance during long-term treatment in patients with ischemic heart disease."( [Dose and time dependence of hemodynamic tolerance development during intravenous nitrate therapy in acute myocardial infarct].
Herrmann, G; Höfig, M; Meissner, A; Schulte, HM; Simon, R; Walek, T, 1991
)
0.28
" Lack of any significant effect of therapeutic dosage of glyceryl trinitrate on platelet--fibrin rich thrombus may explain the absence of a salutary action of this agent."( Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Mehta, JL; Nichols, WW; Nicolini, FA; Saldeen, TG, 1991
)
0.28
", the dose-response relations for NTG-induced reduction in blood pressure were shifted to 25-fold higher doses (P less than ."( Nitrate tolerance: effect of thiol supplementation during prolonged nitroglycerin infusion in an in vivo rat model.
Aldershvile, J; Boesgaard, S; Flachs, H; Petersen, JS; Poulsen, HE, 1991
)
0.52
" In the active drug groups, treatment was initiated with 15 mg/24 hours during the first week of double-blind dosing with subsequent weekly increases until the assigned dose was reached, after which the dose was held constant."( Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering Committee, Transdermal Nitroglycerin Cooperative Study.
, 1991
)
0.5
" Major (coronary substrate, study design) and minor (measuring devices, methods of evaluation) methodological problems make it difficult to precisely evaluate pharmacological effects such as dose-response relationship, duration of action, and selective responses, and to compare the effects of different drugs."( Response of coronary arteries to nitrates, the EDRF-donor SIN-1, and calcium antagonists.
Kober, G; Schulz, W, 1991
)
0.28
" This anti-anginal effect persists during long-term treatment without the development of tolerance; once-daily treatment produces a plasma nitrate profile that is high enough to give anti-anginal protection during the daytime, but low enough during the latter part of the dosage interval to avoid the development of tolerance."( Clinical experience with Imdur in angina pectoris. A review.
Nyberg, G, 1990
)
0.28
" After rapid dosage build-up to the maximal tolerated dose (decrease in pulmonary wedge pressure to 10 mm Hg or systolic blood pressure to 90 mm Hg), nitroglycerin (525 +/- 548 micrograms/min) was administered at a constant continuous intravenous infusion for a total of 24 hours."( Nitrate tolerance in heart failure: differential venous, pulmonary and systemic arterial effects.
Dakak, N; Flugelman, MY; Halon, DA; Lewis, BS; Makhoul, N; Merdler, A; Schneeweiss, A; Shefer, A, 1990
)
0.48
" Exercise tests were performed at time 0 (24 hours from application of last patch), at 4 and 12 hours after dosing at the end of first 7-day washout, at the end of the first month of treatment, at the end of the second month of treatment after crossover, at the end of 3 months of treatment with active patch and at the end of the second 7-day washout period."( Long-term efficacy of nitroglycerin patch in stable angina pectoris.
D'Alterio, D; Greco, R; Schiattarella, M; Tartaglia, P; Wolff, S, 1990
)
0.59
" While the organic nitrates are extremely effective in angina prophylaxis during acute therapy, there is increasing evidence that with many dosing regimens for oral and transdermal therapy, substantial attenuation of the antianginal effects develops."( Nitrate tolerance. A problem during continuous nitrate administration.
Parker, JO, 1990
)
0.28
" Many studies with oral dosing of isosorbide dinitrate or isosorbide-5-mononitrate at least three times daily have proven nitrate tolerance in patients with coronary artery disease and/or congestive heart failure."( Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.
Silber, S, 1990
)
0.5
" The dose-response curve of SNP was shifted to the right, and the relaxation to verapamil was slightly reduced."( Endothelium-derived relaxing factor influences renal vascular resistance.
Förstermann, U; Frölich, JC; Radermacher, J, 1990
)
0.28
" An important indicator for the effect achievable for a certain dose or for the necessary dosage to affect a defined reduction in ventricular filling pressures, is the magnitude of right atrial pressure."( [Nitrates in the treatment of heart failure].
Dirschinger, J; Hall, D; Rudolph, W, 1990
)
0.28
" Continuous administration of a drug should result in better control of the disease with fewer side effects and a marked increase in patient compliance than when traditional dosage forms are used."( Clinical efficacy of current transdermal drug delivery systems: a retrospective evaluation.
Banakar, U; Berba, J, 1990
)
0.28
" and oral dosing of GTN."( Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs.
Benet, LZ; Lee, FW; Metzler, CH; Salmonson, T, 1990
)
0.28
" Both the dosage forms of nitroglycerin administered in the effective amounts (in short- and long-term continuous treatment) significantly lowered the rate and total intensity of myocardial ischemia episodes at the expense of a significant decrease of the frequency and total intensity of PE."( [An assessment of the efficacy of a course of using different forms of prolonged-action nitrates in patients with stable stenocardia with the help of repeated daily ECG monitoring].
Bochkareva, EV; Kokurina, EV; Metelitsa, VI; Vodop'ianova, RS, 1990
)
0.58
" The agent was found to be low toxic and well tolerated in a dosage form."( [Pharmacodynamics and results of a clinical trial of nitrogranulong, a new Soviet long-acting preparation of nitroglycerin].
Alibekov, SD; Belova, LF; Belozerova, OP; Ivanov, AA; Rusakova, KA; Sakovich, GS; Sokolov, SIa; Trumpe, TE, 1990
)
0.49
" The VST method is especially useful to quantify drug plasma levels in pharmacokinetic evaluation of sustained-release dosage forms, where the precise quantification of low levels of drug is critical."( Application of a variance-stabilizing transformation approach to linear regression of calibration lines.
Banfield, C; Bialer, M; Gonzalez, MA; McLean, AM; Ruggirello, DA, 1990
)
0.28
" Six patients had negative results; out of the remaining six, three exhibited a significant increase in the dosage required for provoking ischemia."( Intravenous nifedipine prevents ergonovine-induced myocardial ischemia in patients with stable effort angina.
Brunelli, C; Caponnetto, S; Caudullo, M; Ghigliotti, G; Iannetti, M; Spallarossa, P, 1990
)
0.28
" In conclusion, transdermal nitroglycerin patches offer a convenient and cosmetically acceptable dosage form which has potential use in stable angina if administered as an intermittent regimen providing a patch-free period each night."( Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.
Goa, KL; Langtry, HD; Todd, PA, 1990
)
0.95
" These specific pathways of chemical degradation are likely to trigger off the development of nitrate tolerance if sophisticated dosage regimens are not maintained, because drugs which directly release NO like sodium nitroprusside or amylinitrite do not show this phenomenon."( Mechanisms of nitrate tolerance--influence of the metabolic activation pathways.
Noack, E, 1990
)
0.28
" In own long-term studies on 34 patients with coronary heart disease with clinical and haemodynamic evidence (pathologic increase of the end-diastolic pressure of the pulmonary arteries under ergometric load) of an exercise-induced heart insufficiency the efficacy of pentaerythril tetranitrate (PETN) and isosorbide dinitrate (ISDN) in chronic dosage titration use was tested."( [Long-term nitrate therapy in coronary heart disease--loss of effect by developing tolerance].
Dück, KD; Richard, F, 1990
)
0.28
" The ANF dose-response curves were similar in both tissues, however, relaxation was fast and transient in portal veins whereas it was sustained and of slow onset in aortas."( Different time course of atrial natriuretic factor-induced relaxation in rabbit aorta and portal vein.
Castañeda-Hernández, G; De León, H; Hong, E, 1990
)
0.28
" The dosage we use (a quarter of a stamp for 5 kg bodyweight) seems to be adequate at the beginning of treatment, to be progressively increased according to the way the drug is tolerated."( [Transcutaneous transport of trinitrin in children after application of nitroglycerin patches].
Dupuis, C; Francart, C; Olive, G; Rey, E; Vaksmann, G, 1990
)
0.51
" Dose-response curves for the increase in coronary blood flow produced by nicorandil or cromakalim were shifted to the right in a parallel manner and to similar extents by glibenclamide given intravenously to support dogs."( Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
Satoh, K; Taira, N; Yoneyama, F, 1990
)
0.28
"7 X 10(-4) M) doses or EA solvent (control) for 30 min, and dose-response curves were performed for GTN (10(-9) to 10(-5) M)."( Ethacrynic acid: acute hemodynamic effects and influence on the in vivo and in vitro response to nitroglycerin in the dog.
Abdollah, H; Armstrong, PW; Moffat, JA; Rollwage, D,
)
0.35
" Detailed analysis revealed a correlation between the dosage and favorable dynamics of mapping parameters."( Intravenous clonidine treatment in acute myocardial infarction (with comparison to a nitroglycerin-treated and control group).
Lada, W; Zochowski, RJ, 1986
)
0.5
" At the end of the 2-week control period, exercise performance was assessed with treadmill exercise testing and measurement of oxygen consumption during the final third of the dosing interval."( Comparison of nitroglycerin patches and nifedipine.
Burdick, DC; Eldridge, JE; Hossack, KF; Jones, RH, 1987
)
0.63
" Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators."( Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.
Holzmann, S; Kukovetz, WR, 1987
)
0.27
" The dose-response curve of nifedipine was shifted parallel to the right by the infusion of Bay K 8644 and the dose-ratio was the greatest of the 4 drugs."( Differential antagonism by Bay K 8644 of vasodilator effects of nifedipine, diltiazem, nicorandil and nitroglycerin in dog femoral circulation.
Ishii, K; Sato, Y; Taira, N, 1988
)
0.49
" The study objectives were to define the dose-response effects of NTG-TTS and to examine the influence of baseline haemodynamic status on subsequent response."( Haemodynamic dose-response effects of a transdermal nitrate delivery system in acute myocardial infarction with and without left heart failure.
Hafizullah, M; Jackson, NC; Nelson, GI; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1988
)
0.27
" After elevation of tone with KCl (15 mM), dose-response curves were constructed for nitroglycerin or SIN1 (3-morpholino-syndnonimin) on control and tolerant rings."( Persistence of the response to SIN1 on isolated coronary arteries rendered tolerant to nitroglycerin in vitro or in vivo.
Berkenboom, G; Degre, S; Fontaine, J, 1988
)
0.72
" To evaluate potential inhibitory actions, vessels were contracted by continuous LAD infusion of prostaglandin F2 alpha (PGF2 alpha) or serotonin before dose-response testing with PGE1 or nitroglycerin."( Prostaglandin E1 and nitroglycerin effects on canine epicardial conductance and distal coronary resistance vessels.
Bove, AA; Miller, WL, 1989
)
0.79
" Following exposure for 24 h to a NTG patch (15 mg/24 h), NTG dose-response curves were not altered suggesting there was no development of tolerance to transdermal NTG."( Responsiveness of peripheral veins to transdermal and sublingual nitroglycerin in healthy male volunteers.
Blaschke, TF; Hiremath, AN; Hoffman, BB, 1989
)
0.51
" When the strips were treated with submaximal effective concentrations of NO, some tolerance was observed, as shown by moderate attenuation of the rises in cyclic GMP, and a rightward shift of the dose-response curve of the relaxing effects by a dose factor of 10 (DF = 10)."( Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries.
Holzmann, S; Kukovetz, WR, 1989
)
0.28
" The two vasodilators were infused in ten patients with mild or moderate ARDS at a dosage rate achieving a 20% reduction of the mean arterial pressure."( Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome.
Becker, H; Falke, KJ; Radermacher, P; Santak, B, 1989
)
0.6
"The dose-response effects of vasodilator drugs, nitroglycerin, sodium nitroprusside and hydralazine, on mean arterial pressure (MAP) and mean circulatory filling pressure (MCFP), an index of body venous tone, were investigated in conscious, unrestrained, intact rats as well as in rats treated with the ganglionic blocker, hexamethonium."( Effects of vasodilator drugs on venous tone in conscious rats.
D'Oyley, HM; Pang, CC; Tabrizchi, R, 1989
)
0.53
" Such dosing strategies appear to eliminate or markedly reduce the problem of nitrate tolerance."( Transdermal nitroglycerin in angina pectoris.
Abrams, J, 1989
)
0.66
" For isosorbide dinitrate and isosorbide 5-mononitrate, as well as for transdermal nitroglycerin systems, interval treatment dosing regimens with maintained effectiveness documented in controlled studies have been delineated."( Effectiveness of interval nitrate therapy in angina pectoris.
Bayeric, A; Dirschinger, J; Hall, D; Reiniger, G; Rudolph, W, 1989
)
0.5
" BWA1433U induced a parallel shift of the adenosine dose-response curve to the right; however, it had no significant inhibitory effect on the decrease in lobar arterial pressure in response to ATP."( Adenosine does not mediate the pulmonary vasodilator response of adenosine 5'-triphosphate in the feline pulmonary vascular bed.
Hyman, AL; Kadowitz, PJ; Lippton, H; Neely, CF; Neiman, M, 1989
)
0.28
" Dose-response curves were plotted from data obtained following exposure to histamine (10(-7)-10(-3)) and GTN (10(-9)-10(-7)) and compared to responses from age-matched untreated controls, diabetic and diabetic rats treated with insulin (2 U/day)."( Histamine relaxation of aortic rings from diabetic rats.
Chang, KS; Tanz, RD; Weller, TS, 1989
)
0.28
" Blood pressure significantly decreased and heart rate significantly increased 4 h after TDN dosing (in comparison with placebo) in both the acute studies, but no difference was observed after chronic TDN treatment."( Chronic effects of transdermal nitroglycerin in stable angina pectoris: a within-patient, placebo-controlled study.
Bruno, AM; Corti, D; De Ponti, C; Fiorini, GL; Gibelli, G; Lambiase, M; Magenta, G; Negrini, M; Pollavini, PG; Prina, L, 1989
)
0.56
"Sustonite, a long-acting nitroglycerin drug for oral use (manufactured in Poland), and some other dosage forms of nitrates were studied and compared."( [Evaluation of the antianginal efficacy of sustonit compared with other nitrate drug forms].
Kokurina, EV; Martsevich, SIu; Metelitsa, VI; Slastnikova, ID; Urumbaev, RK, 1989
)
0.58
" Dosage limitations and nitrate-free intervals are frequently recommended to solve this problem (4, 5)."( [Lack of tolerance development with low dose nitrate administration in acute myocardial infarct].
Fanous, Z; Meissner, A; Petermann, W; Schulte, HM; Simon, R, 1989
)
0.28
" The effects of chronic dosing with N-acetylcysteine (NAC), on nitrate-induced haemodynamic changes during the acute and chronic treatment of healthy volunteers with glyceryl trinitrate (GTN) patches (Transiderm nitro) has been investigated."( N-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers.
Henderson, AH; Hogan, JC; Lewis, MJ, 1989
)
0.28
" However, 2 h after dosing there was a significant prolongation during stress testing in the time to onset of both 1 mm ST depression on the ECG (by 28%) and to angina (by 37%) compared with atenolol alone, but no benefit was apparent by 12 h after dosing."( Slow release nifedipine plus atenolol in chronic stable angina pectoris.
Challenor, VF; George, CF; Renwick, AG; Waller, DG, 1989
)
0.28
" In spontaneously hypertensive rats, the dose-response for the hypotensive response to bolus doses of RS93427 was not altered by concomitant steady state infusion of a threshold dose (1 micrograms kg-1 min-1) of GTN."( Selective anti-platelet aggregation synergism between a prostacyclin-mimetic, RS93427 and the nitrodilators sodium nitroprusside and glyceryl trinitrate.
Fulks, J; Hedley, L; Lee, CH; Loveday, M; Smith, DL; VanAntwerp, D; Willis, AL, 1989
)
0.28
"The efficacy of a controlled-release topical dosage form of glyceryl trinitrate (Nitroglycerin Transdermal Therapeutic System, Nitroderm TTS, NTG-TTS) was studied in the experimental model of myocardial ischaemia in beagles."( Efficacy of the glyceryl trinitrate transdermal therapeutic system in a dog model of myocardial ischaemia.
Inukai, T; Nakao, K; Yamamoto, S, 1989
)
0.5
") did not alter the dose-response relation of GTN under tolerance."( Nitrate action on epicardial coronary arteries and tolerance: new aspects based on longterm glyceryl trinitrate infusions in dogs.
Bassenge, E; Holtz, J; Münzel, T; Stewart, DJ, 1989
)
0.28
" Dose-response curves relating 5-6 different doses (0."( Differential vasodilator effect of nitroglycerin on systemic capacitance and resistance vessels in anesthetized dogs, and the mechanism of its action--a study by measuring mean circulatory pressure and total peripheral resistance.
Hirakawa, S; Hirose, I; Ito, H; Minatoguchi, S; Nagata, K; Sahashi, T; Takai, K; Wada, H; Watanabe, I, 1989
)
0.55
"Nirmin, a novel dosage form of nitroglycerin, was used to treat heart failure in 47 patients on days 1-3 after acute myocardial infarction."( [Effects of nirmin on central hemodynamics in patients with heart failure in the acute period of myocardial infarct].
Gorin, VV; Ioseliani, DG; Koval', AN; Liusov, VA; Slavutskiĭ, SIa; Volov, NA, 1989
)
0.56
" An application of the method on comparing the pharmacokinetic parameters in two dosage forms used in Czechoslovakia is shown."( [Determination of nitroglycerin in human plasma using gas chromatography after the administration of dosage forms used in Czechoslovakia].
Cepeláková, H; Hapala, J; Stehlík, P, 1989
)
0.61
" However, in class III, there was a significant shift to the right of the dose-response curves to nitroglycerin and SIN1 (but not to forskolin)."( Alterations of beta-adrenoceptor mediated relaxations of atherosclerotic human coronary arteries.
Berkenboom, G; Degre, S; Fontaine, J, 1989
)
0.49
" However, the dose-response curves for milrinone were shifted dextrally for changes in +dP/dt and LVEDP, whereas the dose-response curve for blood pressure was shifted sinistrally."( Participation of the autonomic nervous system in the cardiovascular effects of milrinone.
Gorczynski, RJ; Shaffer, JE; Vuong, A, 1986
)
0.27
" On days 4 and 5, the dose-response relations for GTN-induced epicardial artery dilation were shifted (p less than ."( Long-term nitroglycerin treatment: effect on direct and endothelium-mediated large coronary artery dilation in conscious dogs.
Bassenge, E; Holtz, J; Stewart, DJ, 1987
)
0.68
" Dose-response relations with regard to guanylate cyclase stimulation of organic nitrates and sodium nitrite were compared in the presence of cysteine and its closely related methylester."( Guanylate cyclase activation by organic nitrates is not mediated via nitrite.
Kukovetz, WR; Romanin, C, 1988
)
0.27
" We observed better vasospastic effect in the first group with the advantage of lesser dosage and less side effects."( [Coronary artery spasm. Study of 66 patients].
Cisneros Martínez, O; Delgado Caro, G; Esparragoza Romano, J; Morales Aceves, R; Solórzano Martín, C,
)
0.13
" Methods also have been developed to determine the skin irritation potential of a drug substance during the preclinical stages of transdermal dosage form development."( Testing of controlled-release transdermal dosage forms. Product development and clinical trials.
Amkraut, AA; Prevo, ME; Shaw, JE, 1987
)
0.27
"Various dosing strategies to determine therapeutic effects of nitroglycerin (NTG) preparations are reviewed."( Hemodynamic attenuation and the nitrate-free interval: alternative dosing strategies for transdermal nitroglycerin.
Flaherty, JT, 1985
)
0.73
" A dose-response relation was apparent with the 3 doses of active spray for heart rate at rest but not for standing systolic blood pressure."( Nitroglycerin lingual spray: clinical efficacy and dose-response relation.
Farrell, B; Parker, JO; Vankoughnett, KA, 1986
)
1.71
" Whereas LV peak dP/dt and LV (dP/dt)/DP40 were significantly decreased after the low dosage of lidocaine, these indexes returned to control values after the 10th min of infusion of the high dosage."( Effects of lidocaine on myocardial contractility and baroreflex control of heart rate in conscious dogs.
Berdeaux, A; Edouard, A; Giudicelli, JF; Langloys, J; Noviant, Y; Samii, K, 1986
)
0.27
" Intravenous NTG was administered through nonadsorbing tubing at a starting dosage of 5-10 micrograms/min and was adjusted as needed."( Influence of cardiopulmonary bypass on nitroglycerin clearance.
Dasta, JF; Howie, MB; Kakos, GS; Smith, DF; Sokoloski, TD; Weber, RJ; Wu, LS, 1986
)
0.54
" Pretreatment with captopril prevents the rebound and reduces the dosage of vasodilator required and, therefore, may be considered an alternative to the well-documented beta-adrenergic blockers."( [Rebound hypertension after controlled hypotension and its prevention by captopril].
Götz, H; Kleierl-Lindner, C; Pasch, T; Pichl, J, 1986
)
0.27
" In the present investigation, the bioavailability of oral nitroglycerin when administered in a capsule dosage form and as a solution was determined."( The bioavailability of oral nitroglycerin.
Benet, LZ; Noonan, PK, 1986
)
0.81
" Under long-term treatment, baseline TEVC was unaffected and the nitroglycerin dose-response relationship for TEVC was shifted to greater than 10-fold higher doses, whereas baseline mean arterial pressure (MAP) was lowered by 17 +/- 3 mm Hg without any shift in nitroglycerin responsiveness."( Altered spectrum of nitroglycerin action in long-term treatment: nitroglycerin-specific venous tolerance with maintenance of arterial vasodepressor potency.
Bassenge, E; Elsner, D; Holtz, J; Sommer, O; Stewart, DJ, 1986
)
0.83
" GTN measurement on multiple plasma samples collected during the dosage interval are therefore required to obtain a reliable estimate of the steady state concentration."( [Pharmacokinetics of glycerol trinitrate].
Menke, G; Rietbrock, N; Woodcock, BG, 1986
)
0.27
" The ejection fraction response was observed with NTG doses less than or equal to 200 micrograms and no dose-response relation was apparent."( Left ventricular dyskinesia reversed by intravenous nitroglycerin: a manifestation of silent myocardial ischemia.
Conti, CR; Feldman, RL; Holland, P; Lambert, CR; Ludbrook, P; McGrath, PD; Pepine, CJ, 1986
)
0.52
" The level and duration of antianginal and hypotensive activity were the same after single or repeated oral dosage of G-1-N to the anaesthetized rat."( [Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs].
Laufen, H; Leitold, M; Yeates, RA, 1986
)
0.27
" Patients treated with simultaneous IV nitroglycerin and IV heparin must be monitored often to avoid inadequate anticoagulation, and heparin dosage should be decreased when stopping IV nitroglycerin therapy to avoid hemorrhage."( Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly.
Habbab, MA; Haft, JI, 1987
)
0.81
" Isolated bovine pulmonary arteries and veins were contracted submaximally and cumulative dose-response relationships to glyceryl trinitrate were obtained; the vein was approximately 10 times more sensitive than the artery to glyceryl trinitrate induced relaxation."( A comparative study of glyceryl trinitrate biotransformation and glyceryl trinitrate induced relaxation in bovine pulmonary artery and vein.
Brien, JF; Kawamoto, JH; Marks, GS; Nakatsu, K, 1987
)
0.27
"Because of the high efficacy of existing nitrates, alternative dosage formulations have been developed rather than new compounds."( Determination of nitrates in plasma.
Jaeger, H; Lutz, D; Michaelis, K; Salama, ZB, 1987
)
0.27
" In a double-blind study the effects of continuous (24 h/day) and intermittent (16 h/day) application of transdermal nitroglycerin in a dosage of 10 mg/day were compared with the effects of placebo in 12 patients with chronic stable angina receiving treatment with beta-adrenergic blocking or calcium channel blocking agents."( Transdermal nitroglycerin in angina pectoris: efficacy of intermittent application.
Coxon, R; Luke, R; Sharpe, N, 1987
)
0.86
" A dorsal hand vein was preconstricted with submaximally effective doses of phenylephrine and a dose-response curve with nitroglycerin was established."( Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans.
Blaschke, TF; Eichler, HG; Hiremath, A; Hoffman, BB; Katzir, D, 1987
)
0.72
" Additionally, a discussion of which specific nitrate formulation are least likely to have tolerance associated with their use is included, such as short-acting nitrate formulations with the exception of the intravenous dosage form."( Tolerance to organic nitrates in ischemic heart disease.
Zeller, FP, 1987
)
0.27
" New nitrate delivery systems have recently become available which provide considerable dosing flexibility, further increasing the interest in this group of compounds."( Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.
Abrams, J, 1987
)
0.59
" A dose-response relationship is not well defined."( Controversies in the use of transdermal nitroglycerin systems.
Klamerus, KJ; Zeller, FP, 1987
)
0.54
" Isosorbide dinitrate required fewer retitration episodes and less increases in dosage than nitroglycerin at 24 hours."( Effect of intravenous isosorbide dinitrate versus nitroglycerin on elevated pulmonary arterial wedge pressure during acute myocardial infarction.
Cintron, GB; Conti, CR; Glasser, SP; Linares, E; Weston, BA, 1988
)
0.75
" Finally, appropriate dosing strategies are suggested that should eliminate the potential problem of nitrate tolerance."( Nitrates.
Abrams, J, 1988
)
0.27
" The relation of NTG patch efficacy with dosage and different subsets of patients during acute and chronic patch therapy was analyzed."( Relation of transdermal nitroglycerin efficacy with dosage in different subsets of patients.
Rezaković, DE, 1988
)
0.58
" Nifedipine pharmacokinetics after a single oral dose and sustained dosing (three times daily for five days) were not significantly different."( Haemodynamic effects of combined oral nifedipine and sublingual nitroglycerin in patients with chronic stable angina.
Boje, KM; Fung, HL; Parker, JO; Yoshitomi, K, 1987
)
0.51
" Thus the haemodynamic and antiischaemic effects of glyceryl trinitrate in the described dosage were largely absent after continuous 24-hour intravenous infusion."( [Anti-ischemia effect of continuous 24-hour infusion of glyceryl trinitrate in patients with stable angina pectoris].
Kaltenbach, M; Kett, U; Schneider, W, 1988
)
0.27
" Ninety-one patients (93 percent), 80 men and 11 women, mean age 62 +/- 1 years, completed the trial, which included two weeks receiving standard nifedipine followed by 12 weeks receiving nifedipine GITS starting at a dosage equal to the 24-hour total dose of nifedipine capsules and titrated upward as necessary."( Nifedipine gastrointestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine.
Cole, S; Parker, VE; Procacci, PM; Tabatznik, B; Terry, R; Vetrovec, GW, 1987
)
0.27
" Adequate monitoring of PTT and heparin dosage adjustment are thus required during combined heparin and NG administration."( [Inhibition of the heparin effect by nitroglycerin].
Lüderitz, B; Nitsch, J; Pizzulli, L, 1988
)
0.55
" The evaporation rate of nitroglycerin was controlled by its vapour pressure and by the matrix effect of the dosage forms."( Sublingual nitroglycerin. I. Comparative evaluation of the physical stability of commercially available tablets.
Duchateau, AM; Lagas, M, 1988
)
0.97
" The aim was to demonstrate an antianginal effect and to look for a dose-response relationship and for attenuation of effect if any on continued administration."( Oral nitroglycerin in angina pectoris--evaluation of effect by computerized exercise testing using two different doses.
Kardash, MM; Khurmi, NS; Kohli, RS; Lahiri, A; Raftery, EB, 1988
)
0.79
" After a 2-week placebo run-in period, each patient was randomized to either nicardipine or nifedipine; each drug was titrated up to either blood pressure normalization, appearance of adverse effects, or maximal dosage (40 mg, three times a day with nicardipine and 30 mg, three times a day with nifedipine) and then administered for 4 weeks."( A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension.
Bonandi, L; Dei Cas, L; Feroldi, P; Metra, M; Nodari, S; Nordio, G; Raddino, R; Visioli, O, 1988
)
0.27
" Both reperfusion rates were similar except for dosage and the duration of infusion."( Indications for and limitations of coronary thrombolysis.
Andoh, T; Kajiwara, N; Kanmatsuse, K; Onikura, S; Satoh, Y, 1985
)
0.27
" Maximal symptom limited treadmill exercise tests were performed three and 12 hours after dosage at each dose."( Oral labetalol in the management of stable angina pectoris in normotensive patients.
Akhras, F; Jackson, G; Upward, JW, 1985
)
0.27
" Further increase in dosage failed to induce further reduction of integrated areas of coronary vasodilatation, and a correlation was found between the extent of the reduction of the integrated areas of coronary vasodilatation and the dose of indomethacin (r = ."( Late phase of nitroglycerin-induced coronary vasodilatation blunted by inhibition of prostaglandin synthesis.
Condorelli, M; Cuocolo, A; De Simone, A; Ricciardelli, B; Trimarco, B; Van Dorne, D; Volpe, M, 1985
)
0.63
" Dosage for the bepridil group was constantly maintained for each patient at a level observed to be clinically effective."( Long-term efficacy of bepridil in patients with chronic stable angina pectoris: results of a multicenter, placebo-controlled study of extended bepridil use.
Alpert, JS; Chesler, E; DiBianco, R; Katz, RJ; Spann, JF, 1985
)
0.27
" TNS dosage ranged from 10 cm2 (5 mg per 24 h) to 60 cm2 (30 mg per 24 h) based on the patient's dosage prior to commencement of the study."( A double-blind multiple crossover trial evaluating a transdermal nitroglycerin system vs placebo.
Dickstein, K; Knutsen, H, 1985
)
0.51
" The overall hemodynamic response to nitrate administration will be modulated by the degree of sympathetic reflex discharge, the presence or absence of congestive heart failure, the dosage of administered nitrate, and the presence or absence of nitrate tolerance."( Hemodynamic effects of nitroglycerin and long-acting nitrates.
Abrams, J, 1985
)
0.58
", shorter duration of action, loss of intensity of effect) with long-term dosing in this clinical setting."( Nitrate tolerance.
Leier, CV, 1985
)
0.27
" It is appropriate that the patient's dosage of nitrates be administered with a formulation most likely to be both clinically effective and well tolerated."( Pharmacology of nitroglycerin and long-acting nitrates.
Abrams, J, 1985
)
0.62
" Presently, there is still considerable controversy regarding the extent and duration of action as well as the dosage requirements."( [High-dose transdermal nitroglycerin therapy: loss of effect within 24 hours?].
Blasini, R; Dirschinger, J; Kraus, F; Reiniger, G; Rudolph, W, 1985
)
0.58
" The average daily dosage of nicardipine for optimal angina relief was 89 mg (range 40 to 160)."( Nicardipine for angina pectoris at rest and coronary arterial spasm.
Feldman, RL; Gelman, JS; Pepine, CJ; Scott, E, 1985
)
0.27
" Attainment of steady-state drug levels appeared more rapid with the PE administration sets, but in three out of eight animals, these infusion systems appeared to produce a "bolus" dosing effect."( Effect of infusion administration set on the delivery rate and plasma concentration of nitroglycerin in dogs.
Fung, HL; Lai, CM; Look, ZM; McNiff, EF; Yacobi, A, 1985
)
0.49
" Taking into consideration that the range of the effective doses was very wide (15-150 micrograms/min), the authors believe that intravenous NTG infusion is indicated mainly in cases of manifest heart failure and should be administered under strict control of the dosage and with careful monitoring of the therapeutic effects."( Haemodynamic effects of nitroglycerin infusion in patients with postinfarction heart failure.
Korewicki, J; Kraska, T; Opolski, G; Ostrzycki, A, 1985
)
0.58
" Preconstriction was induced with norepinephrine and cumulative dose-response curves were obtained for the vasodilators."( Effects of magnesium on the action of vasodilatory agents.
Arnold, TH; Tackett, RL, 1985
)
0.27
" Accordingly, this study was carried out in ten patients with angiographically-documented coronary artery disease, stable exercise-induced angina pectoris and reproducible ST-segment depression, to assess the extent and duration of antianginal and anti-ischemic action of nitroglycerin patch treatment at an intermediate dosage of 15 mg/24 hours after the initial application, after renewed patch application on the second day and after patch application on the third day which had been preceded by a ten-hour patch-free interval in the night."( [Therapy of coronary heart disease with nitroglycerin patches. Behavior of anti-ischemic effectiveness in continuous administration and following patch free interval].
Reiniger, G; Rudolph, W, 1985
)
0.71
" After a 2-week placebo period ISMN was administered in a single-blind fashion with the dosage being titrated at 2-week intervals."( Isosorbide-5-mononitrate--effective monotherapy in chronic stable angina.
Akhras, F; Jackson, G; Jefferies, S, 1985
)
0.27
" New dosing modes involving nitrate-free intervals appear to hold promise in avoiding the occurrence of tolerance."( Nitrate formulations and drug delivery systems--an overview.
Fung, HL, 1985
)
0.27
" Additional animal studies to evaluate the dosage and frequency effects on tolerance and intraocular pressure are indicated."( The effect of nitroglycerin ointment on the external ocular structures of rabbits.
Karlin, KM; Zalta, AH; Ziegler, L; Zimmerman, TJ, 1985
)
0.63
" Hence it is concluded that practolol is an effective drug in treating angina, and in the dosage used is of potential value in patients with asthmatic bronchitis and angina."( Clinical evaluation of practolol, a new cardioselective beta-blocking agent in angina pectoris.
Clayton, GA; Sandler, G, 1970
)
0.25
" The NE dose-response curves shifted to the left."( Potentiation of the contractile effects of norepinephrine by hypoxia.
Cooper, T; Epstein, SE; Kent, KM, 1972
)
0.25
" At the higher dosage verapamil produced a significant improvement in frequency of angina, trinitrin consumption, and exercise tolerance, and had a favourable and significant effect on the amount and duration of ischaemic S-T depression occurring in the electrocardiogram during exercise."( Clinical evaluation of verapamil in angina pectoris.
Clayton, GA; Sandler, G; Thornicroft, SG, 1968
)
0.25
" Dose-response curves to intra-arterial administration of arachidonic acid (12 to 200 microgram kg-1), bradykinin (0."( Responses to arachidonic acid and other dilator agonists and their modification by inhibition of prostaglandin synthesis in the canine hindlimb.
Morcillo, E, 1980
)
0.26
" When despite a sufficient dosage no satisfying improvement takes place an additional prescription of beta-blocking agents is recommended."( [Actual and theoretical points of view in the application of coronary therapeutic agents].
Döring, D, 1980
)
0.26
" Nitroglycerin applied in a low dosage with exclusive venodilator effect was added for treatment of pulmonary edema and left ventricular failure."( [Hemorrhagic pulmonary edema and cardiac failure following isolated head injury. Treatment with dobutamine and nitroglycerin (author's transl)].
Jüngst, BK; Schranz, D; Stopfkuchen, H, 1981
)
1.38
" Comparative studies with beta adrenergic blocking agents with different ancillary properties, utilizing intravenous preparations, acute single and multiple oral dosing and sustained oral therapy prescribed for several weeks or months, show that if used in equipotent doses all beta adrenergic blocking agents are equally effective antianginal agents."( Beta adrenergic blocking agents for exertional angina pectoris.
Thadani, U, 1982
)
0.26
" Medical treatment should be considered a failure only if maximal dosage of nitrates and beta blockers is attained without satisfactory control of symptoms."( What is optimal drug therapy in angina pectoris?
Brest, AN; Frankl, WS, 1983
)
0.27
" At conventional dosage the most important action of nitrates is a pooling of blood in the large systemic venous capacitance vessels which leads to a decrease of central venous pressure and ventricular filling pressure."( [Effect of nitrates, nitrate-like substances, calcium antagonists and beta-adrenergic receptor blockers on peripheral circulation].
Bassenge, E; Busse, R, 1982
)
0.26
"Nifedipine is a strong calcium antagonist; it blocks the excitation-contraction coupling, yet at therapeutic dosage levels it has few side effects."( What is preferable in unstable angina, beta-blockade or calcium-inhibition?
Hugenholtz, PG; Serruys, PW; Simoons, ML, 1983
)
0.27
" Its cardioselectivity, ease of dosing and complete absence of side effects makes BTX an attractive choice as antianginal agent for chronic use."( Dose related efficacy of betaxolol in combination with nitroglycerin in patients with angina pectoris: a double blind cross-over study.
Kesteloot, H; Stroobandt, R, 1984
)
0.51
" The metabolic profiles of PETN in rat urine and feces following intra-arterial and oral dosing of this organic nitrate were then re-examined."( Rapid microbial degradation of organic nitrates in rat excreta. Re-examination of the urinary and fecal metabolite profiles of pentaerythritol tetranitrate in the rat.
Fung, HL; King, SY,
)
0.13
" A moderate hypotension was induced by CV-1808, nifedipine, and nitroglycerin, while a significant reduction in cardiac function was seen after dosing with propranolol."( Effect of 2-phenylaminoadenosine (CV-1808) on ischemic ST-segment elevation in anesthetized dogs.
Fujiwara, S; Hirata, M; Imamoto, T; Kawazoe, K; Matsumoto, N; Tanabe, M,
)
0.37
"A new topical dosage form of nitroglycerin has been developed in which nitroglycerin and its vehicle are incorporated in a polymer gel matrix of fixed dimension."( The nitroglycerin polymer gel matrix system: a new method for administering nitroglycerin evaluated with plasma nitroglycerin levels.
Colfer, H; Lucchesi, BR; Pitt, B; Stetson, P; Wagner, J,
)
0.98
" Dose-response curves to NTG were determined on some of these blood vessels and on controls using an isolated tissue bath apparatus."( Effect of dosage regimen on the development of tolerance to nitroglycerin in rats.
Fung, HL; Sutton, SC,
)
0.37
" Twenty-four-hour ambulatory ECG recordings showed a decrease in mean hourly heart rate throughout the dosing period, with preservation of diurnal variation."( Atenolol: once-daily cardioselective beta blockade for angina pectoris.
Harrison, DC; Jackson, G; Kates, RE; Schwartz, J; Winchester, M, 1980
)
0.26
" The long duration of action (at least 8 hours) allows prolonged dosage intervals."( [Prolonged hemodynamic effects of pentaerythrityl tetranitrate combined with piridoxylate].
Baudet, M; Hericotte, P, 1983
)
0.27
" Reasonably good temporal and dose-response correlations between cyclic GMP elevation and relaxation were obtained with acetylcholine."( Possible role for cyclic GMP in endothelium-dependent relaxation of rabbit aorta by acetylcholine. Comparison with nitroglycerin.
Chu, EB; Diamond, J, 1983
)
0.48
" With the conventional tablet and capsule dosage forms, the amount of drug absorbed through the gastrointestinal (GI) tract varies depending on the quantity and types of food in the stomach, on the GI motility and transit time."( Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system.
Karim, A, 1983
)
0.57
"Nitroglycerin bound to cellulose (Nitroglin) was investigated in patients with coronary heart disease as to the oral long-term effects in a dosage of 10 mg (n = 10) and 20 mg (n = 10) in comparison with 40 mg sustained release isosorbide dinitrate (n = 10) and placebo (n = 10)."( [Long-term effect of a new delayed-action nitroglycerin compared to isosorbide dinitrate. Double-blind hemodynamic study].
Hochrein, H; Lehmann, HU; Traue, P; Witt, E, 1983
)
1.97
" New dosage forms and new delivery systems have become available, which have resulted in potential confusion to all concerned with the proper use of these systems."( Pharmaceutical considerations of nitroglycerin.
Amann, AH; Baaske, DM; Yacobi, A, 1983
)
0.55
" These data suggest that continuous absorption occurred throughout the 6-hour dosing interval, that a trend toward increased AUC and Cmax occurred with the larger surface area, and that, in general, doubling the dose of NTG-O doubles the AUC."( Effect of dose and ointment application technique on nitroglycerin plasma concentrations.
Caranasos, GJ; Curry, SH; Gotz, VP; Iafrate, RP; Yost, RL,
)
0.38
" When GTN is infused through PVC tubing, the dosage cannot be controlled and any assessment of pharmacokinetics or absolute bioavailability becomes invalid."( [The effect on biologic availability of the choice of infusion material in nitroglycerin therapy].
Bonn, R; Cawello, W, 1983
)
0.5
"A rapid, precise, sensitive, and specific assay for nitroglycerin in sublingual, sustained-release, and ointment dosage forms using high-performance liquid chromatography is described."( High-performance liquid chromatographic determination of nitroglycerin in sublingual, sustained-release, and ointment dosage forms.
Olsen, CS; Scroggins, HS, 1983
)
0.76
" Careful titration of dosage is required (beginning at 5 micrograms/min), and if the infusion sets contain polyvinylchloride, the delivered dose is lower than that calculated, because of adsorption of glyceryl trinitrate onto the plastic tubing."( Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.
Brogden, RN; Romankiewicz, JA; Sorkin, EM, 1984
)
0.55
" Comparison of these effects with oral single dosage of 20 mg 5-isosorbide mononitrate (ISMN) showed that two simultaneously administered plasters did not achieve efficacy of 20 mg 5-ISMN, four plasters, however, were more effective."( [Effect of nitroglycerin plasters on hemodynamics and stress tolerance of patients with coronary heart disease].
Hilger, HH; Jansen, W; Osterspey, A; Simon, P; Tauchert, M; Ulbrich, T, 1984
)
0.66
" The cumulative dose-response curve showed an earlier and more pronounced response in shunted rats receiving nitroglycerin intraportally, suggesting a marked increase in bioavailability."( Portal-systemic shunting and the hemodynamic effects of nitroglycerin in the rat.
Blei, AT; Gottstein, J; O'Reilly, DJ, 1984
)
0.73
" Conventional dosage forms such as tablets, capsules, or elixirs describe a peak-and-valley curve when their dosage intervals are charted, demonstrating great fluctuations in the safety and effectiveness of a drug during the dosage interval."( Rationale for rate-controlled drug delivery of cardiovascular drugs by the transdermal route.
Breimer, DD, 1984
)
0.27
" The ratio of maximum to minimum plasma levels during a dosing interval was 2 for oral Catapres and approximately 1 for Catapres -TTS."( Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.
Shaw, JE, 1984
)
0.59
" At all dosage levels, Nitro-Dur also decreased resting systolic blood pressure and increased resting heart rate."( Clinical studies with transdermal nitroglycerin.
Go, M; Hollenberg, M, 1984
)
0.55
" A graded infusion of nitroglycerin was administered initially to establish the dose-response relation for nitroglycerin and estimate the dose of topical nitroglycerin to be applied."( Sustained beneficial hemodynamic responses to large doses of transdermal nitroglycerin in congestive heart failure and comparison with intravenous nitroglycerin.
Demma, FJ; Goldberg, LI; Rajfer, SI, 1984
)
0.81
" An alternate dosing mode is proposed that speculatively may provide an improvement in producing and maintaining nitrate action in long-term angina therapy."( Pharmacokinetic determinants of nitrate action.
Fung, HL, 1984
)
0.27
" Additionally, when patients given intravenous nitroglycerin for various reasons were followed for 48 hours, the majority receiving infusions via polyvinyl chloride tubing (group 2) did not require dosage adjustments."( Specialized delivery systems for intravenous nitroglycerin. Are they necessary?
Farmer, JA; Fennell, WH; Luck, JC; Pratt, CM; Roberts, R; Young, JB, 1984
)
0.78
"Two studies were performed to evaluate two nitroglycerin dosage forms."( Evaluation of two nitroglycerin dosage forms: a metered spray and a soft gelatin capsule.
Erb, R; Stoltman, W, 1983
)
0.86
" In 11 patients, acute dosing with 10, 20 and 30 cm2 of TGTN (designed to deliver 5, 10 and 15 mg GTN over 24 hours) improved treadmill walking time 2 and 4 hours after application, but no clinical effects were seen at 24 hours."( Transdermal nitroglycerin in angina pectoris.
Fung, HL; Parker, JO, 1984
)
0.65
" The mean plasma concentration of nitroglycerin during ointment dosing was approximately 200% to 400% that during skin patch dosing."( Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin.
Culp, JR; Curry, SH; Kwon, HR; Pepine, CJ; Perrin, JH; Stevens, JL; Yu, WC, 1984
)
1
" The applicability of this method to the analysis of whole blood from dogs orally dosed with trinitroglycerin is described."( Application of high-pressure liquid chromatography and thermal energy analyzer to analysis of trinitroglycerin and its metabolites in blood.
Keck, RG; Spanggord, RJ, 1980
)
0.7
"Eight-five patients who required vasodilator therapy in the postoperative period after cardiac surgery were studied to compare the haemodynamic effects of nitroglycerin and nitroprusside, to evaluate local and systemic toxicity, and to develop long-range dosage recommendations."( Vasodilator therapy after cardiac surgery: a review of the efficacy and toxicity of nitroglycerin and nitroprusside.
Finlayson, DC; Kaplan, JA; Woodward, S, 1980
)
0.68
" Six collaborators were supplied with 6 composites of sublingual tablets, representing 3 different dosage levels."( Semiautomated method for analysis of nitroglycerin in sublingual tablets: collaborative study.
Juhl, YH, 1980
)
0.53
" The presented exposure calculations could be used for international comparison and dose-response discussions in future epidemiological studies on chronic effects of nitrate esters."( Nitroglycol and nitroglycerine exposure in a dynamite industry 1958-1978.
Davidsson, B; Hogstedt, C, 1980
)
0.61
" Comparisons, however, are difficult owing to different methods and dosage regimens and to the isolated character of too many case-reports."( [Long-acting nitrate compounds (author's transl)].
Lhoste, F, 1980
)
0.26
" The 15 mg initial dose of PCNG was progressively increased until optimal dosage was reached."( [Treatment of left ventricular failure with percutaneous nitroglycerin (author's transl)].
Bonin, M; Guermonprez, JL; Lancelin, B; Maurice, P, 1980
)
0.51
" The dose-response curve shifted to the right in the presence of NG noncompetitively in all the conditions employed to develop the tension."( Actions of nitroglycerine on the membrane and mechanical properties of smooth muscles of the coronary artery of the pig.
Ito, Y; Kitamura, K; Kuriyama, H, 1980
)
0.65
" Verapamil caused no side effects forcing a reduction in dosage or a discontinuation."( A controlled trial of verapamil for Prinzmetal's variant angina.
Hillis, LD; Johnson, SM; Mauritson, DR; Willerson, JT, 1981
)
0.26
" Either diltiazem in two dosage schedules (120 mg/day and 240 mg/day), or placebo was administered in a randomized double-blind program over 10 weeks."( Effect of diltiazem in patients with variant angina: a randomized double-blind trial.
Conti, CR; Curry, RC; Feldman, RL; Pepine, CJ; Whittle, J, 1981
)
0.26
"Seventeen patients suffering from angina pectoris completed a double-blind trial comparing the efficacy and safety of metoprolol Durules administered once daily and metoprolol tablets administered twice daily both at a daily dosage of 200 mg."( Treatment of angina pectoris with metoprolol. A comparison between Durules administered once daily and tablets administered twice daily.
Orö, L, 1981
)
0.26
" and may be preferred by some patients because of the simple dosage regimen."( Metoprolol in angina pectoris complicated by essential hypertension. A clinical comparison of the antianginal efficacy of metoprolol slow-release tablets (Durules) given once daily and propranolol tablets given twice daily.
BLoem, TJ; Lindner, PC, 1981
)
0.26
" Aortic strips from SHR previously dosed with captopril showed equivalent or greater contractile responses to potassium chloride (KCl) and NE, when compared with strips from untreated age-matched controls."( Effects of captopril on vascular reactivity of SHR in vivo and in vitro.
Antonaccio, MJ; Kotler, D; Rubin, B,
)
0.13
" Dose-response curves resulting from graded intravenous infusions of glyceryl trinitrate (8 and 25 microgram/min) were used as standard of comparison for the pharmacologic response resulting from an oral dose of 800 microgram."( Noninvasive assessment of portal-systemic shunting: evaluation of a method to investigate systemic availability of oral glyceryl trinitrate by digital plethysmography.
Bircher, J; Porchet, H, 1982
)
0.26
" In the remaining 13 patients nitroglycerin produced partial relief of pain in 17 +/- 5 minutes and complete relief in 127 +/- 65 minutes, requiring a cumulative dosage of 23."( Large dose sublingual nitroglycerin in acute myocardial infarction: relief of chest pain and reduction of Q wave evolution.
Kim, YI; Williams, JF, 1982
)
0.87
" These observations should prove helpful in choosing dosage schedules for intracoronary NTG."( Analysis of coronary responses to various doses of intracoronary nitroglycerin.
Conti, CR; Feldman, RL; Marx, JD; Pepine, CJ, 1982
)
0.5
" This mode of dosing did not lead to complete avoidance of first-pass metabolism of nitroglycerin in rats."( Rectal absorption of nitroglycerin in the rat: avoidance of first-pass metabolism as a function of rectal length exposure.
Fung, HL; Kamiya, A; Ogata, H, 1982
)
0.81
"Anesthetic management and dosage schedules of vasodilators have not been standardized in many studies of aortic cross clamping (CCL)."( Hemodynamics of intravenous nitroglycerin during aortic clamping.
Guffin, AV; McNeill, DC; Perdue, G; Smith, R; Zaidan, JR, 1982
)
0.56
" The resultant decrease in the administered dose of NTG renders dose-response data invalid when PVC-containing systems are used to deliver NTG."( Hemodynamic effects of intravenous nitroglycerin: importance of the delivery system.
Cote, DD; Culligan, JD; Mutch, WA; Thomson, IR, 1982
)
0.54
" Treatment of strips with PCMB and DTNB did not alter the dose-response curves for GTN."( Investigations into the role of sulfhydryl groups in the mechanism of action of the nitrates.
Armstrong, PW; Marks, GS; Moffat, JA, 1982
)
0.26
" In vitro, the dose-response curves of norepinephrine in isolated intact aortic and mesenteric rings form the exercise trained-SHR were significantly lower than those from the untrained-SHR."( Chronic exercise enhances endothelium-mediated dilation in spontaneously hypertensive rats.
Ding, YA; Lee, YM; Sheu, JR; Yang, JH; Yen, MH, 1995
)
0.29
"), twice-daily dosing of standard or sustained-release forms, or frequent intermittent low dosages."( Oral nitrate preparations: an update.
Bomber, JW; De Tullio, PL, 1995
)
0.29
"5 microM) had no significant effect on relaxation dose-response curves (DRCs) to ACh, NTG or NO."( Role of calcium-activated K+ channels in vasodilation induced by nitroglycerine, acetylcholine and nitric oxide.
Khan, SA; Mathews, WR; Meisheri, KD, 1993
)
0.52
"Continuous nitroglycerin (NTG) administration causes pharmacologic tolerance in humans and animals, whereas intermittent dosing is capable of avoiding or reducing tolerance development."( Continuous versus intermittent nitroglycerin administration in experimental heart failure: vascular relaxation and radioligand binding to adrenoceptors and ion channels.
Bauer, JA; Fung, HL; Gopalakrishnan, M; Kwon, YW; Triggle, DJ; Zheng, W, 1993
)
0.96
" A rapid, transient relaxation was observed during the cumulative dose-response and a new plateau of equilibrium was seen following an increase in developed force after the last dose of SP."( Substance P induces biphasic endothelium-dependent relaxations in pig and rabbit carotid arteries.
Arden, WA; Fiscus, RR; Gross, DR; Lanzo, S; Maley, RH; Salley, RK, 1994
)
0.29
" The acetylcholine dose-response curve shifted to the right after the induction of nitroglycerin tolerance."( Effect of captopril on acetylcholine-induced relaxation in the presence of nitroglycerin tolerance in isolated rabbit aorta.
Aikawa, J; Akatsuka, N; Fukazawa, M; Ishikawa, M; Moroi, M; Namiki, A; Yamaguchi, T,
)
0.59
"Early development of nitrate tolerance with either continuous administration of intravenous or topical nitrate preparations or frequent dosing of oral nitrates leads to significant attenuation of nitrate-mediated hemodynamic and anti-ischemic effects."( Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
Ajit-Uppal, J; Elkayam, U; Gogia, H; Johnson, JV; Mehra, A; Parikh, S; Raman, M, 1995
)
0.29
" Both studies compared the controlled-delivery dosage form to the same total daily dose of immediate-release diltiazem administered three times daily (tid) and to placebo."( Antianginal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID.
Annable, L; Baird, M; Boulet, AP; Juneau, M; Klinke, WP; Lakhani, Z; Larivière, L; Warnica, W; Waters, D, 1995
)
0.29
"25 micrograms/kg per minute with stepwise dosage increases until a diastolic blood pressure (BP) of 100 mmHg was achieved."( Effects of nitroglycerin on the uterine and umbilical circulation in severe preeclampsia.
Carlström, K; Grunewald, C; Kublickas, M; Lunell, NO; Nisell, H, 1995
)
0.68
" A combination of slow-release nitroglycerin (Nitro-Mack retard) as venodilator in the dosage of 20 mg/day and Dihydralazin SPOFA as arteriodilator in dosage of 100-200 mg/day under continuing cardiotonic and diuretic treatment were used."( Long-term vasodilator therapy for heart failure: noninvasive evaluation and noninvasive predictors of survival.
Riecansky, I, 1995
)
0.58
"The combination of hydralazine and nitrates has been shown to provide long-term benefit in congestive heart failure, despite a nitrate dosage that should induce tolerance."( Interaction between hydralazine and nitrovasodilators in vascular smooth muscle.
Berkenboom, G; Fontaine, J; Unger, P, 1993
)
0.29
" Simple, well-designed dosing schedules can avoid tolerance and rebound phenomena and can improve patient compliance."( The rationale for nitrates in angina pectoris.
Held, P; Olsson, G, 1995
)
0.29
" The dose-response relation of intracoronary nitroglycerin was assessed in 14 patients (7 control subjects and 7 patients with aortic stenosis [study A]) using quantitative coronary angiography."( Reduced epicardial coronary vasodilator capacity in patients with left ventricular hypertrophy.
Boj, H; Hess, OM; Jakob, M; Kaufmann, P; Kiowski, W; Vassalli, G; Villari, B, 1995
)
0.55
" The three nitrate compounds currently available in the United States--nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate--are provided in a variety of dosage forms, including sublingual, transmucosal, oral, and transdermal preparations."( The role of nitrates in coronary heart disease.
Abrams, J, 1995
)
0.52
" Appropriate dosing regimens of controlled-release formulations of isosorbide dinitrate (ISDN) and controlled-release NTG during long-term therapy have not been established."( Short and long-acting oral nitrates for stable angina pectoris.
Lipicky, RJ; Thadani, U, 1994
)
0.29
" Dose-response curves for sodium nitroprusside, nitroglycerin, isoproterenol, amrinone, and PGE1 were then generated."( Pulmonary vascular smooth muscle relaxation by cGMP- versus cAMP-mediated mechanisms.
Banerjee, A; Fullerton, DA; Hahn, AR; Harken, AH, 1994
)
0.54
" Employing additional short term infusions, dose-response curves were obtained by giving nicorandil or glyceryl trinitrate at increasing dosages both in the preinfusion control state and 4 h after terminating the nicorandil infusion."( Long term increases in coronary arterial conductance during five day infusion of low dose nicorandil.
Bassenge, E; Fink, B; Huckstorf, C; Sommer, O, 1994
)
0.29
" However, at the higher dose there was a shift of the dose-response curve of both nicorandil and glyceryl trinitrate to the right, indicating some tolerance."( Long term increases in coronary arterial conductance during five day infusion of low dose nicorandil.
Bassenge, E; Fink, B; Huckstorf, C; Sommer, O, 1994
)
0.29
" In healthy volunteers and at this dosage (10 mg twice a day), cross tolerance between nicorandil and nitroglycerin does not occur."( Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers.
Billon, N; Funck-Brentano, C; Jaillon, P; Tabone, X, 1994
)
0.77
" NITRO-MACK retard (venodilator) in the dosage of 20 mg per day and DIHYDRALAZIN (arteriodilator) in the dosage of 100-200 mg per day were combined simultaneously with continuous administration of cardiotonics and diuretics."( [Non-invasive assessment of the efficacy of long-term vasodilator therapy of cardiac decompensation in patients with dilated cardiomyopathy].
Bzdúchová, O; Havlínová, K; Plachá, L; Riecanský, I; Schreinerová, Z; Zelenay, J, 1993
)
0.29
" The two enantiomers showed almost the same dose-response curves in rabbit aortic strips contracted with phenylephrine."( Pharmacological comparison of the stereoisomers of glyceryl-1-nitrate.
Laufen, H; Leitold, M; Riedel, KD; Stoss, P; Zimmermann, T, 1994
)
0.29
" Tolerance is most likely to occur with frequent dosing or with the use of long-acting nitrates or transdermal applications resulting in constant plasma concentrations."( [Nitroglycerin preparations. Effect and tolerance].
Aldershvile, J; Boesgaard, S; Kjøller-Hansen, L; Laursen, JB; Poulsen, HE, 1994
)
1.2
" Rings of thoracic aorta from rats were constricted by use of norepinephrine, and cumulative dose-response relationships to methacholine and nitroglycerin were evaluated in the presence of serum from heartworm-infected dogs or serum from noninfected (control) dogs."( Effect of serum from dogs infected with Dirofilaria immitis on endothelium-dependent relaxation of rat aorta in vitro.
Kaiser, L; Lamb, VL; Williams, JF, 1993
)
0.49
" The establishment of a GDN plasma concentration-effect relationship together with the relatively high plasma levels of GDN achieved following GTN dosing supports the hypothesis that the GDNs contribute significantly to the hemodynamic effect observed with GTN."( Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glyceryl dinitrate upon blood pressure in healthy volunteers.
Benet, LZ; Gumbleton, M, 1993
)
0.29
" This ratio is different from those obtained after iv bolus and oral dosing indicating that the biotransformation of GTN to 1,2-GDN and 1,3-GDN differs for each dosing route."( Pharmacokinetics and pharmacodynamics of nitroglycerin and its dinitrate metabolites in conscious dogs: intravenous infusion studies.
Benet, LZ; Lee, FW; Salmonson, T, 1993
)
0.55
"Asymmetric dosage regimes have been introduced to circumvent development of nitrate tolerance."( Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetric isosorbide dinitrate treatment in patients with ischemic heart disease.
Jørgensen, LH; Refsum, HE; Thaulow, E, 1994
)
0.29
"Thirty-seven patients with chronic, stable angina pectoris were included in a randomized, double-blind cross-over study to assess the efficacy of once- and twice-daily dosage regimens of 60 mg isosorbide-5-mononitrate, in a controlled-release formulation (5-ISMN Durules, Astra)."( Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
Nordlander, R; Walter, M, 1994
)
0.29
" Nitroglycerin pre-exposure (10 microM for 30 min) provoked a significant shift to the right of the dose-response curve to nitroglycerin in aortae isolated from rats of 8 weeks, 12 and 18 months."( Nitrate tolerance and aging in isolated rat aorta.
Berkenboom, G; Brékine, D; Fontaine, J; Unger, P, 1993
)
1.2
"025 micrograms/kg) was given 50 min after beginning the GDN infusion and compared with plasma concentrations following a similar GTN dose in the absence of dosed GDNs."( Nitroglycerin dinitrate metabolites do not affect the pharmacokinetics and pharmacodynamics of nitroglycerin in the dog: a preliminary report.
Benet, LZ; Hu, J; Lee, FW; Metzler, CH, 1993
)
1.73
" Identical dose-response curves were produced by PGF2 alpha in arteries from OH and LN dogs."( Decreased potency of contraction to alpha-adrenoceptor stimulation in renal arteries from obese hypertensive dogs.
Granger, JP; Ratz, PH; West, DB, 1993
)
0.29
" None of the K+ channel blockers had an effect on the dose-response curve to NO, on the noradrenaline-induced contraction or on the relaxation to nitroglycerine (GTN)."( Prejunctional modulation of the nitrergic innervation of the canine ileocolonic junction via potassium channels.
Boeckxstaens, GE; De Man, JG; De Winter, BY; Herman, AG; Pelckmans, PP; Van Maercke, YM, 1993
)
0.49
"Full dose-response curves were constructed in 13 hypercholesterolemic and 12 normocholesterolemic subjects by infusing bradykinin (0."( Responsiveness to bradykinin in veins of hypercholesterolemic humans.
Bedarida, GV; Blaschke, TF; Bushell, E; Haefeli, WE; Hoffman, BB, 1993
)
0.29
" By this method we have shown that NTG td 10 mg dilates venous beds to a low extent; this approach will be utilized in future studies aimed at elucidating dose-response and regimen effect of these drugs."( [The noninvasive quantitative evaluation of the acute hemodynamic effects of sublingual and transdermal nitroglycerin in man].
Avanzini, F; Bonaglia, M; Ghio, S; Latini, R; Manni, B; Peci, P; Pizzetti, F, 1993
)
0.5
" The dose-response curves for blood flow were shifted markedly to the right of the response of conductance vessels so that the proximal vessels had reached 50% of their maximum vasodilation before significant increases in blood flow."( Heterogeneous effects of nitroglycerin on the conductance and resistance coronary arterial vasculature.
Cobb, FR; Somers, M; Zhang, J, 1993
)
0.59
"Patients admitted to the coronary care unit who received both intravenous nitroglycerin and heparin were studied to evaluate heparin dosage requirements."( Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease.
Berk, SI; Bodenheimer, MM; Grunwald, A; Pal, S, 1993
)
0.83
" dosing schedule) oral treatment with isosorbide-5-mononitrate (IS-5-MN; 5 mg kg-1) indicative of the induction of tolerance to GTN but not to SIN-1."( Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies.
Mollace, V; Pistelli, A; Salvemini, D, 1993
)
0.29
"Nitroglycerin dosage was not advanced appropriately in 78% of episodes despite evidence of bradycardia, hypertension and peripheral vasoconstriction."( Evaluation and revision of a vasopressin/nitroglycerin protocol for use in variceal bleeding.
Burns, SM; Luer, J; Martin, M; Merrill, P; Stone, DD, 1993
)
1.99
" However, no carefully controlled studies are available on the effects of these preparations (and their dosing schedule) on the occurrence of "silent" ischemic events during unrestricted daily activities."( Transdermal nitroglycerin reduces the frequency of anginal attacks but fails to prevent silent ischemia.
Bonetti, F; Chierchia, SL; Luca, C; Rossetti, E, 1993
)
0.66
"Only the intermittent dosing schedule afforded a small but significant improvement in exercise tolerance and prolonged exercise duration and time to ST segment depression."( Transdermal nitroglycerin reduces the frequency of anginal attacks but fails to prevent silent ischemia.
Bonetti, F; Chierchia, SL; Luca, C; Rossetti, E, 1993
)
0.66
" The effects of cytochrome P-450 inhibitor [2-dimethylaminoethyl-2,2-diphenyl-n-pentanoate (SKF-525A) and metyrapone] on the response of rabbit aortic rings to GTN was determined by recording cumulative GTN dose-response curves in the presence of either or both inhibitors."( Lack of evidence for the involvement of cytochrome P-450 or other hemoproteins in metabolic activation of glyceryl trinitrate in rabbit aorta.
Brien, JF; Liu, Z; Marks, GS; McLaughlin, BE; Nakatsu, K, 1993
)
0.29
" Dose-response curves induced by bolus injection (i."( Effects of a K+ATP channel opener, lemakalim, on systemic, coronary and regional vascular dynamics in conscious dogs: comparison with nifedipine, adenosine, nitroglycerin and acetylcholine.
Shen, YT; Vatner, SF, 1993
)
0.48
" The beneficial nitrate effect can be preserved by appropriate dosing which provides a period of many hours of nitrate washout during each 24 h period."( Nitrate tolerance--problems both new and old.
Parker, JO, 1996
)
0.29
" Carefully designed dosing regimens and/or appropriate use of nitrate formulations (to include a nitrate-free period each day) will decrease or eliminate the problem of nitrate tolerance."( Therapy of angina pectoris with long-acting nitrates: which agent and when?
Abrams, J, 1996
)
0.29
"We used the dorsal hand vein compliance technique to construct full dose-response curves to the beta 2-agonist isoproterenol (2 to 270 ng/min) in hand veins preconstricted with phenylephrine in 11 young white subjects and in 11 young Asian Indian subjects."( Impaired beta 2-adrenergic agonist-induced venodilation in Indians of Asian origin.
Adubofour, KO; Dachman, WD; Kapoor, C; Singarajah, C; Takahashi, B; Vajo, Z; Zafar, H, 1996
)
0.29
" Specific advantages have been identified such as stable dose-response effect, less hypotensive and tachycardial effects during the use of iv nicardipine in treatment of hypertensive patients."( Comparison of antihypertensive effects of nicardipine with nitroglycerin for perioperative hypertension.
Chen, TL; Cheng, YJ; Lee, TS; Lin, CJ; Lin, SY; Sun, WZ, 1995
)
0.53
" Glibenclamide (30 microM) had no significant effect on relaxation of the dose-response curve to nitroglycerin and almost completely abolished the relaxation by cromakalim, a known opener of ATP-sensitive potassium channels."( Effect of selective inhibition of potassium channels on vasorelaxing response to cromakalim, nitroglycerin and nitric oxide of canine coronary arteries.
Hohn, J; Papp, JG; Pataricza, J; Penke, B; Toth, GK, 1995
)
0.73
" In patients with arterial hypertension, blood flow responses to infusions of organic nitrates were significantly impaired over the entire dose-response curve compared with those of normotensive controls (220 nmol/min GTN 13."( Impaired effectiveness of nitric oxide-donors in resistance arteries of patients with arterial hypertension.
Feelisch, M; Kelm, M; Preik, M; Strauer, BE, 1996
)
0.29
" Dose-response relaxation curves were determined for acetylcholine (ACh; 10(-8) to 10(-5) M), which stimulates endothelial nitric oxide production, and for nitroglycerine (10(-9) to 10(-6) M), which directly provides nitric oxide in vivo."( A novel nonanticoagulant heparin prevents vascular endothelial cell dysfunction during hyperdynamic sepsis.
Chaudry, IH; Morrison, AM; Wang, P, 1996
)
0.49
" The dose-response characteristics of two nitrovasodilators, sodium nitroprusside and nitroglycerin, and two nonnitrovasodilators, prostaglandin E2 and 5'-N-ethylcarboxamidoadenosine, were studied."( Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension.
Kavanagh, BP; Pearl, RG; Thompson, JS, 1996
)
0.52
" In contrast, pretreatment with L-NAME resulted in no changes in the dose-response characteristics of the cyclic adenosine monophosphate-mediated, NO-independent vasodilators prostaglandin E1 and 5'-N-ethylcarboxamidoadenosine."( Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension.
Kavanagh, BP; Pearl, RG; Thompson, JS, 1996
)
0.29
" In the first part of the study, we determined the dose-response to increased NO concentrations from 5 to 40 ppm."( Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension.
Blaise, G; Charbonneau, M; Van Obbergh, LJ, 1996
)
0.55
" Vessels were exposed to thiacetarsamide and dose-response relationships were applied to methacholine and nitroglycerin."( Thiacetarsamide depresses relaxation of canine pulmonary artery in vitro.
Kaiser, L; Maksimowich, DS; Williams, JF, 1996
)
0.51
" Dose-response curves to bradykinin (a stimulator of nitric oxide synthesis), arachidonic acid (the precursor of prostanoid production) and GTN (a nitric oxide donor) were constructed before and 1 h after endotoxin."( Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction?
Bhagat, K; Collier, J; Moss, R; Vallance, P, 1996
)
0.29
" First, basal recordings with saline were followed by intravenous infusions of glyceryl trinitrate or VIP at different infusion rates to achieve dose-response relationships."( Nitrergic inhibition of migrating myoelectric complex in the rat is mediated by vasoactive intestinal peptide.
Hellström, PM; Ljung, T, 1996
)
0.29
"The gastrointestinal therapeutic system formulation of nifedipine enables a once-daily dosing resulting in predictable, relatively constant plasma concentrations."( Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN).
Bernink, PJ; Claessens, RJ; de Vries, RJ; Dunselman, PH; Kingma, JH; Lok, DJ; Pasteuning, WH; van den Heuvel, AF, 1996
)
0.29
" Dose-response determinations were made for each drug before and after an intra-arterial infusion of the reduced thiol, N-acetylcysteine, at rates estimated to achieve a physiological concentration of 1 mmol/L."( N-acetylcysteine does not influence the activity of endothelium-derived relaxing factor in vivo.
Boles, K; Creager, MA; Roddy, MA; Stamler, JS, 1997
)
0.3
" Cumulative dose-response relations to norepinephrine, nitroglycerin, and methacholine were determined."( Effect of arsenical drugs on in vitro vascular responses of pulmonary artery from heartworm-infected dogs.
Bell, TG; Kaiser, L; Maksimowich, DS; Williams, JF, 1997
)
0.54
" However, the high incidence of side effects limits the clinical applicability of this therapeutic strategy at least at the dosage used in the present study."( Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris.
Ardissino, D; Bertocchi, F; Demicheli, G; Falcone, C; Ghio, S; Marinoni, G; Merlini, PA; Montemartini, C; Mussini, A; Savonitto, S; Zanini, P, 1997
)
0.61
" When dosed orally JTV-506 (0."( Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs.
Aisaka, K; Hirata, Y, 1997
)
0.3
" Notably, nearly identical dose-response curves were obtained when corresponding molar quantities of the most potent agents, SNP and SIN-1, were applied either via transbronchial or via intravascular routes, with respect to rapidity of onset, extent (pressure reduction to near baseline) and duration (>90 min) of vasorelaxation."( Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation.
Grimminger, F; Mayer, K; Otterbein, J; Schütte, H; Seeger, W; Spriestersbach, R; Walmrath, D, 1997
)
0.3
" We used a previously developed pharmacokinetic-pharmacodynamic (PK/PD) model of NTG tolerance in experimental heart failure to test whether dosage regimens, designed from this model, may allow avoidance of tolerance development upon continuous NTG infusion."( Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure.
Balthasar, JP; Bauer, JA; Fung, HL, 1997
)
0.52
" The good anti-anginal and hypotensive efficacy and safety of amiodipine with once daily dosage regimen makes this drug an excellent choice of treatment for hypertensive patients with severe coronary artery disease."( [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension].
Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997
)
0.3
"With this dosage regimen, amrinone provides a higher cardiac output, more favorable oxygen dynamics, and lower pulmonary vascular resistance than dopamine and nitroglycerin."( Amrinone versus dopamine-nitroglycerin after reconstructive surgery for complete atrioventricular septal defect.
Happonen, JM; Korpela, R; Laitinen, P; Leijala, M; Peltola, K; Rautiainen, P; Sairanen, H, 1997
)
0.8
" Log dose-response curves for TNG, 10(-9) to 10(-5) M, were constructed for each tissue."( Placental tissue enhances uterine relaxation by nitroglycerin.
Csavoy, AN; Datta, S; Segal, S, 1998
)
0.56
" The duration of intravenous nitroglycerin therapy ranged from 14-55 days, and the maximum dosage was 50-400 microg/minute."( Intravenous nitroglycerin tolerance in patients with ischemic cardiomyopathy and congestive heart failure.
Earl, GL; Spinler, SA; Stanek, EJ,
)
0.8
" To assess whether an unattenuated antiischemic and antianginal efficacy during the hours of intermittent dosing can be maintained, a modified drug-release profile with increasing plasma concentrations was evaluated using a double-blind, placebo-controlled crossover protocol."( Increasing nitroglycerin release from patches enables circumvention of early nitrate tolerance.
Lehmann, G; Reiniger, G, 1998
)
0.69
" ISO displaced to the left the dose-response curves to all nitrovasodilators and increased the negative logarithm of their median effective concentration (EC50) values."( Potentiation by isoniazid of relaxation induced by nitrovasodilators in rat aorta.
Fernández, G; Vidrio, H, 1998
)
0.3
" The chronotherapy of peptic ulcer disease achieved by the evening dosing of H 2-receptor antagonists and of asthma by the evening dosing of special drug delivery forms of theophylline and morning methylprednisolone administration has proven to be beneficial."( Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease.
Portaluppi, F; Smolensky, MH, 1999
)
0.3
"With the dosage regimen used, supplemented with epinephrine, amrinone provides a higher cardiac output and more favorable oxygen dynamics than a combination of dopamine and nitroglycerin."( Amrinone versus dopamine and nitroglycerin in neonates after arterial switch operation for transposition of the great arteries.
Happonen, JM; Laitinen, P; Peltola, K; Rautiainen, P; Sairanen, H, 1999
)
0.79
"0 mg NTG produced a marked shift of the dose-response curve for arterial pressure depression induced by intravenous injection of the challenge doses of NTG."( Increased nitric oxide concentrations in posterior hypothalamus and central sympathetic function on nitrate tolerance following subcutaneous nitroglycerin.
Byrns, R; Ignarro, LJ; Li, XY; Ma, SX, 1999
)
0.5
"Nitroglycerin infusion caused a significant increase in maternal and fetal heart rate and a significant decrease in maternal and fetal mean arterial pressure at a dosage of 10 microram/kg per minute, without a change in blood gas values."( Effects of nitroglycerin and indomethacin on fetal-maternal circulation and on fetal cerebral blood flow and metabolism in sheep.
Harrison, MR; Heymann, MA; Morris, JA; Roman, C; Skarsgard, ED; VanderWall, KJ, 1999
)
2.14
" The addition of superoxide dismutase (SOD), 100 U/ml produced a shift to the left in the antiaggregant dose-response curve for XOR."( Inhibition of platelet aggregation with glyceryl trinitrate and xanthine oxidoreductase.
Benjamin, N; Blake, D; Millar, T; O'Byrne, S; Shirodaria, C; Stevens, C, 2000
)
0.31
" Dose-response curves to bradykinin and nitroglycerin were obtained from 12 subjects with OSAS and 12 matched control subjects."( Vascular reactivity in obstructive sleep apnea syndrome.
Blaschke, TF; Duchna, HW; Faul, JL; Guilleminault, C; Hoffman, BB; Moreno, H; Stoohs, RA, 2000
)
0.57
" The dose-response curve of CpCr(NO)2Cl was displaced to the right by hemoglobin, as well as methylene blue, showing involvement of the NO/cGMP pathway."( Vasodilator effects of organotransition-metal nitrosyl complexes, novel nitric oxide donors.
Legzdins, P; Pang, CC; Poon, JS; Wang, YX, 2000
)
0.31
" Particular attention was reserved to some controversial topics, such as the tilting angle, the duration of the passive and pharmacological stages of the test, the type and dosage of the drug utilized."( [The tilt test enhanced with oral nitroglycerin in patients with unexplained syncope: the Italian Protocol. The Working Group on Syncope of the Associazione Italiana di Aritmologia e Cardiostimolazione--the Arrhythmia Area of the Associazione Nazionale Me
Alboni, P; Ammirati, F; Bartoletti, A; Brignole, M; Del Rosso, A; Foglia Manzillo, G; Menozzi, C; Raviele, A, 2000
)
0.59
" The time course and dose-response characteristics indicate that these are two separate actions of NO on human muscle working in vivo."( The influence of nitric oxide on in vivo human skeletal muscle properties.
Folland, JP; Jones, DA; Maas, H, 2000
)
0.31
" The circulatory and metabolic conditions under induced hypotensive anesthesia were influenced by both vasodilators and anesthetics, and the dosage of vasodilator to decrease arterial blood pressure was dependent on the anesthetic used simultaneously."( [Comparisons of vasodilators and anesthetics in their effects on the circulatory and metabolic conditions during hypotensive anesthesia].
Toi, T, 2000
)
0.31
" This dose of ZD2574 markedly blunted the pressor response to ET-1, indicating effective blockade of ET(A) receptors, and also abolished the initial transient depressor response to ET-1, indicating that blockade of endothelial ET(B) receptors also occurred using this dosage regimen for ZD2574."( Endothelin receptor antagonism does not prevent the development of in vivo glyceryl trinitrate tolerance in the rat.
Adams, MA; Bennett, BM; Fraser, AB; Ratz, JD; Rees-Milton, KJ, 2000
)
0.31
"To study smooth muscle function in atherosclerosis, we calculated dose-response curves in patients with coronary artery disease and in controls by measuring changes in brachial artery diameter after incremental sublingual doses of nitroglycerin."( Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis.
Celermajer, DS; Raitakari, OT; Seale, JP, 2001
)
0.78
" Using an ex vivo model of coronary perfusion in rabbits, we found a dose-response relationship between VEGF and the efficiency of adenoviral gene transfer."( Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium.
Donahue, JK; Lawrence, JH; Marbán, E; Nagata, K, 2001
)
0.31
" After baseline, maximal contraction of the rings was achieved using 60 mmol/l of KCl, they were exposed to increasing doses of ISDN and NTG (10-100 microg/ml), and dose-response curves were recorded."( Vasoactive response of different parts of human internal thoracic artery to isosorbide-dinitrate and nitroglycerin: an in-vitro study.
Frolkis, I; Gurevitch, J; Kramer, A; Locker, C; Mohr, R; Paz, Y; Pevni, D; Shapira, I, 2001
)
0.53
" Vasodilator response to bradykinin, expressed as the within-subject mean difference in the area under the dose-response curve between phases, was significantly increased at midcycle compared with that in the early menstrual phase (486."( Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women.
Chan, NN; Colhoun, HM; Hingorani, AD; MacAllister, RJ; Vallance, P, 2001
)
0.31
" In two groups of 12 patients, nitroglycerin was added to the perfusate either in a dosage of 3 microg."( Changes in coronary vessel resistance during postischemic reperfusion and effectiveness of nitroglycerin.
Gams, E; Godehardt, E; Kalweit, GA; Schipke, JD, 2001
)
0.82
" There was different selectivity in dosage between arterial and venous vasodilatation, and the change in hemodynamics was independent of dosage."( Effect of intravenous nitroglycerin on hemodynamics in infants and children with congestive heart failure.
Du, J; Li, W; Sun, L; Zeng, H, 2000
)
0.62
" The dose-response effects of CpCr(NO)(2)Cl and nitroglycerin on the mean arterial pressure and the mean circulatory filling pressure (index of the body venous tone) were obtained in rats continuously infused with either normal saline or noradrenaline."( Venodilator action of an organotransition-metal nitrosyl complex.
Pang, CC; Poon, KS, 2002
)
0.57
" Vitamin C inhibited relaxation to GTN but potentiated relaxations to NP and SNAP, causing a parallel shift to a lower concentration range of the log dose-response curve by approximately one log unit at the highest dose."( Divergent effects of vitamin C on relaxations of rabbit aortic rings to acetylcholine and NO-donors.
Chowienczyk, PJ; de Saram, K; Khokher, S; McNeill, KL; Ritter, JM, 2002
)
0.31
"The vasodilator response to bradykinin, expressed as the within-subject mean difference in area under the dose-response curve between study 2 and study 1, was significantly diminished (-744."( The effects of hormone replacement therapy on endothelial function in women with Turner's syndrome.
Chan, NN; Colhoun, HM; Conway, GS; Hingorani, AD; MacAllister, RJ; Vallance, P, 2002
)
0.31
" The rats were anesthetized with sodium pentobarbital 18-24 h after the last dosing with ISDN or its vehicle."( Penile erectile responses to cavernous nerve stimulation in rats are not affected by nitrate tolerance.
Adachi, H, 2002
)
0.31
" After preconstriction with methoxamine (10(-4) mol/L), a dose-response study was performed using 6 cumulative doses of NTG or SNAP (10(-7) to 3 x 10(-5) mol/L)."( Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers.
Cadelina, GW; Dudenhoefer, AA; Groszmann, RJ; Gupta, T; Loureiro-Silva, MR, 2002
)
0.65
" However, the optimal combination, and dosage of cardiovascular drugs to minimize side effects, and to improve outcome has yet to be found."( Combination drug therapy with vasopressin, adrenaline (epinephrine) and nitroglycerin improves vital organ blood flow in a porcine model of ventricular fibrillation.
Benditt, D; Iskos, DN; Lindner, KH; Lurie, KG; McKnite, SH; Sugiyama, A; Voelckel, WG; Wenzel, V; Zielinski, TM, 2002
)
0.55
" A larger placebo-controlled study is necessary to establish the optimum dosage level and to minimize the side effects."( Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: a pilot study.
Berman, JR; Berman, LA; Vierregger, K; Walsh, KE,
)
0.42
"The aim of this study was to determine the optimal dose and dosing interval of nitroglycerin ointment to heal chronic anal fissures."( A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissures.
Bailey, HR; Beck, DE; Billingham, RP; Binderow, SR; Gibbons, RD; Gottesman, L; Hull, TL; Larach, SW; Margolin, DA; Milsom, JW; Potenti, FM; Rafferty, JF; Riff, DS; Sands, LR; Senagore, A; Stamos, MJ; Yee, LF; Young-Fadok, TM, 2002
)
0.85
"This study addressed the dose-response to three different concentrations of GTN ointment compared with placebo in a double blind randomised controlled trial."( A dose finding study with 0.1%, 0.2%, and 0.4% glyceryl trinitrate ointment in patients with chronic anal fissures.
Athanasiadis, S; Bock, JU; Herold, A; Marla, B; Pröls, M; Richter, HJ; Scholefield, JH, 2003
)
0.32
" These results show that, at these dosage levels, provision of substrate for NO production or provision of an NO donor were beneficial to the recovery of myocardial and pulmonary vascular function."( Effect of L-arginine or nitroglycerine during deep hypothermic circulatory arrest in neonatal lambs.
Hatsuoka, S; Mayer, JE; Nagashima, M; Sakamoto, T; Stock, UA, 2003
)
0.63
" The diagnosis of paroxystic ischemic mitral regurgitation was confirmed and a treatment based on high dosage of calcium-blocker was decided."( [Mitral insufficiency related to a spasm of the left anterior descending artery. A case report].
Avierinos, JF; Bonnet, JL; Collart, F; Dieuzaide, P; Franceschi, F; Habib, G; Mesana, T; Quilici, J; Sbragia, P; Thuny, F, 2003
)
0.32
" Currently, an intermittent dosing strategy is the only practical way to limit the development of tolerance or attenuation of nitrate actions."( How to use nitrates.
Abrams, J, 2002
)
0.31
" After baseline contraction of the rings, achieved using 60 mmol/L of KCl, they were exposed to increasing doses of ISDN and NTG (10 to 100 microg/ml), and dose-response curves were recorded."( Comparison of vasoactive response of left and right internal thoracic arteries to isosorbide-dinitrate and nitroglycerin: an in vitro study.
Frolkis, I; Kramer, A; Lev-Ran, O; Mohr, R; Paz, Y; Pevni, D; Shapira, I,
)
0.34
" Dosing schedules that include a nitrate-free period often fail to ameliorate the development of nitrate tolerance, and, in fact, can result in an increase in rebound ischemia."( Organic nitrate tolerance and endothelial dysfunction: role of folate therapy.
Leopold, JA; Loscalzo, J, 2003
)
0.32
" After individual dose-response curves to phenylephrine had been established, veins were preconstricted to 70% of the maximal phenylephrine-induced constriction."( Venous response to nitroglycerin is enhanced in young, healthy carriers of the 825T allele of the G protein beta3 subunit gene (GNB3).
Bührmann, S; Mitchell, A; Nürnberger, J; Philipp, T; Schäfers, RF; Seifert, A; Siffert, W; Wenzel, RR, 2003
)
0.65
" Resistance to ID, SF in group 1 was relative and depended on dosage form of nitrates."( [Nitrates in therapy of effort angina in hypotensive patients].
Borovkova, NV; Chernov, VI; Demochko, AV; Idrisova, EM; Karpov, RS; Kladieva, EA; Shishkina, AA; Vorob'eva, EV, 2003
)
0.32
" Treadmill exercise 12 hours (trough) and 4 hours (peak) after dosing was assessed after 2, 6 (trough only), and 12 weeks of treatment."( Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA, 2004
)
0.32
" Furthermore, we determined whether a reduced dosage of estrogen may maintain its beneficial effects."( New methods to evaluate endothelial function: Non-invasive method of evaluating endothelial function in humans.
Akita, H; Hashimoto, M; Matsuda, Y; Miyamoto, Y, 2003
)
0.32
"We examined the effects of dose and dosing protocol on the pharmacodynamics of in vivo nitroglycerin (NTG) tolerance in conscious rats."( Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol.
Balthasar, JP; Fung, HL; Wang, EQ, 2004
)
0.84
"Our data showed that in vivo nitrate tolerance was dose- and dosing protocol-dependent."( Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol.
Balthasar, JP; Fung, HL; Wang, EQ, 2004
)
0.62
" Data were abstracted from published reports and meeting abstracts, assessing method of randomization, blinding, "intention to treat" and dropouts, therapies, supportive measures, dosing and frequency, and crossovers."( A systematic review of medical therapy for anal fissure.
Nelson, R, 2004
)
0.32
" Prazosin caused an average of 16 mm Hg depression in MAP, and it only slightly potentiated the hypotensive effects of bolus doses of NTG both after acute dosing and during continuous infusion."( Prazosin potentiates the acute hypotensive effects of nitroglycerin but does not attenuate nitrate tolerance in normal conscious rats.
Fung, HL; Wang, EQ, 2004
)
0.57
" These findings suggest that effect of NTG on nNOS at a high dosage may involve the cycloxygenase pathway and that activation of the peripheral 5-HT1B/D receptors is not able to modify this effect."( Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan.
Pardutz, A; Schoenen, J; Szatmári, E; Vecsei, L, 2004
)
1.77
" A daily dosage of 75 to 150 mg is sufficient to reduce the rate of future cardiac events."( [Risk management of coronary artery disease--pharmacological therapy].
Hofmann, T, 2004
)
0.32
"This study was performed to investigate the risk of cardiac events by eccentric or continuous dosing of nitrates in patients with healed myocardial infarction."( Eccentric dosing of nitrates does not increase cardiac events in patients with healed myocardial infarction.
Haku, R; Ishikawa, K; Kai, T; Kanamasa, K; Kitayama, K; Morii, H; Nagatani, Y; Naito, N; Nakano, K; Tanaka, Y; Yonekawa, O, 2004
)
0.32
" However, because the physiologic response has resolved in fewer than 20 minutes, the dosing regime should be reassessed."( Manometric effect of topical glyceryl trinitrate and its impact on chronic anal fissure healing.
Kennedy, ML; King, DW; Thornton, MJ, 2005
)
0.33
"The efficacy and safety of a once-daily graded-release diltiazem hydrochloride (GRD) formulation dosed at 10 PM in doses of 180, 360, and 420 mg were compared with placebo and with GRD 360 mg dosed once daily at 8 AM in patients (n = 311) with chronic stable angina pectoris."( Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris.
Albert, KS; Gana, TJ; Glasser, SP; Pascual, LG, 2005
)
0.33
"Bedtime GRD significantly increases exercise tolerance in patients with angina pectoris over the 24-hour dosing interval."( Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris.
Albert, KS; Gana, TJ; Glasser, SP; Pascual, LG, 2005
)
0.33
" Effects of each nitrate on pulse wave reflection (augmentation index (AIx)), platelet response to adenosine di-phosphate (ADP 1 micromol l(-1)), nitroglycerine (NTG 100 micromol l(-1)) and the non-nitrate NO donor sodium nitroprusside (SNP 10 micromol l(-1)), were measured pre-dose, 4 and 8 h post dose, on three occasions: 1) at the end of a pre-nitrate phase, 2) after dosing for 7 days and 3) following 14 days of full dose therapy with either nitrate."( Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.
Chirkov, YY; Holmes, AS; Horowitz, JD; Pereira, J; Poropat, S; Willoughby, SR, 2005
)
0.79
" Dose-response curves with increasing GTN infusions after 24 h GTN-patch pretreatment revealed a significant attenuation of the MAP decrease compared to placebo."( Nitroglycerin-patch induced tolerance is associated with reduced ability of nitroglycerin to increase exhaled nitric oxide.
Agvald, P; Gustafsson, LE; Hammar, L, 2005
)
1.77
"000) and the difference was significantly greater in lower dosage of nitroglycerin compared with higher dosage."( Clinical trial of nitroglycerin-induced controlled hypotension with or without acupoint electrical stimulation in microscopic middle ear surgery under general anesthesia with halothane.
Ahmadi, A; Rezvani, M; Saghaei, M, 2005
)
0.9
"A placebo-controlled, double-blind, dose-response study of amlodipine (1."( A double-blind, placebo-controlled, parallel dose-response study of amlodipine in stable exertional angina pectoris.
Cocco, G; Jackson, N; Lee, P; Taylor, SH, 1991
)
0.28
" Incubation with CGRP8-37 (10(-6) M) specifically during the 90-minute desensitization period with nitroglycerin resulted in even greater impairment in the response to nitroglycerin in tolerant rings, even though the calcitonin gene-related peptide antagonist had been washed out before completion of the nitroglycerin dose-response curve."( Nitroglycerin-induced release of calcitonin gene-related peptide from sensory nerves attenuates the development of nitrate tolerance.
Ghatta, S; O'Rourke, ST, 2006
)
1.99
" This study compares conventional digital application with precise intra-anal dosing of nitroglycerin using a specialized dose-delivery device and anal cannula."( Controlled dose delivery in topical treatment of anal fissure: pilot study of a new paradigm.
Salgado, G; Torrabadella, L, 2006
)
0.56
"Controlled intra-anal dosing of topical nitroglycerin produces a significantly greater reduction in sphincteric pressure and lower incidence of headaches than with perianal administration of the same dose of ointment."( Controlled dose delivery in topical treatment of anal fissure: pilot study of a new paradigm.
Salgado, G; Torrabadella, L, 2006
)
0.6
"Stable patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or placebo twice a day for 6 weeks."( Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH, 2006
)
0.33
"It has been reported that the nitrate tolerance related to continuous dosing of nitrates reduces drug efficacy, and therefore eccentric dosing of nitrates is recommended."( Inhibition of nitrate tolerance without reducing vascular response during eccentric dosing of nitrates.
Kanamasa, K; Morii, H; Naito, N; Nakano, K, 2006
)
0.33
" Knowledge deficits were evident concerning the proper dosage and administration of SLN, even in patients with a longstanding history of angina."( NURSE: Nitroglycerin Use: Revisiting Strategies for Efficacy.
Duke, S; Nichols, N; Oldford, D, 2007
)
0.79
"With close monitoring of blood pressure and heart rate, men with stable coronary artery disease who have taken sildenafil may tolerate intravenous NTG (( Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.
Bart, BA; Glue, P; Jen, F; Koren, MJ; Malhotra, B; Parker, JD; Siegel, RL; Wang, H; Webb, DJ, 2007
)
0.65
" The 4 high-dose NTG pulse injections produced a marked shift in the dose-response curves for arterial pressure depression induced by intravenous injection of the challenge doses of NTG, but did not alter hypotensive responses to sodium nitroprusside."( Effects of nitric oxide and noradrenergic activation in the posterior hypothalamus on arterial pressure tolerance to nitroglycerin in rats.
Guettler, DL; Ma, SX, 2008
)
0.56
" However, the preferred type of beta-adrenergic receptor agonist and dosage are unclear."( Acute tocolysis for uterine activity reduction in term labor: a review.
de Heus, R; Derks, JB; Mulder, EJ; Visser, GH, 2008
)
0.35
" The clinical experience including indications for use, contraindications, dosage and monitoring has been reviewed."( Nesiritide: the clinical experience.
Weeks, SG, 2008
)
0.35
" Whereas the discussion of leaching of plasticizers is focussed on the toxicological properties of a drug packaging system, the sorption of drug formulation compounds has an influence on the dosage of the active pharmaceutical ingredient resulting in a reduced drug delivery to the patient."( Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application.
Brandsch, R; Treleano, A; Welle, F; Wolz, G, 2009
)
0.63
" Once-daily dosing with 22."( Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss.
Grimes, JP; Hoover, DR; Wilson, AC; Wimalawansa, SJ, 2009
)
0.73
"A dose-response study was performed in 17 patients with cardiogenic shock (n = 9) or end-stage chronic heart failure (n = 8) admitted to Erasmus University Medical Center."( Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure.
Caliskan, K; den Uil, CA; Jewbali, LS; Lagrand, WK; Simoons, ML; Spronk, PE; van der Ent, M; van Kuijk, JP, 2009
)
0.65
"Prophylactic GTN is useful for prevention of post-ERCP pancreatitis, but the optimal dosage and the optimal route and timing of administration need further clarification before this treatment can come into routine clinical use."( Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Bai, Y; Gao, J; Li, ZS; Xu, C; Yang, X; Zou, DW, 2009
)
0.35
" We examined whether NMD is impaired in obesity by performing a GTN dose-response study, as this is a potentially more sensitive measure of arterial smooth muscle function."( Severe obesity is associated with impaired arterial smooth muscle function in young adults.
Ayer, JG; Celermajer, DS; David, C; Harmer, JA; S Steinbeck, K; Seale, JP, 2011
)
0.37
" However, no study has evaluated the comparative safety, efficacy, and biomarkers of optimally dosed nesiritide versus nitroglycerin in ADHF."( Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure.
Chew, E; Chow, SL; Heywood, JT; O'Barr, SA; Pak, F; Patel, P; Patterson, JH; Peng, J; Quist, R, 2011
)
0.81
" Anecdotal references regarding the use of topical nitroglycerin ointment for lower extremity pain are frequently encountered when discussing treatment options with other wound care specialists but no specific dosing information was found after searching current literature."( Treatment of chronic lower extremity wound pain with nitroglycerin ointment.
Jimenez, ER; Whitney-Caglia, L,
)
0.63
" New insight has been gained regarding volume management, including dosing strategies for intravenous loop diuretics and the role of ultrafiltration in patients with heart failure and renal dysfunction."( Acute decompensated heart failure: update on new and emerging evidence and directions for future research.
Albert, NM; Butler, J; Carson, PE; Collins, SP; Colvin-Adams, M; Dimarco, JP; Ezekowitz, JA; Fang, JC; Givertz, MM; Hernandez, AF; Hershberger, RE; Katz, SD; Krishnamani, R; Rogers, JG; Spertus, JA; Starling, RC; Stevenson, WG; Stough, WG; Sweitzer, NK; Tang, WH; Teerlink, JR; Walsh, MN; Westlake Canary, CA, 2013
)
0.39
" Thus, CVP can be used to guide NG dosage and fluid administration at horizontal position."( Nitroglycerine and patient position effect on central, hepatic and portal venous pressures during liver surgery.
Houltz, E; Lundin, S; Rizell, M; Sand, L; Stenqvist, O; Wiklund, J, 2014
)
1.85
" Nitroglycerin has a rapid onset of action and short half-life and there is a clear dose-response curve on both global hemodynamics and peripheral circulation."( Impact of intravenous nitroglycerin in the management of acute decompensated heart failure.
Brugts, JJ; den Uil, CA, 2015
)
1.64
" The primary outcomes include: the frequency of angina pectoris attack; the dosage of nitroglycerin; body limited dimension of Seattle Angina Questionnaire."( Traditional Chinese medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial.
Du, Y; Kong, D; Liu, Y; Wang, Y; Yang, G; Zhang, F; Zhang, H; Zhang, Z, 2014
)
0.63
"The increasing doses of NTG determined a progressive increase of NMD in both groups, but the dose-response curve was significantly lower in smokers compared to controls (p < 0."( Effect of smoking on endothelium-independent vasodilatation.
Crea, F; Di Franco, A; Lamendola, P; Lanza, GA; Russo, G; Spera, FR; Villano, A, 2015
)
0.42
" Outcomes were (i) delay from bag-to-bloodstream arrival and (ii) the dosage showing on the infusion pump when the sham drug first exits the cannula (aka the 'presumed initial dosage')."( How intravenous nitroglycerine transit time from bag-to-bloodstream can be affected by infusion technique: a simulation study.
Brindley, PG; Corry, A; Douma, MJ; O'Dochartaigh, D, 2015
)
0.76
"There was a statistically significant difference in both (i) time-to-bloodstream arrival and (ii) the dosage showing on the infusion pump as the sham first exits the cannula with (i) different cannulae, (ii) different accessories and (iii) presence of a carrier line."( How intravenous nitroglycerine transit time from bag-to-bloodstream can be affected by infusion technique: a simulation study.
Brindley, PG; Corry, A; Douma, MJ; O'Dochartaigh, D, 2015
)
0.76
"(i) Cardiac shock wave therapy improves the angina pectoris symptom (including the decrease of Canadian Cardiovascular Society class [-0·86 (-1·12, -0·65), P < 0·00001], nitroglycerin dosage (times/weeks) [-0·71 (-1·08, -0·33), P = 0·0002] and a increase of Seattle Angina Questionnaire score [5·64 (3·12, 8·15), P < 0·0001)]); (ii) CSWT leads to a reduce in heart failure (including a reduction of New York Heart Association functional class [-0·49 (-0·62, -0·37), P < 0·00001], a stable rise in 6-min walking distance [68·38 (39·70, 97·05), P < 0·00001] and a growth in left ventricular ejection fraction with echocardiography screening [6·73 (4·67,8·80), P < 0·00001]); (iii) CSWT improves myocardial viability within improving in total score of perfusion imaging [-5·19 (-8·08, -2·30), P = 0·0004] and total score of metabolism imaging [-5·33 (-7·77, -2·90), P < 0·0001]."( Clinical effect of cardiac shock wave therapy on patients with ischaemic heart disease: a systematic review and meta-analysis.
Guo, T; Liu, L; Pan, X; Wang, J; Zhou, C, 2015
)
0.61
" Future studies should pay attention to the delicate balance between sufficient dosing and timely normalization of plasma haem levels."( Vascular and metabolic effects of the haem oxygenase-1 inducer haem arginate in subjects with the metabolic syndrome: A translational cross-over study.
Bilos, A; Dekker, D; Dorresteijn, MJ; Pennings, SW; Peters, WH; Smits, P; Wagener, FA, 2016
)
0.43
"The protocols varied widely in terms of medication and dosing choices, as well as listed contraindications to treatments."( Chest Pain of Suspected Cardiac Origin: Current Evidence-based Recommendations for Prehospital Care.
Barger, JA; Brown, JF; Gilbert, GH; Koenig, KL; Rudnick, EM; Salvucci, AA; Savino, PB; Sporer, KA, 2015
)
0.42
"Twenty-one consecutive patients with CHF and CSR (apnea-hypopnea index [AHI] ≥15/h) underwent right heart catheterization with titration of intravenous (IV) glyceryltrinitrate (GTN) to a maximum tolerable dosage and inhalation of iloprost 10 μg/mL after a washout phase."( Acute improvement of pulmonary hemodynamics does not alleviate Cheyne-Stokes respiration in chronic heart failure-a randomized, controlled, double-blind, crossover trial.
Bitter, T; Dimitriadis, Z; Fox, H; Horstkotte, D; Oldenburg, O; Schmalgemeier, H; Spiesshöfer, J; Wellmann, B; Zwenke, A, 2016
)
0.43
" Because no standard dose of GTN is available following emergent large vessel occlusion, we performed a dose-response (3."( Intra-arterial nitroglycerin as directed acute treatment in experimental ischemic stroke.
Bix, GJ; Fraser, JF; Gorman, A; Learoyd, AE; Maniskas, ME; Roberts, JM; Trueman, R, 2018
)
0.83
" Currently, there is no research on direct observations of the vasodilatory effect of nitroglycerin sublingual tablets, which is the generally used dosage form."( Vasodilatory effect of nitroglycerin in Japanese subjects with different aldehyde dehydrogenase 2 (ALDH2) genotypes.
Miura, T; Nishinaka, T; Terada, T; Yonezawa, K, 2017
)
0.99
" Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen."( Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Ackerstaff, J; Becker-Pelster, EM; Fey, P; Follmann, M; Geiss, V; Gerisch, M; Griebenow, N; Jautelat, R; Kern, A; Knorr, A; Kretschmer, A; Kroh, W; Lang, D; Li, V; Lustig, K; Mittendorf, J; Mondritzki, T; Redlich, G; Sandner, P; Schirok, H; Schlemmer, KH; Stasch, JP; Straub, A; Tinel, H; Trübel, H; Wunder, F, 2017
)
0.46
" Only 1 method of preventing nitrate tolerance remains widely accepted: the use of a dosing strategy that provides an interval of no or low nitrate exposure during each 24-h period."( The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.
Divakaran, S; Loscalzo, J, 2017
)
0.83
" Many patients do not understand how to correctly apply a transdermal dosage patch."( PATIENTS' KNOWLEDGE OF MEDICAL PATCHES IN HUNGARY.
Somogyi, O; Zelko, R, 2016
)
0.43
" Although there are Free Open Access Medical Education (FOAM) based podcasts as well as few studies to suggest the use of HDN, the evidence is limited by statistical flaws, incomplete dosing parameters and inconsistent methods of administration."( Recognition of Sympathetic Crashing Acute Pulmonary Edema (SCAPE) and use of high-dose nitroglycerin infusion.
Clarkson, L; Paone, S; Punnapuzha, S; Sin, B, 2018
)
0.7
"Based on this systematic review, Sini decoction can reduce the dosage of nitroglycerin,\ when compared with isosorbide dinitrate group."( Sini decoction as an adjuvant therapy for angina pectoris: a systematic review of randomized controlled trials.
Fei, Y; Wu, J; Xia, W; Yang, G; Yang, M; Yuan, D; Zhang, H; Zhang, Z, 2017
)
0.69
" Administration of ASA increased the infarct severity; however, concomitant dosing with NTG somewhat attenuated this effect."( Nitroglycerin application and coronary arteriogenesis.
Bramlage, P; Buschmann, IR; Dawid, R; Dülsner, A; Gatzke, N; Gorath, M; Güc, N; Hillmeister, P; Pagonas, N; Smith, KH, 2018
)
1.92
" However, these different dosage forms are not all equal in terms of safety and efficacy, and not every one is commercially available for use in clinical practice."( Use of nitroglycerin ointment to treat primary and secondary Raynaud's phenomenon: a systematic literature review.
Chan, T; Cruz, JE; Hermes-DeSantis, ER; Luen, M; Qiu, O, 2018
)
0.94
"Based on the clinical drug dosage analysis, the modeling of cardiovascular system with baroreceptor model is mathematically modeled using compartmental approach, considering the relationship between the volume and flow rate of blood during each heartbeat."( Controlled infusion of intravenous cardiac drugs using global optimization.
Sivakumar, VM; Sowparnika, GC; Thirumarimurugan, M; Vinoth, N,
)
0.13
" Future well-designed randomized controlled trials are needed to elucidate optimal dosing strategies and confirm safety and efficacy of high-dose nitrates."( Role of high-dose intravenous nitrates in hypertensive acute heart failure.
Samai, K; Wang, K, 2020
)
0.56
" This study investigated the effects of nitroglycerin on oxytocin-desensitized and oxytocin-naïve human myometrium and the subsequent response to oxytocin dose-response testing in vitro."( The Effects of Nitroglycerin on the Oxytocin Dose-Response Profile in Oxytocin-Desensitized and Naïve Human Myometrium: An In Vitro Study.
Balki, M; Carvalho, JCA; Jayasooriya, GS; Luca, A, 2021
)
1.24
" All groups then underwent oxytocin dose-response testing."( The Effects of Nitroglycerin on the Oxytocin Dose-Response Profile in Oxytocin-Desensitized and Naïve Human Myometrium: An In Vitro Study.
Balki, M; Carvalho, JCA; Jayasooriya, GS; Luca, A, 2021
)
0.97
" On oxytocin dose-response testing, motility index was highest in oxytocin-naïve and no nitroglycerin samples (group 4) (1."( The Effects of Nitroglycerin on the Oxytocin Dose-Response Profile in Oxytocin-Desensitized and Naïve Human Myometrium: An In Vitro Study.
Balki, M; Carvalho, JCA; Jayasooriya, GS; Luca, A, 2021
)
1.2
" The pooled results also demonstrated that BADs provided a significant benefit in reducing the dosage of nitroglycerin required (P = ."( Effect of Chinese medicine for promoting blood circulation on microvascular angina: A systematic review and meta-analysis.
Chen, B; Chen, Y; Jin, Z; Zhong, L; Zhuang, J, 2020
)
0.77
" The proposed sensing method was applied successfully for the analysis of nitroglycerin and isosorbide dinitrate in dosage forms within concentration range of (0."( Fluorescent sensing for some nitric oxide donors in dosage forms and biological matrices.
ElOnsy, S; Keshk, RM; Talaat, W, 2021
)
0.85
" Further study is required to provide evidence for inhaled nitroglycerin use in this setting including the appropriate dosing and potential side effects with repeated administration."( Nitroglycerin inhalation for acute treatment of pulmonary arterial hypertension in children with congenital heart disease.
Marwali, EM; Rayhan, M; Roebiono, PS, 2021
)
2.31
"The effects were independent of the dosage used."( Effectiveness of topical glyceryl trinitrate in treatment of tendinopathy - systematic review and meta-analysis.
Johansson, J; Juhola, J; Kemppi, V; Saltychev, M, 2022
)
0.72
" The norepinephrine dosage necessary in the operation was of no difference in two groups (P > 0."( Milrinone is better choice for controlled low central venous pressure during hepatectomy: A randomized, controlled trial comparing with nitroglycerin.
Chen, X; Gao, S; Hai, B; Huang, X; Xiong, W; Yang, P, 2021
)
0.82
"In patients with STEMI ischemia, giving nitroglycerin 10 min after aspirin dosing (compared to giving them simultaneously) leads to a greater than 20% reduction in need for additional nitroglycerin, a greater than 7% decrease in subjective pain experienced by the patient and reduced need for additional opioids."( The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome.
Todoroski, KB, 2021
)
1.16
" As such, a higher dosage of GTN is required in order to achieve the same vasodilatory and antiplatelet effects."( The Generation of Nitric Oxide from Aldehyde Dehydrogenase-2: The Role of Dietary Nitrates and Their Implication in Cardiovascular Disease Management.
Bosco, F; Cardamone, A; Carresi, C; Coppoletta, A; Gliozzi, M; Macrì, R; Maiuolo, J; Mollace, R; Mollace, V; Muscoli, C; Musolino, V; Oppedisano, F; Palma, E; Scarano, F, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (2 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care2

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Attitude Sensitive Skin Conditioner - Extra Gentle and Volumizing - Fragrance Free -- 8 fl ozAttitudeBeauty & Personal Carecitric acid, cetearyl alcohol, citric acid, glycerin, glyceryl, oat, sodium benzoate, sodium hydroxide2024-11-29 10:47:42
Tree to Tub Clarifying Shampoo for Oily Hair & Sensitive Scalp -- 8.5 fl ozTree to TubBeauty & Personal Carecaprylyl glycol, citric acid, 4-terpineol, citric acid, cocamidopropyl betaine, decyl glucoside, glyceryl caprylate, glyceryl, sodium benzoate2024-11-29 10:47:42

Roles (7)

RoleDescription
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
vasodilator agentA drug used to cause dilation of the blood vessels.
nitric oxide donorAn agent, with unique chemical structure and biochemical requirements, which generates nitric oxide.
explosiveA substance capable of undergoing rapid and highly exothermic decomposition.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
tocolytic agentAny compound used to suppress premature labour and immature birth by suppressing uterine contractions.
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
nitroglycerolA nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Muscle contraction7721
Smooth Muscle Contraction2015
Nitric Oxide Signaling Pathway128
nitroglycerin degradation17

Bioassays (105)

Assay IDTitleYearJournalArticle
AID178068Inhibition of methacholine-induced ECG changes in the anesthetized rat after intravenous administration.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID60299Collateral index in anesthetized dog at the dose of 0.03 mg/kg, i.v. after 60 minutes of administration2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232773Selectivity index as the ratio of doses requires to induce a reduction in MABP and that required to prevent ECG changes.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID76451In vitro NO (nitrous oxide) release by nitrite quanititation using Griess reaction without N-acetyl-cysteamine2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage-clamp studies of 2-nitrooxyethyl 1,4-dihydro- 2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate enantiomers.
AID77513In vitro nitric oxide release incubated in the absence of N-acetyl-cysteamine in phosphate buffer2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
AID374757Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID167355Vasorelaxation activity in the isolated endothelium-denuded rabbit aorta1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID1449015Vasorelaxant activity in normal Chinchilla rabbit saphenous artery ring administered at the beginning of the last resting period of 28 mins2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID227030Nitric oxide released from prodrug in the presence of cysteine1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Water soluble furoxan derivatives as NO prodrugs.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60814Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 1.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID457932Induction of NO release in presence of 5 mM L-cysteine2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.
AID437029Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma at 100 uM treated 2 mins before ADP challenge by turbidimetric method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
NO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs.
AID374763Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring in presence of chloral hydrate to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID218881In vitro vascular relaxation in canine mesenteric veins precontracted with phenylephrine.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID374759Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after ALDH2 inhibitor chloral hydrate treatment2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID374764Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded cross tolerant thoracic aortic ring preincubated with 0.55 mM GTN for 1 hr followed by washing to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ri2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID175492Compound was tested for its vasodilator effects on endothelium-denuded strips of rat aorta precontracted with noradrenaline1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID58416Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 0.3 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID318681Anticarcinogenic activity in rat assessed as induction of tumors per day2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
AID321900Nitric oxide release in PBS in presence of 5 mM L-cysteine at pH 7.4 in 37 degC after 1.5 hrs2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.
AID175666Effective concentration for relaxation of isolated rat aortic strips, submaximally contracted with phenylephrine at 0.1 uM was determined2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Neuroprotection against ischemic brain injury conferred by a novel nitrate ester.
AID58420Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 3.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID58418Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 1.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID1333730Induction of NO release in DMSO incubated up to 6 hrs by Griess assay2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Nitric oxide-donating derivatives of hederacolchiside A
AID175471Capacity to increase [Ca2+] entry into the vascular smooth muscle was evaluated on rat aorta strips partially depolarized with 50 mM K2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New 1,4-dihydropyridines endowed with NO-donor and calcium channel agonist properties.
AID225247Inhibition of crude cAMP phosphodiesterase from canine cardiac aorta (NR = no effect at 100 ug)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID60816Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 3.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID195179Relaxation of endothelium denucleated strips of rat aorta precontracted with noradrenaline1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Water soluble furoxan derivatives as NO prodrugs.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID60819Percent change heart rate after intravenous administration in anesthetized dogs at 0.3 mg/kg (NC<10%)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID457931Induction of NO release in phosphate buffer at pH 7.42010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID641620Vasorelaxation activity against KCl-induced contraction in isolated Wistar rat thoracic endothelium-denulated aortic rings2011Journal of medicinal chemistry, Nov-24, Volume: 54, Issue:22
Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.
AID395247Cardiac protection in Wistar rat assessed as decrease in infarct size at 5 ug/min/kg for 13 hrs prolonged treatment terminated 3 hrs before ischemia2008Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895
Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID60821Percent change in heart rate after intravenous administration in anesthetized dogs at 3.0 mg/kg (NC<10%)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID227028Nitric oxide released from prodrug in the absence of cysteine1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Water soluble furoxan derivatives as NO prodrugs.
AID77510In vitro release of nitric oxide by nitrite quantitation in the absence of N-acetyl-cysteamine by Griess reaction1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
The design of (-)-(S)-2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl) pyridine-5-carboxylate: a cardioselective positive inotropic derivative of Bay K 8644.
AID309710Vasodilatory effect in pig pulmonary artery assessed as inhibition of PGF2-alpha-induced contraction2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
NO donors. Part 16: investigations on structure-activity relationships of organic mononitrates reveal 2-nitrooxyethylammoniumnitrate as a high potent vasodilator.
AID76452In vitro NO (nitrous oxide) release by nitrite quanititation using Griess reaction in presence of N-acetyl-cysteamine2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage-clamp studies of 2-nitrooxyethyl 1,4-dihydro- 2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate enantiomers.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID60813Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 0.3 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID374760Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after 1 uM soluble guanylate cyclase heme site inhibitor ODQ treatment2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID733827Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction at 0.001 uM to 10 uM treated after KCl-challenge relative to control2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors.
AID173808Concentration required to reduce mean arterial blood pressure in rat after intravenous administration.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID352262Vasorelaxant activity in pig pulmonary artery by organ bath experiment2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
NO donors. Part 18: Bioactive metabolites of GTN and PETN--synthesis and vasorelaxant properties.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449016Vasorelaxant activity in nirate-tolerant Chinchilla rabbit saphenous artery ring administered at the beginning of the last resting period of 28 mins in presence of sorbide dinitrate2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID59574Maximum hypertension was measured in anesthetized dog as percent at the dose of 0.03 mg/kg, i.v.2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties.
AID374756Vasodilatory activity in Wistar rat endothelium-denuded cross tolerant thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction preincubated with 0.55 mM GTN for 1 hr followed by washing2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID226296Ratio of the CIAUC value to that of nitroglycerin (NTG ratio)2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties.
AID437026Induction of NO release in Wistar rat liver homogenate at 200 uM by amperometric detection method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
NO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs.
AID245849Concentration required for relaxation of PGF2-alpha (3 uM)-precontracted porcine pulmonary arteries; activity expressed as pD22004Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19
Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the beta-receptor blocking drug propranolol.
AID187573Percent recovery of noradrenergic tone after washing aortic preparations with fresh Kreb's buffer1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation.
AID1067178Inhibition of alpha-glucosidase (unknown origin) assessed as hydrolysis of pNP-alpha-Glu into pNP measured for 10 mins by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, nitric oxide release, and α-glucosidase inhibition of nitric oxide donating apigenin and chrysin derivatives.
AID77511In vitro release of nitric oxide by nitrite quantitation in the presence of N-acetyl-cysteamine by Griess reaction1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
The design of (-)-(S)-2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl) pyridine-5-carboxylate: a cardioselective positive inotropic derivative of Bay K 8644.
AID77514In vitro nitric oxide release incubated in the presence of N-acetyl-cysteamine in phosphate buffer2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID218879In vitro vascular relaxation in canine coronary arteries precontracted with prostaglandin F2alpha.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID59741Maximum collateral index in anesthetized dog at the dose of 0.03 mg/kg, i.v.2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID733826Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction treated after KCl-challenge2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID374758Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after ALDH2 inhibitor benomyl treatment2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID437027Vasorelaxant activity in endothelium-denuded Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
NO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs.
AID60820Percent change heart rate after intravenous administration in anesthetized dogs at 1.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1278461Suppression of elevated intraocular pressure in lasered monkey eye at 150 ug at 6 hrs2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy.
AID225250Inhibition of crude cGMP phosphodiesterase from canine thoracic aorta (NR = no effect at 100 ug)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID219085In vitro increase in contractile force in ferret papillary muscle strips (NR = not reached at 100 ug)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID374762Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring in presence of benomyl to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID167787Myocardial infarction (MI) size was calculated as a percentage of the infarct area to the total area of the left ventricle of male chinchilla rabbits1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Synthesis of some hydroxynaphthazarins and their cardioprotective effects under ischemia-reperfusion in vivo.
AID352494Nitric oxide release in phosphate buffer containing 5 mM L-cysteine at pH 7.4 incubated at 34 degC after 1.5 hrs2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies.
AID321898Nitric oxide release in PBS at pH 7.4 in 37 degC after 1.5 hrs2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1067179Induction of nitric oxide release at 10'-4 M after 1 hr by Griess assay in presence of L-cysteine relative to control2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, nitric oxide release, and α-glucosidase inhibition of nitric oxide donating apigenin and chrysin derivatives.
AID178994Inhibition of vasopressin-induced ECG changes in rat1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID352500Nitric oxide release in phosphate buffer at pH 7.4 incubated at 34 degC after 1.5 hrs2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11,899)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905280 (44.37)18.7374
1990's2894 (24.32)18.2507
2000's2189 (18.40)29.6817
2010's1188 (9.98)24.3611
2020's348 (2.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 102.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index102.34 (24.57)
Research Supply Index9.61 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index197.16 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (102.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2,240 (17.69%)5.53%
Reviews911 (7.20%)6.00%
Case Studies884 (6.98%)4.05%
Observational17 (0.13%)0.25%
Other8,607 (67.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (171)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Correlation Analysis of the Effects of Management Pressure Goals (Controlled Hypotension) and Control Volume Goals (Cardiac Output, Stroke Volume Variability, Central Venous Pressure) on Intraoperative Blood and Visual Field Quality [NCT03917004]160 participants (Anticipated)Interventional2019-04-01Recruiting
A Randomized Comparison of Nitroglycerin Versus Placebo as Spasmolytic Regimen to Prevent Moderate to Severe Radial Artery Spasm in Radial Center [NCT03889470]Phase 41,000 participants (Anticipated)Interventional2018-03-31Recruiting
A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12 [NCT01171170]Phase 2223 participants (Actual)Interventional2011-01-31Completed
A Randomized Comparison of Post-procedural/Pre-hemostasis Intraarterial Nitroglycerin Versus Nicardipine to Reduce Radial Artery Occlusion After Transradial Catheterization [NCT03622060]Phase 3600 participants (Actual)Interventional2018-06-04Completed
Assessment of Subclinical Atherosclerosis in Healthy Adult Immigrant Asian Indians Using Flow Mediated Endothelial Dysfunction Method [NCT01104597]0 participants (Actual)Interventional2010-04-30Withdrawn(stopped due to No subjects were enrolled into the study)
Application of Intraoperative Transesophageal Echocardiography Imaging of Vein and Controlled Low Central Venous Pressure in Early Prediction and Intervention of Acute Renal Injury Associated With Cardiac Surgery [NCT05682716]137 participants (Actual)Interventional2022-07-15Completed
The Effect of Subcutaneous Nitroglycerin on the Success Rate of Arterial Catheterization in Pediatric Patients: a Randomized Controlled Trial [NCT03849183]116 participants (Actual)Interventional2019-03-20Completed
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function [NCT03357731]Phase 249 participants (Actual)Interventional2017-11-30Completed
The Underlying Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia [NCT02059018]20 participants (Actual)Interventional2014-02-28Completed
Sex Differences in Symptomatic Non-Obstructive Coronary Disease: Do Women Have a Unique Coronary Pathophysiology? [NCT00823563]126 participants (Anticipated)Observational2007-06-30Recruiting
Application of Vitamin E Acetate Ointment vs Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure [NCT03787030]Phase 3160 participants (Actual)Interventional2018-12-21Completed
The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems [NCT03716050]Phase 2/Phase 317 participants (Actual)Interventional2018-01-30Terminated(stopped due to PI decision due to slow accrual)
Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis [NCT05711199]Early Phase 125 participants (Anticipated)Interventional2023-03-01Recruiting
The Effect of Nitroglycerin on the Incidence of Cardiorespiratory Side Effect During the Intra-arterial Chemotherapy in Pediatric Patients With Retinoblastoma: a Randomized, Double-blind, Placebo-controlled, Crossover Study [NCT04564521]36 participants (Anticipated)Interventional2020-09-28Recruiting
Yangxinshi Pills Plus Conventional Treatment Versus Placebo Plus Conventional Treatment on the Exercise Tolerance of the Patients With Coronary Heart Disease: a Multi-center,Randomised Controlled Clinical Trial [NCT03478332]Phase 290 participants (Anticipated)Interventional2017-06-01Recruiting
Subcutaneous Administration of Nitroglycerin to Facilitate Trans-radial Access in Coronary Procedures: a Randomized Clinical Trial (NITRAD-Sub Study). [NCT03304496]Phase 41,400 participants (Anticipated)Interventional2017-03-30Recruiting
Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial [NCT02413268]Phase 32,400 participants (Anticipated)Interventional2016-03-31Recruiting
Non-invasive Imaging of Human Gingival Microcirculation: Effect of Nitric Oxide [NCT03605095]40 participants (Actual)Interventional2018-07-25Completed
Efficacy of Phonophoresis With Topical Glyceryl Trinitrate in Treatment of Non-insertional Achilles Tendinopathy: a Randomized Controlled Trial [NCT05561959]64 participants (Actual)Interventional2022-11-01Completed
GOT-IT Trial: A Pragmatic Group Sequential Placebo Controlled Randomised Trial to Determine the Effectiveness of Glyceryl Trinitrate for Retained Placenta. [NCT02085213]Phase 41,107 participants (Actual)Interventional2014-09-30Completed
NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI [NCT05635851]Phase 226 participants (Anticipated)Interventional2023-09-30Not yet recruiting
A Novel Approach to Reduce Radial Artery Occlusion After Trans-Radial Catheterization: Post-Procedural/Pre-Hemostasis Intra-Arterial Nitroglycerin [NCT02105493]1,706 participants (Actual)Interventional2013-10-31Completed
Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients [NCT02577718]Phase 1/Phase 260 participants (Actual)Interventional2015-11-30Completed
Evaluation of the Effect of 0.4 mg Nitroglycerin Spray After Pretreatment With Multiple Once Daily Oral Doses of 2.5 mg, 5 mg and 10 mg Vericiguat (BAY 1021189) Each Given Over 14 ± 3 Days on Safety, Tolerability and Blood Pressure in a Multi-center, Rand [NCT02617550]Phase 136 participants (Actual)Interventional2015-11-18Completed
Nitroglycerin as a Sensitizer in the Treatment of Non Small Cell Lung Cancer: a Phase II Trial [NCT01210378]Phase 247 participants (Actual)Interventional2011-12-31Terminated(stopped due to Accrual stopped)
Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography. [NCT02258620]442 participants (Actual)Interventional2013-06-30Completed
Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial [NCT02280850]Phase 4300 participants (Anticipated)Interventional2014-10-31Not yet recruiting
Topical 5% Minoxidil Versus 0.2%Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure: a Randomized Controlled Trial [NCT03528772]62 participants (Actual)Interventional2018-05-10Completed
Effect of Nitric Oxide Donors on Uterine and Subendometrial Blood Flow in Patients With Unexplained Infertility [NCT03481582]60 participants (Actual)Interventional2017-11-01Completed
High Versus Low Dose Nitroglycerin in Management of Sympathetic Crashing Acute Pulmonary Edema [NCT06107465]Phase 2/Phase 360 participants (Anticipated)Interventional2023-11-10Enrolling by invitation
Perianal vs Endoanal Application of Glyceryl Trinitrate 0.4% Ointment in the Treatment of Chronic Anal Fissure: Results of a Randomized Controlled Trial. [NCT01132391]Phase 360 participants (Actual)Interventional2009-01-31Completed
Flushing Reduction Associated With Nitrates [NCT02714205]Phase 2141 participants (Actual)Interventional2017-04-24Completed
The Use of Topical Glyceryl Trinitrate (GTN) and Eccentric Exercises in the Treatment of Midportion Achilles Tendinopathy: a Randomized Placebo Controlled Trial [NCT02499484]76 participants (Actual)Interventional2016-09-30Completed
Absorption and Pharmacokinetics of Nitroglycerin as a Tablet or in the Form of Rapidly Degradable Capsule in Young Healthy [NCT03777605]Phase 410 participants (Anticipated)Interventional2018-12-23Not yet recruiting
The Effect Of Nebulizied Nitroglycerin As An Adjuvant Drug In Management Of Persistent Pulmonary Hypertension Of Newborns [NCT05741229]80 participants (Anticipated)Interventional2023-05-20Not yet recruiting
The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study [NCT01996436]Phase 4330 participants (Anticipated)Interventional2016-08-29Recruiting
A Phase 4, Multiple-dose, Pharmacokinetic, Safety, and Exploratory Efficacy Study of Nitroglycerin Ointment 0.4% (RECTIV®) in Adolescents (Age ≥12 to <17 Years) With Moderate to Severe Pain Due to Chronic Anal Fissure [NCT01920074]Phase 40 participants (Actual)Interventional2013-06-30Withdrawn(stopped due to Study stopped due to study enrollment challenges that impacted the feasibility of conducting the study.)
NITROGLYCERINE SKIN PATCH VS PLACEBO PATCH FOR ENHANCING CERVICAL RIPENING IN LABOR INDUCTION: A RANDOMIZED CONTROLLED TRIAL [NCT03320187]Phase 2/Phase 3100 participants (Actual)Interventional2016-12-31Completed
Anesthetic Advantages of Dexmedetomidine Compared With Nitroglycerin for Hypotensive Anesthesia in Orthognathic Surgery. A Randomized Clinical Trial. [NCT02083055]40 participants (Actual)Interventional2012-12-31Completed
New Perspective on Exploring the Post-apneic Blood Pressure Surge in Patients With Obstructive Sleep Apnea [NCT06172998]Early Phase 1350 participants (Anticipated)Interventional2022-04-01Recruiting
A Single Centre, Open-label, Randomised, Single Dose, Six Period, Reference Replicate, Crossover Study to Evaluate the Bioavailability of MED2005 [NCT04008732]Phase 140 participants (Actual)Interventional2017-11-15Completed
Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes [NCT01097551]38 participants (Actual)Observational2011-01-31Completed
Phase II Study That Evaluates Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer [NCT00886405]Phase 240 participants (Anticipated)Interventional2006-07-31Recruiting
INVERT: IV Nitroglycerin for Versions Trial - a Randomized Placebo-controlled Trial in Nulliparous Women [NCT00896311]82 participants (Actual)Interventional2003-03-31Completed
Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack [NCT04220606]39 participants (Actual)Interventional2015-04-30Completed
Perianal Application of Glyceryl Trinitrate 0.4% Ointment vs Percutaneous Posterior Tibial Nerve Stimulation in the Treatment of Chronic Anal Fissure [NCT02700438]Phase 380 participants (Actual)Interventional2014-01-31Completed
A Phase III, Dose Ranging, Multi-centre, Randomised, Double Blind, Placebo Controlled, Home Use, Parallel Group Clinical Trial of Topically-applied Glyceryl Trinitrate for the Treatment of Erectile Dysfunction, With an Open Label Extension [NCT03813992]Phase 31,005 participants (Actual)Interventional2018-11-01Completed
A Cohort Prospective Study of Predictors Influencing the Quality of Visualization of the Operating Field During Orthognathic Surgery [NCT05814991]100 participants (Anticipated)Observational2023-05-29Enrolling by invitation
Screening for Colorectal Cancer in Average and High Risk Iraqi Population: A Pilot Study [NCT04017845]Early Phase 1537 participants (Actual)Interventional2015-04-01Completed
The Effect of Two Different Rates of Nitroglycerin Infusion on Cerebral Rewarming During Rewarming Period of Hypothermic Cardiopulmonary Bypass [NCT03251599]Phase 478 participants (Actual)Interventional2017-08-16Completed
A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon [NCT00934427]Phase 3100 participants (Anticipated)Interventional2009-06-30Active, not recruiting
The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure [NCT00953303]Phase 2/Phase 3102 participants (Actual)Interventional2009-01-31Completed
A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon [NCT00700518]Phase 110 participants (Anticipated)Interventional2008-06-30Completed
Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study [NCT00707928]Phase 4100 participants (Anticipated)Interventional2008-02-29Completed
Transdermal Nitroglycerin and Nifedipine for Managing Preterm Labor: a Randomized Clinical Trial [NCT02583633]Phase 4112 participants (Actual)Interventional2013-10-31Completed
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO) [NCT00803634]Phase 3117 participants (Actual)Interventional2008-12-31Completed
A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue [NCT02688270]Phase 265 participants (Actual)Interventional2016-06-30Completed
Trial of a Topical Nitroglycerin Challenge to Detect Reversible Microcirculatory Dysfunction in Patients With Circulatory Shock. [NCT05102734]25 participants (Actual)Observational2021-09-01Completed
MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects [NCT00841594]Phase 112 participants (Anticipated)Interventional2009-02-28Completed
Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects [NCT00810381]14 participants (Actual)Interventional1999-01-31Completed
Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris: Randomised, Double Blind, Placebo Controlled Trial [NCT04270071]Phase 480 participants (Anticipated)Interventional2020-12-31Not yet recruiting
Effect of Low Childhood Socioeconomic Status (SES) on Adult Endothelial Function and Nitric Oxide Bioavailability in Vivo and ex Vivo [NCT02115724]74 participants (Actual)Interventional2014-04-30Active, not recruiting
A Prospective, Collaborative, International, Multicentre, Randomised, Parallel-group, Single and Outcome Blinded, Controlled, Factorial Trial to Investigate the Safety and Efficacy of Treatment With Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, a [NCT00989716]Phase 33,500 participants (Anticipated)Interventional2001-07-31Recruiting
The Role of Nitric Oxide in Cognition in Schizophrenia; The NOC Study (Nitric Oxide in Cognition) [NCT02906553]19 participants (Actual)Interventional2016-09-30Completed
Comparative Effect of Hypotensive Anaesthesia Using Nitroglycerine vs Phentolamine on Event Related Potentials, Quantitative Electroencephalograghy and Cognitive Function in Patients Undergoing Septoplasty [NCT04110808]Early Phase 160 participants (Anticipated)Interventional2019-10-15Not yet recruiting
A Randomized. Double-blind, Placebo-controlled, Multi-national Study to Determine the Effect of Cellegesic Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With a Chronic Anal Fissure [NCT00522041]Phase 3248 participants (Actual)Interventional2007-08-31Completed
Efficacy of Nebulized PGI2 Versus Nebulized Nitroglycerine for Management of Pulmonary Hypertension After Valve Replacement Surgeries [NCT04594629]Phase 1120 participants (Anticipated)Interventional2020-11-30Recruiting
A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon [NCT00577304]Phase 3200 participants (Anticipated)Interventional2007-12-31Active, not recruiting
Effect of Subcutaneous Nitroglycerin on the Prevention of Radial Artery Occlusion After Radial Artery Catheterization in Pediatric Patients - a Prospective Randomized Controlled Trial [NCT05443061]200 participants (Anticipated)Interventional2022-09-08Recruiting
Intravenous (IV) Nitroglycerin for Versions in Multiparous Women [NCT00901758]44 participants (Actual)Interventional2003-03-31Completed
Reversal of No-reflow/Slow-flow During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction--a Prospective Randomized Study Comparing Intracoronary Infusion of Diltiazem, Verapamil and Nitroglycerin [NCT00712894]Phase 4102 participants (Actual)Interventional2006-12-31Completed
A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer [NCT00616031]Phase 2150 participants (Anticipated)Interventional2008-01-31Recruiting
Ultrasound Evaluation of the Change in Diameter of the Posterior Tibial Artery and Dorsalis Pedis Artery After the Administration of Topical Nitroglycerin. [NCT04155476]Early Phase 180 participants (Anticipated)Interventional2019-12-30Not yet recruiting
Comparison of the Hypotensive Efficacy of Propofol Infusion Versus Nitroglycerin Infusion in Functional Endoscopic Sinus Surgery [NCT04220281]Phase 1/Phase 240 participants (Actual)Interventional2019-12-01Terminated(stopped due to the number of patients needed for the study have been collected)
Topical Glyceryl Trinitrate Versus Lidocaine Cream as Analgesia for IUD Insertion: A Randomized Controlled Trial [NCT02708251]Phase 4150 participants (Actual)Interventional2016-10-31Completed
Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients [NCT04686760]278 participants (Actual)Interventional2020-11-15Completed
The Effect of Topical Administration of Lidocaine/Nitroglycerin Combination Versus Placebo on Radial Artery Access in Patients Undergoing Cardiac Catheterization Via the Radial Artery [NCT01155167]Phase 2/Phase 386 participants (Actual)Interventional2010-07-31Completed
The Effect of Periradial Injection of Papaverine Versus Nitroglycerine on Radial Artery Diameter Prior to Cannulation. [NCT04030663]Early Phase 190 participants (Actual)Interventional2019-02-05Completed
Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial [NCT04661709]Phase 4502 participants (Anticipated)Interventional2021-03-01Not yet recruiting
Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers. [NCT02801305]Phase 290 participants (Actual)Interventional2016-06-30Completed
Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine [NCT00541736]30 participants (Actual)Interventional2007-10-31Completed
An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke [NCT01422616]Phase 34,587 participants (Actual)Interventional2012-03-31Completed
Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Nitroglycerin as Active Comparator) (ECLIPSE-NTG) [NCT00093886]Phase 3629 participants (Actual)Interventional2004-04-30Completed
MQX-503 Applied to the Fingers vs. Nitroglycerin Ointment 2%, USP, Applied to the Chest: A Pharmacokinetic Comparison in Normal Subjects [NCT00513994]Phase 16 participants (Anticipated)Interventional2007-08-31Completed
The Effect of Remote Ischaemic Preconditioning and Glyceryl Trinitrate on Peri-operative Myocardial Injury in Cardiac Bypass Surgery Patients (ERIC-GTN Study) [NCT01864252]Phase 3192 participants (Actual)Interventional2014-01-31Completed
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon [NCT00480753]Phase 215 participants (Anticipated)Interventional2007-05-31Completed
[NCT00484133]Phase 480 participants (Anticipated)Interventional2007-06-30Recruiting
The Evaluation of the Effect of Nitroglycerine Versus Placebo on the Microcirculation by Means of SDF Imaging in Septic Patients on the ICU [NCT00493415]Phase 370 participants (Actual)Interventional2007-06-30Completed
Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC) [NCT00512759]Phase 4781 participants (Actual)Interventional2007-12-10Completed
Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension [NCT02425566]Phase 112 participants (Anticipated)Interventional2015-04-30Active, not recruiting
Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: a Randomized Study [NCT00535808]Phase 230 participants (Actual)Interventional2007-10-31Completed
Ointment Therapy and Prevention of Cannulation-Induced Superficial Phlebitis [NCT04685031]Phase 1/Phase 2110 participants (Anticipated)Interventional2021-02-01Not yet recruiting
Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy [NCT00927849]63 participants (Actual)Interventional2002-09-30Completed
Physiologic Effects of Inhaled Nitric Oxide, Nitroglycerin, and Placebo in Study Subjects With Sickle Cell Anemia [NCT00001716]Phase 258 participants Interventional1998-07-31Completed
The Effect of Glyceryl Trinitrate and Diamox on Blood-Oxygenation-Level-Dependent.Signal (BOLD-Signal) and Cerebral Haemodynamics With the Use of a 3-Tesla MRI-Scan. [NCT00363792]12 participants InterventionalRecruiting
A Prospective Double Blinded Study on the Effect of Intravenously Administrated Nitroglycerine on Gastric Tissue Microvascular Bloodflow and Microvascular Hemoglobin Saturation During Gastric Tube Reconstruction [NCT00335010]32 participants Interventional2005-05-31Completed
The Relaxant Effect of Nitroglycerin on Oxytocin Desensitized Human Myometrium and the Return of Contractility on Re-exposure to Oxytocin- an in Vitro Study [NCT03408054]17 participants (Actual)Interventional2018-01-03Completed
The Effects of Organic Nitrates on Osteoporosis: Part 2 [NCT00252421]Phase 3243 participants (Actual)Interventional2005-10-31Completed
The Use of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure [NCT05837403]Phase 3460 participants (Actual)Interventional2020-10-01Completed
Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease [NCT00090558]Phase 230 participants Interventional2004-08-31Completed
"Phase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon" [NCT00419419]Phase 380 participants Interventional2006-12-31Completed
A Randomized, Double-Blind, Placebo-Controlled Phase II Dose-Ranging Study of the OrthoDerm Transdermal Nitroglycerin Patch for Patients With Chronic Lateral Epicondylitis [NCT00447928]Phase 2164 participants Interventional2007-04-30Not yet recruiting
Acute Effect of Nitroglycerin on Cyclosporine-Induced Hypertension After Cardiac Transplantation [NCT00449059]Phase 420 participants Interventional2003-01-31Completed
Investigation of the Time Course of the Interaction of the Hypotensive Effects of Sildenafil Citrate and Sublingual Glyceryl Trinitrate (GTN) in Men With Stable Angina Pectoris [NCT00479908]Phase 420 participants (Actual)Interventional2004-01-31Completed
Comparative Safety and Efficacy of Cervical Lidocaine-Prilocaine Cream Versus Glyceryl Trinitrate Cream on Pain Perception During Levonorgestrel- Intrauterine Device Insertion Among Nulliparous Women: a Randomized Double-blind Controlled Trial [NCT04355598]Phase 4195 participants (Anticipated)Interventional2020-04-30Not yet recruiting
Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs. [NCT02343276]Phase 3328 participants (Actual)Interventional2015-02-28Completed
Topical Nitroglycerin as a Mechanism for Cutaneous Vaso-modulation and Improved Wound Healing After Breast Reduction [NCT04321967]Phase 30 participants (Actual)Interventional2019-08-20Withdrawn(stopped due to Unable to recruit patients)
Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. [NCT00431691]Phase 422 participants (Actual)Interventional2006-09-30Completed
A Validation Study of Nitroglycerin Induced Acute Drop of Pd/Pa (NTG-Pd/Pa) in Clinical Practice [NCT04700397]100 participants (Anticipated)Observational [Patient Registry]2021-01-02Recruiting
Investigation of the Endothel Dependent and Independent Vasodilatation in Human Gingiva: Comparison of the Effect of NO and ACH [NCT04918563]24 participants (Actual)Interventional2020-09-15Completed
[NCT00000503]Phase 30 participants Interventional1982-08-31Completed
The Analgesic Efficacy of Nitroglycerin Patches for Postoperative Pain in Patients Undergoing Total Knee Arthroplasty [NCT00375362]50 participants Interventional2006-07-31Recruiting
Prevention of Postmenopausal Bone Loss With Nitric Oxide [NCT00043719]Phase 3200 participants Interventional2002-07-31Completed
The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure [NCT00223717]Phase 1152 participants (Actual)Interventional2001-01-31Completed
A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage [NCT00226096]404 participants (Actual)Interventional2005-11-30Completed
Does Chronic Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function in Non-Diabetic Patients With Chronic Kidney Disease? [NCT00586261]36 participants (Actual)Interventional2006-03-31Terminated(stopped due to Low enrollment because of the specifics of the inclusion criteria)
[NCT01675700]10 participants (Actual)Interventional2009-01-31Completed
Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris: Multicenter, Randomised, Double Blind, Placebo Controlled Trial [NCT04270279]Phase 4120 participants (Anticipated)Interventional2020-12-31Not yet recruiting
The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter [NCT00686231]Phase 119 participants (Actual)Interventional2008-05-31Completed
Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension for Sinus Endoscopic Surgery. [NCT03809065]Phase 440 participants (Actual)Interventional2019-01-19Completed
Intravenous Terbutaline Versus Intravenous Nitroglycerine for External Cephalic Version: A Double-Blinded Randomized Controlled Trial in Nulliparous Women [NCT02115256]Phase 2/Phase 36 participants (Actual)Interventional2014-07-31Terminated(stopped due to difficult recruitment)
A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin. [NCT00842023]Phase 489 participants (Actual)Interventional2006-07-31Completed
Transdermal Application of Acetylcholine and Nitroglycerin Without Iontophoresis. [NCT00259701]20 participants Observational2005-06-30Completed
Impact of rhCu/Zn SOD on Inflammation-Induced Impairment of Vascular Reactivity [NCT00264186]Phase 143 participants Interventional2005-06-30Completed
Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon [NCT00253331]Phase 2/Phase 336 participants Interventional2004-11-30Completed
"Phase III in-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon" [NCT00266669]Phase 3200 participants Interventional2005-12-31Completed
Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital [NCT01631409]0 participants (Actual)Observational2013-09-30Withdrawn(stopped due to The study has been withdrawn due to organizational problems)
A Single Center Study of Perivascular Coronary Inflammation in Patients With Myocardial Ischemia or Infarction With Non-Obstructive Coronary Arteries [NCT05031520]100 participants (Anticipated)Observational2021-07-12Recruiting
Phase I Dose Escalation Trial of Nitroglycerin in Addition to 5-flourouracil and Radiation Therapy for Neo-adjuvant Treatment of Operable Rectal Cancer [NCT01407107]Phase 113 participants (Actual)Interventional2011-01-31Completed
Treatment of Suspected Cholelithiasis With Nitroglycerin: a Randomized, Prospective Double-blind Trial [NCT01715220]Phase 262 participants (Anticipated)Interventional2014-10-31Recruiting
Non-Invasive HaemoDYNAMICs in Primary and Secondary Hypertension: the DYNAMIC-study [NCT01742702]2,000 participants (Anticipated)Observational2006-05-25Recruiting
Understanding the Role Played by Serum and Membrane Lipids in Immune Cell Function in Patients With Systemic Lupus Erythematosus (SLE) and Healthy Donors [NCT04361734]300 participants (Anticipated)Observational2016-02-15Recruiting
The Field Administration of Stroke Therapy-Blood Pressure Lowering Pilot Trial [NCT01811693]Phase 24 participants (Actual)Interventional2013-04-30Terminated(stopped due to The funding period for the study has ended.)
Randomized Controlled Trial of IV Nitroglycerin in Cesarean Deliveries After Second Stage Arrest for the Prevention of Uterine Extension [NCT02265965]Phase 418 participants (Actual)Interventional2015-10-31Completed
Contrast Nephropathy and Nitrates [NCT01999517]Phase 4122 participants (Actual)Interventional2013-06-30Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of PletaalÒ(Cilostazol) in Subjects With Vasospastic Angina (STELLA) [NCT01444885]Phase 250 participants (Actual)Interventional2011-10-31Completed
Understanding the Role of the External Carotid Artery in the Pathophysiology of Migraine Pain [NCT03026101]20 participants (Anticipated)Interventional2017-01-31Enrolling by invitation
A Randomised, Double-blind, Placebo-controlled, Home Use, Cross-over Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED) [NCT02495467]Phase 2232 participants (Actual)Interventional2015-05-15Completed
Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality [NCT02961946]Phase 4198 participants (Actual)Interventional2017-03-15Completed
Comparison Between the Use of Phentolamine Versus Glyceryl Trinitrate for Their Effect on Renal Function in Pre-eclampsia Patients in ICU [NCT05687669]Phase 4170 participants (Anticipated)Interventional2023-01-12Not yet recruiting
Department of Anestheia and Intensive Care Unit,Cairo University [NCT03059316]Early Phase 140 participants (Actual)Interventional2016-06-10Completed
The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study [NCT01490073]24 participants (Actual)Interventional2012-03-01Completed
A Comparative Study Between Nitroglycerine Infusion and Dexmedetomidine Infusion in Intraoperative Management of Uncontrolled Hypertension [NCT04953156]77 participants (Actual)Observational2021-07-03Completed
Changes in Cerebral Oxygenation and Cognitive Functions During Controlled Hypotension [NCT04948957]40 participants (Actual)Observational2014-03-01Completed
Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia [NCT05310929]200 participants (Actual)Interventional2019-08-28Completed
Efficacy and Safety of Oral Nitroglycerin on Esophageal Food Impaction [NCT03305848]Phase 420 participants (Actual)Interventional2017-08-25Completed
Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis [NCT01608880]154 participants (Actual)Interventional2012-08-31Completed
A Double-blind, Randomized, Crossover Evaluation of the Hemodynamic Response to Sublingual Glyceryl Trinitrate in Patients Receiving TA-1790, Sildenafil, and Placebo [NCT01616485]Phase 1106 participants (Actual)Interventional2004-03-31Completed
Comparison of Local Anesthesia and Induced Hypotensive Anesthesia on Quality of External Dacryocystorhinostomy Operation Under General Anesthesia [NCT05241054]64 participants (Anticipated)Interventional2022-03-31Not yet recruiting
Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass(CPB) in Cardiac Surgery: a Randomized, Controlled Trial [NCT01212874]70 participants (Actual)Interventional2010-12-31Completed
Nitrates and Bone Turnover (NABT): Trial to Select the Best Nitrate Preparation [NCT01387672]Phase 3265 participants (Actual)Interventional2011-09-30Completed
Safety and Tolerability of Topical Nitroglycerin to Dilate the Radial Artery Prior to Transradial Coronary Angiography [NCT05239013]Early Phase 120 participants (Anticipated)Interventional2022-05-01Not yet recruiting
Comparison Between Single Dose Pregabalin and Magnesium Sulfate in Controlled Hypotension During Functional Endoscopic Sinus Surgery [NCT05442931]Phase 1/Phase 260 participants (Anticipated)Interventional2022-05-01Recruiting
Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention [NCT02832115]Phase 4100 participants (Actual)Interventional2016-09-30Completed
Peroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease [NCT00554853]Phase 3143 participants (Actual)Interventional2007-11-30Completed
Efficacy and Safety of Propionibacterium Extract Gel Versus 0.4% Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: a Randomised Controlled Trial [NCT05616455]Phase 4120 participants (Actual)Interventional2021-10-01Completed
Efficacy of Intracoronary Infusion of Different Medicine With Targeted Perfusion Catheter on Myocardial Perfusion in Patients With STEMI Undergoing Primary PCI:an Open,Prospective,Randomized,Multicenter Trial. [NCT03252665]Phase 4600 participants (Anticipated)Interventional2017-09-01Not yet recruiting
Discovering the Functional Role of the Glymphatic System in the Genesis of the Migraine Attack [NCT05907655]50 participants (Anticipated)Observational2023-04-30Recruiting
Nitroglycerin Infusion During Rewarming in Cardiac Surgery and Its Effects on Tissue Perfusion and Coagulation [NCT01901419]80 participants (Actual)Interventional2013-07-08Completed
Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease [NCT02209636]Phase 466 participants (Actual)Interventional2014-09-15Completed
A Randomised, Double-blind, Parallel Group, Efficacy and Safety Study of Transdermal Patch Nitroglycerin in the Prevention of Coronary Artery Spasm, During Coronary Angiography/ Angioplasty (NURSE-TTS - Nitrate Use to Obtain Radial Spasm Embarrassment) [NCT04766151]Phase 3150 participants (Anticipated)Interventional2021-01-01Recruiting
Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin [NCT03158532]Phase 32,128 participants (Anticipated)Interventional2017-07-06Recruiting
Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon Visited in Imam Reza Hospital, Mashhad, Iran [NCT02254252]Phase 454 participants (Actual)Interventional2012-03-31Completed
Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation [NCT02164318]11 participants (Actual)Interventional2014-09-01Terminated(stopped due to Lack of enrollment)
Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon [NCT03296670]Phase 457 participants (Actual)Interventional2015-08-01Completed
Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke [NCT02327793]Phase 265 participants (Actual)Interventional2009-06-30Completed
Cheese Consumption and Human Microvascular Function [NCT03376555]Phase 1/Phase 215 participants (Actual)Interventional2016-03-31Completed
Topical Application of GTN 0.4% in the Treatment of Anismus Following Stapled Haemorrhoidopexy [NCT01279551]Phase 2/Phase 340 participants (Actual)Interventional2004-01-31Completed
Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock [NCT03235921]Phase 2100 participants (Anticipated)Interventional2016-03-31Recruiting
Habituation of the Nociceptive Blink Reflex in Experimentally Induced Migraine Attack: a Cross-over, Randomized Controlled Study [NCT05718310]22 participants (Anticipated)Interventional2022-11-01Recruiting
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents [NCT04703751]10 participants (Anticipated)Interventional2022-09-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00522041 (3) [back to overview]Percentage of Responders
NCT00522041 (3) [back to overview]Change From Baseline in Pain Intensity at Days 14-18
NCT00522041 (3) [back to overview]Time to an Improvement in Pain Intensity
NCT00554853 (2) [back to overview]Brachial Artery Diameter Change From Baseline in Response to Reactive Hyperemia
NCT00554853 (2) [back to overview]Rheumatoid Arthritis Disease Activity
NCT00586261 (1) [back to overview]Change in Brachial Arterial Reactivity
NCT00686231 (2) [back to overview]Percent Change in Diameter of Radial Artery as a Dose Test for Nitroglycerin
NCT00686231 (2) [back to overview]Percent Change From Baseline in Radial Artery Diameter to Compare Combination of Nitroglycerin or Placebo and Lidocaine (20mg or 40mg)
NCT00803634 (11) [back to overview]Number of Patients That Require Intubation During Study Drug Administration up to 96 Hours
NCT00803634 (11) [back to overview]Percentage Falling Below Lower Limit of SBP Target Range at Any Time During Study
NCT00803634 (11) [back to overview]Percentage Falling Below Lower Limit of SBP Target Range Within First 30 Minutes
NCT00803634 (11) [back to overview]Percentage of Patients Who Received Any Alternative IV Antihypertensive Drug at Any Time During Study Drug Treatment
NCT00803634 (11) [back to overview]Percentage of Patients With at Least One Episode of SBP < 90 mm Hg During Study Drug Administration (up to 96 Hours)
NCT00803634 (11) [back to overview]Percentage Reaching Prespecified Target Range Without Falling Below Lower Limit of Target Range Within First 30 Minutes
NCT00803634 (11) [back to overview]Percentage to First Achieve Initial Prespecified SBP Target Range [≥20 mm Hg and ≤40 mm Hg Apart] and 15% Reduction From Baseline Within First 30 Minutes
NCT00803634 (11) [back to overview]SBP Area Under the Curve (AUC) Outside Prespecified Target Range
NCT00803634 (11) [back to overview]Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes
NCT00803634 (11) [back to overview]Time to Use Other IV Antihypertensives During the Study Drug Administration
NCT00803634 (11) [back to overview]Change From Baseline in Dyspnea (Measured By VAS) at Each Time Point
NCT00842023 (3) [back to overview]Inflammatory Markers
NCT00842023 (3) [back to overview]Renal Function by Serum Creatinine
NCT00842023 (3) [back to overview]Serum Levels of Cystatin-C
NCT00927849 (1) [back to overview]Relieve of Anal Pain
NCT01155167 (3) [back to overview]Change in Radial Artery Diameter
NCT01155167 (3) [back to overview]Radial Artery Spasm During Catheterization
NCT01155167 (3) [back to overview]Radial Artery Patency
NCT01212874 (2) [back to overview]Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour
NCT01212874 (2) [back to overview]Title: Systolic Hypertension
NCT01387672 (2) [back to overview]Bone Turnover Markers
NCT01387672 (2) [back to overview]Headache
NCT01407107 (2) [back to overview]Number of Participants With a Pathological Complete Response (pCR)
NCT01407107 (2) [back to overview]The Number of Participants Experiencing Dose Limiting Toxicities (DLT)
NCT01490073 (2) [back to overview]Provider Ease With Intrauterine Device Insertion Measured on a 100 mm VAS
NCT01490073 (2) [back to overview]Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS
NCT01811693 (3) [back to overview]Participants Exhibiting Neurological Deterioration as Indicated by a Two-point or Greater Worsening in the Glasgow Coma Scale
NCT01811693 (3) [back to overview]Participants With Systolic Blood Pressure Change of 8mmHg or More
NCT01811693 (3) [back to overview]Participants With Systolic Blood Pressure Less Than 120 mm/Hg
NCT01901419 (30) [back to overview]Plasma Lactate Level, After Protamine Administration
NCT01901419 (30) [back to overview]Cardiac Index, After Protamine Administration
NCT01901419 (30) [back to overview]Activated Coagulation Time, Before Start of CPB
NCT01901419 (30) [back to overview]Activated Coagulation Time, After Protamine Administration
NCT01901419 (30) [back to overview]Cerebral Oximetry, Before Start of CPB, Right Forehead
NCT01901419 (30) [back to overview]Plasma Glucose Level, After Protamine Administration
NCT01901419 (30) [back to overview]Mean Arterial Blood Pressure ≤ 40 mmHg After Initiation of NTG Infusion
NCT01901419 (30) [back to overview]Length of ICU Stay
NCT01901419 (30) [back to overview]Cerebral Oximetry, Release of Aortic Clamp, Right Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, Release of Aortic Clamp, Left Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, Cessation of CPB, Right Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, Cessation of CPB, Left Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, Beginning Rewarming, Right Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, Beginning Rewarming, Left Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, Before Start of CPB, Left Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, After Protamine Administration, Right Forehead
NCT01901419 (30) [back to overview]Cerebral Oximetry, After Protamine Administration, Left Forehead
NCT01901419 (30) [back to overview]Cardiac Index, Upon Arrival at ICU
NCT01901419 (30) [back to overview]Cardiac Index, Cessation of CPB
NCT01901419 (30) [back to overview]Cardiac Index, Before Start of CPB
NCT01901419 (30) [back to overview]Plasma Glucose Level, Before Incision
NCT01901419 (30) [back to overview]Plasma Glucose Level, Before Start of CPB
NCT01901419 (30) [back to overview]Plasma Glucose Level, Release of Aortic Clamp
NCT01901419 (30) [back to overview]Plasma Glucose Level, Upon Arrival at ICU
NCT01901419 (30) [back to overview]Plasma Lactate Level, Before Incision
NCT01901419 (30) [back to overview]Plasma Lactate Level, Before Start of CPB
NCT01901419 (30) [back to overview]Plasma Lactate Level, Release of Aortic Clamp
NCT01901419 (30) [back to overview]Plasma Lactate Level, Upon Arrival at ICU
NCT01901419 (30) [back to overview]Post-op Dopamine Infusion
NCT01901419 (30) [back to overview]Time to Extubation
NCT01999517 (1) [back to overview]Change in GFR
NCT02115256 (4) [back to overview]Successful Version of the Fetus Into the Vertex Position
NCT02115256 (4) [back to overview]Tachycardia
NCT02115256 (4) [back to overview]Hypotension
NCT02115256 (4) [back to overview]Need for Cesarean Delivery
NCT02209636 (8) [back to overview]Phosphorus Balance Sub-study (COMIRB 15-0384)
NCT02209636 (8) [back to overview]Aortic Pulse-wave Velocity
NCT02209636 (8) [back to overview]Brachial Artery Flow-mediated Dilation
NCT02209636 (8) [back to overview]C-reactive Protein to Measure Systemic Inflammation
NCT02209636 (8) [back to overview]Interleukin-6 to Measure Systemic Inflammation
NCT02209636 (8) [back to overview]Oxidative Stress-associated Suppression of EDD
NCT02209636 (8) [back to overview]Oxidized Low-density Lipoprotein (Ox-LDL) to Measure Systemic Oxidized Stress
NCT02209636 (8) [back to overview]Vascular Endothelial Cell Protein Expression
NCT02254252 (3) [back to overview]Angina Episode Frequnecy
NCT02254252 (3) [back to overview]Angina Episode Intensity
NCT02254252 (3) [back to overview]Canadian Cardiovascular Society (CCS) Grading of Angina Pectoris
NCT02265965 (8) [back to overview]Surgical Blood Loss
NCT02265965 (8) [back to overview]Total Operative Time in Minutes
NCT02265965 (8) [back to overview]Umbilical Artery Blood pH
NCT02265965 (8) [back to overview]APGAR at 5 Minutes
NCT02265965 (8) [back to overview]Fetal Extraction Time in Seconds
NCT02265965 (8) [back to overview]Number of Participants With Deliveries After Which Neonate is Admitted to NICU
NCT02265965 (8) [back to overview]Number of Participants With Deliveries in Which Cord Blood Base Deficit is More Negative Than or Equal to Negative 12
NCT02265965 (8) [back to overview]Number of Participants With Uterine Extension of Hysterotomy
NCT02343276 (3) [back to overview]Pain Assessment Using Visual Analogue Scale
NCT02343276 (3) [back to overview]Radiation Exposure
NCT02343276 (3) [back to overview]Procedure Duration
NCT02495467 (12) [back to overview]Sexual Desire Domain Score of the International Index of Erectile Function (IIEF)
NCT02495467 (12) [back to overview]Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 5
NCT02495467 (12) [back to overview]Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 4
NCT02495467 (12) [back to overview]Orgasmic Function Domain Score of the International Index of Erectile (IIEF)
NCT02495467 (12) [back to overview]Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2
NCT02495467 (12) [back to overview]Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2
NCT02495467 (12) [back to overview]Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1
NCT02495467 (12) [back to overview]Intercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF)
NCT02495467 (12) [back to overview]Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF)
NCT02495467 (12) [back to overview]Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 3
NCT02495467 (12) [back to overview]Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 1
NCT02495467 (12) [back to overview]Overall Satisfaction Domain Score of the International Index of Erectile Function (IIEF)
NCT02577718 (2) [back to overview]Number of Participants With Drug-Related Hypotension
NCT02577718 (2) [back to overview]Incidence of Catheter-Associated Infections
NCT02688270 (2) [back to overview]Raynaud's Symptom Severity (Percentage of Responders)
NCT02688270 (2) [back to overview]Raynaud's Symptom Severity (Change From Baseline)
NCT02714205 (9) [back to overview]Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
NCT02714205 (9) [back to overview]Change From Baseline Hot Flash Related Daily Interference Scale (HFRDIS) Score
NCT02714205 (9) [back to overview]Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score
NCT02714205 (9) [back to overview]Change From Baseline Center for Epidemiologic Studies Depression (CES-D) Score
NCT02714205 (9) [back to overview]Change From Baseline Hot Flash Frequency
NCT02714205 (9) [back to overview]Change in Baseline Frequency of Moderate-to-severe Hot Flashes
NCT02714205 (9) [back to overview]Change in Baseline Total Hot Flash Severity Score
NCT02714205 (9) [back to overview]Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score
NCT02714205 (9) [back to overview]Number of Participants With Treatment Related Severe Adverse Events Defined by Common Terminology Criteria for Adverse Events (CTCAE) Severity Grade 3 or Higher.
NCT02832115 (5) [back to overview]Change in Radial Artery Dimension Measured in mm^2.
NCT02832115 (5) [back to overview]Radial Pulse at End of Procedure
NCT02832115 (5) [back to overview]Radial Artery Spasm
NCT02832115 (5) [back to overview]Patient Discomfort or Pain During Procedure (Visual Analog Scale 0-10)
NCT02832115 (5) [back to overview]Number of Patients With Procedural Failure
NCT02961946 (1) [back to overview]Coronary Artery Diameter Change
NCT03305848 (1) [back to overview]Medications/Procedures Performed During Visit
NCT03357731 (7) [back to overview]Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG
NCT03357731 (7) [back to overview]Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
NCT03357731 (7) [back to overview]Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
NCT03357731 (7) [back to overview]Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
NCT03357731 (7) [back to overview]Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
NCT03357731 (7) [back to overview]Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
NCT03357731 (7) [back to overview]Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo
NCT03716050 (6) [back to overview]Number of Participants Requiring Wound Care Management Modalities for Treatment of Delayed Wound Healing Complications
NCT03716050 (6) [back to overview]Number of Participants Requiring Outpatient Prescription for Antibiotics or Requiring Hospital Admission for IV Antibiotics
NCT03716050 (6) [back to overview]Number of Participants With Delayed Wound Healing
NCT03716050 (6) [back to overview]Number of Participants With Operative Intervention Secondary to Perfusion Related Problems
NCT03716050 (6) [back to overview]Number of Participants With Surgical Site Infection
NCT03716050 (6) [back to overview]Number of Soft Tissue Ischemia/Loss

Percentage of Responders

"Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated. The left-end of the visual analog scale was labelled least possible pain and the right-end of the visual analog scale was labelled worst possible pain. The pain rating ranged from 0 to 100, with a higher score indicating more pain. A responder was defined as a participant with either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in the 24 hour average pain intensity averaged over Days 14 to 18." (NCT00522041)
Timeframe: Baseline to Day 18

,
InterventionPercentage of responders (Number)
≥ 50% decrease≥ 10 mm decrease
Cellegisic (Nitroglycerin 0.4%)72.488.6
Placebo64.585.5

[back to top]

Change From Baseline in Pain Intensity at Days 14-18

"Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated and used to determine the change from Baseline. The left-end of the visual analog scale was labelled least possible pain and the right-end of the visual analog scale was labelled worst possible pain. The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement." (NCT00522041)
Timeframe: Baseline to Day 18

InterventionUnits on a scale (Mean)
Cellegesic (Nitroglycerin 0.4%)-40.4
Placebo-34.9

[back to top]

Time to an Improvement in Pain Intensity

"Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale (VAS) at Baseline and on each of the 21 treatment days of the study. The left-end of the visual analog scale was labelled least possible pain and the right-end of the visual analog scale was labelled worst possible pain. The pain rating ranged from 0 to 100, with a higher score indicating more pain. Improvement was defined as either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in rated pain intensity." (NCT00522041)
Timeframe: Baseline to Day 21

,
InterventionDays (Mean)
≥ 50% decrease≥ 10 mm decrease
Cellegisic (Nitroglycerin 0.4%)10.76.1
Placebo13.27.2

[back to top]

Brachial Artery Diameter Change From Baseline in Response to Reactive Hyperemia

This measure represents the percentage change in diameter of brachial artery in response to reactive hyperemia. The data is presented intentionally and only for the results at the conclusion of the study. (NCT00554853)
Timeframe: 8 months

Intervention% changes in diameter of artery (Mean)
Study Drug (Pioglitazone) Then Placebo8.3
Placebo Then Study Drug (Pioglitazone)9.43

[back to top]

Rheumatoid Arthritis Disease Activity

"Quantification of disease activity using validated assessments (disease activity score on 28 joints (DAS28) and and C-reactive protein ( CRP) (Inflammatory marker) as a combined score (DAS-28CRP)).~Mean decrease in DAS-28-CRP score when compared to baseline was measured. The range of DAS-28-CRP is 0-10, with 0 meaning no active disease detected and 10 being the most severe active disease detected by joint count and C-reactive protein levels in blood." (NCT00554853)
Timeframe: 8 mo

Interventionmean decrease in DAS28-CRP score (Mean)
All Participants While on Placebo0.15
All Participants While on Study Drug (Pioglitazone).31

[back to top]

Change in Brachial Arterial Reactivity

Brachial arterial reactivity was measured by ultrasound. A blood pressure cuff was placed around the right forearm. Using the ultrasound probe of the ultrasound, 2-dimensional images clearly defining the anterior and posterior intimal wall of the brachial artery were collected. Flow velocities were then measured using pulsed wave Doppler. The blood pressure cuff previously placed around the patient's right forearm was inflated to 200 mmHg. The cuff remained inflated for 5 minutes as the patient remained motionless and quiet. Prior to deflation, the patient was asked to remain still as flow velocities and 2-dimensional images were obtained immediately following cuff deflation. Then a 0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication and all measurements were repeated. (NCT00586261)
Timeframe: After 6 months of treatment

Interventionmm (Mean)
Pioglitazone Arm0.8476
Placebo Arm2.6058

[back to top]

Percent Change in Diameter of Radial Artery as a Dose Test for Nitroglycerin

Radial artery diameter was measured with ultrasonography using a high-frequency (13 MHz) linear array transducer 2 cm proximal to the radial styloid process. (NCT00686231)
Timeframe: Baseline, 10 minutes, 30 minutes, 60 minutes, and 120 minutes after topical application at Visit 1

,,
Interventionpercent diameter change (Mean)
10 minutes30 minutes60 minutes120 minutes
15mg Nitroglycerin-0.20.810.28.8
30mg Nitroglycerin6.414.921.528.5
Placebo-0.82.53.35.9

[back to top]

Percent Change From Baseline in Radial Artery Diameter to Compare Combination of Nitroglycerin or Placebo and Lidocaine (20mg or 40mg)

Radial artery diameter was measured with ultrasonography using a high-frequency (13 MHz) linear array transducer 2 cm proximal to the radial styloid process. To compare combination of (Lidocaine + Nitroglycerin) or (Lidocaine + placebo), at visit 2, participants randomized to Comparison A received 30mg NTG + 20mg Lidocaine on one wrist, and placebo + 20mg Lidocaine on the other wrist; participants randomized to Comparison B received 30mg Nitroglycerin + 40mg Lidocaine on one wrist, and placebo + 40mg Lidocaine on the other wrist. (NCT00686231)
Timeframe: Baseline, 10 minutes, 30 minutes, 60 minutes, and 120 minutes after topical application at Visit 2

,,,
Interventionpercent diameter change (Mean)
10 minutes30 minutes60 minutes120 minutes
Lidocaine 20mg + Nitroglycerin 30mg4.911.018.218.5
Lidocaine 20mg + Placebo45.38.45.7
Lidocaine 40mg + Nitroglycerin 30mg3.410.617.222.1
Lidocaine 40mg + Placebo1.62.92.54.1

[back to top]

Number of Patients That Require Intubation During Study Drug Administration up to 96 Hours

The number of patients requiring intubation was calculated based on the total number of mITT patients. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPatients (Number)
Clevidipine0
Standard of Care0

[back to top]

Percentage Falling Below Lower Limit of SBP Target Range at Any Time During Study

The percentage of patients in whom the SBP fell below the lower limit of the prespecified target range at any time during the entire study drug treatment period (up to 96 hours) was calculated within each treatment group using the number of mITT patients achieving the endpoint divided by the number of mITT patients and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine68.2
Standard of Care70.7

[back to top]

Percentage Falling Below Lower Limit of SBP Target Range Within First 30 Minutes

The percentage of patients in whom the SBP fell below the lower limit of the prespecified target range at any time during the first 30 minutes was calculated within each treatment group using the number of mITT patients achieving the endpoint divided by the number of mITT patients and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine34.1
Standard of Care2.4

[back to top]

Percentage of Patients Who Received Any Alternative IV Antihypertensive Drug at Any Time During Study Drug Treatment

The percentage of patients who received any alternative IV antihypertensive drug at any time during the study drug treatment period (up to 96 hours) was calculated using mITT patients within each treatment group. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine15.9
Standard of Care51.2

[back to top]

Percentage of Patients With at Least One Episode of SBP < 90 mm Hg During Study Drug Administration (up to 96 Hours)

The percent of patients with at least one episode of SBP <90 mm Hg was calculated as the number of mITT patients who had at least one episode of SBP<90 mm Hg during study drug administration up to 96 hours divided by mITT patients, and multiplied by 100 for each treatment group. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine5.9
Standard of Care1.9

[back to top]

Percentage Reaching Prespecified Target Range Without Falling Below Lower Limit of Target Range Within First 30 Minutes

The percentage of patients reaching this endpoint was calculated within each treatment group using the number of mITT patients reaching the endpoint divided by the number of mITT patients, and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine45.5
SOC IV Therapy51.2

[back to top]

Percentage to First Achieve Initial Prespecified SBP Target Range [≥20 mm Hg and ≤40 mm Hg Apart] and 15% Reduction From Baseline Within First 30 Minutes

Analysis of the percentage of patients achieving both components of this composite endpoint (attainment of the initial prespecified SBP target range and a 15% reduction in SBP from baseline) was calculated within each treatment group using the number of mITT patients achieving the SBP reduction goal divided by the number of mITT patients, and multiplied by 100. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine70.5
Standard of Care36.6

[back to top]

SBP Area Under the Curve (AUC) Outside Prespecified Target Range

The magnitude and duration of SBP excursions was calculated as the area under the curve (AUC) for each patient, using the trapezoidal rule, related to time (in minutes) that each patient's SBP was outside the target range. AUC was determined based on data collected from the initiation of study medication through the end of monotherapy treatment up to 96 hours, normalized per hour, and expressed as mmHg × minute/hour. (NCT00803634)
Timeframe: Initiation of study drug through end of monotherapy (up to 96 hours)

Interventionmm Hg x min/h (Mean)
Clevidipine494.96
Standard of Care966.15

[back to top]

Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes

Time to first achieve the initial pre-specified systolic blood pressure (SBP) target range and a 15% SBP reduction from baseline is the time in minutes between the initiation of study medication and the time the patient first achieved both components. Median time was estimated using Kaplan Meier method. 95% two-sided confidence interval of the median time is from 'Simon and Lee, 1982'. If patients did not reach both components within 30 minutes from the initial treatment with study medication, or another antihypertensive agent was administered, the patient was censored at 30 minutes or the time when another antihypertensive agent is given, whichever came first. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionMinutes (Median)
Clevidipine15.0
Standard of CareNA

[back to top]

Time to Use Other IV Antihypertensives During the Study Drug Administration

The length of time to use other IV antihypertensive agents was defined as the duration in hours from the initiation of study drug through the time when any other concomitant IV antihypertensive agent was administered, thus, representing the time period without use of any other concomitant IV antihypertensive agent. Median time to use other IV antihypertensive agents was obtained using Kaplan-Meier method. If a patient did not receive any concomitant IV antihypertensive during the 96-hour treatment period, this patient was considered censored at 96 hours. If study drug was stopped less than 96 hours and the patient has no concomitant IV antihypertensive agent, the patient was considered censored when study drug was stopped. (NCT00803634)
Timeframe: Initiation of study drug through any other concomitant IV antihypertensive agent administered, up to 96 hours

InterventionHours (Median)
ClevidipineNA
Standard of Care5.7

[back to top]

Change From Baseline in Dyspnea (Measured By VAS) at Each Time Point

A validated visual analog scale (VAS) with a horizontal ruler showing increments from 0 to 100 mm with 0 = Best and 100 = Worst was used. The test was asked from the patient's perspective and had to be administered with patient sitting. Relative change in VAS from baseline is the value at each time point minus the baseline value. Relative change from baseline was summarized descriptively (with associated two-tailed 95% CIs of the mean values) at 15, 30 and 45 minutes and at 1, 2, 3 hours and 12 hours, and 1 hour post termination of study drug treatment. (NCT00803634)
Timeframe: Baseline (immediately prior to study drug administration) through 1 hour after study drug termination

,
Interventionmillimeters (mm) (Mean)
Baseline Through Initial 15 Min- CLV n=44;SOC n=38Baseline Through Initial 30 Min- CLV n=43;SOC n=39Baseline Through Initial 45 Min- CLV n=43;SOC n=39Baseline Through Initial 1 H- CLV n=41;SOC n=38Baseline Through Initial 2 H- CLV n=29;SOC n=29Baseline Through Initial 3 H- CLV n=14;SOC n=22Baseline Through Initial 12 H- CLV n=0;SOC n=7Baseline Through 1 H Post Drug- CLV n=41;SOC n=33
Clevidipine-18.6-28.8-37.1-43.6-45.2-47.9NA-50.1
Standard of Care-16.1-22.8-27.9-34.6-35.3-40.5-57.9-50.1

[back to top]

Inflammatory Markers

Interleukin-6 (NCT00842023)
Timeframe: 48 hours

Interventionpg/mL (Mean)
Nesiritide Infusion25
Nitroglycerin Infusion50

[back to top]

Renal Function by Serum Creatinine

Serum creatinine values and changes in serum creatinine (NCT00842023)
Timeframe: Baseline, 24 hours, 48 hours

,
Interventionmg/dL (Mean)
Serum creatinine at baselineSerum creatinine at 24 hoursSerum creatinine at 48 hours
Nesiritide1.31.31.3
Nitroglycerin1.31.41.4

[back to top]

Serum Levels of Cystatin-C

Cystatin-C is a protease inhibitor and a sensitive endogenous marker of renal function. (NCT00842023)
Timeframe: Baseline, 24 hours, 48 hours

,
Interventionng/mL (Mean)
Cystatin-C at BaselineCystatin-C at 24 HoursCystatin-C at 48 Hours
Nesiritide133214751449
Nitroglycerin202631082739

[back to top]

Relieve of Anal Pain

using a visual analog scale (VAS) with which each patients noted the severity of pain at each evaluated time using a linear between zero (no pain) and 10 ( severe pain) (NCT00927849)
Timeframe: one year after the procedure

Interventionscore in scale (Mean)
Surgical Group Lateral Sphincterotomy4.16
Glycein Trinitrate Group4.18
Botilinium Toxin Injection4.2

[back to top]

Change in Radial Artery Diameter

The cross-sectional radial artery area was measured using a high frequency linear array transducer. All ultrasound measurements were made 2 cm proximal to the radial styloid process. Each measurement was performed 3 times and averaged. At least 30 minutes after the application of topical creams, the radial artery diameter was again measured in the same fashion. (NCT01155167)
Timeframe: Baseline and after 30 minutes of drug application

InterventionPercent change (Mean)
Placebo-5.6
Topical Dilator16.5

[back to top]

Radial Artery Spasm During Catheterization

The blinded clinical operator recorded whether radial artery spasm occurred, as detected by resistance to advancing the catheter through the radial artery, by difficulty in torquing the catheter, or by difficulty in removing the catheter. (NCT01155167)
Timeframe: 2 hours

,
Interventionparticipants (Number)
SpasmNo spasm
Placebo1030
Topical Dilator1030

[back to top]

Radial Artery Patency

Prior to discharge, color doppler ultrasound was used at the site where the sheath had been inserted to determine whether the radial artery was patent (open, unobstructed). (NCT01155167)
Timeframe: 24 hours

,
Interventionparticipants (Number)
Patent radial arteryEarly radial artery occlusion
Placebo391
Topical Dilator430

[back to top]

Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour

Area under the curve (AUC) of Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour from Anesthesia Induction to Initiation of Cardiopulmonary Bypass (NCT01212874)
Timeframe: Participants were followed from Anesthesia Induction to Initiation of Cardiopulmonary Bypass, an average of 5 hours

InterventionmmHg*min/prebypass hour (Median)
Esmolol97.9
Nitroglycerin45.6

[back to top]

Title: Systolic Hypertension

Area under the curve (AUC) of Systolic Blood Pressure Excursions Beyond Predetermined Upper Limits, Normalized Per Hour from Anesthesia Induction to Initiation of Cardiopulmonary Bypass (NCT01212874)
Timeframe: Participants were followed from Anesthesia Induction to Initiation of Cardiopulmonary Bypass, an average of 5 hours

InterventionmmHg*min / prebypass hour (Median)
Esmolol48.6
Nitroglycerin145.8

[back to top]

Bone Turnover Markers

"Markers of Bone Formation:~Serum Procollagen type 1 amino- terminal propeptide (P1NP)~Serum Osteocalcin (OC)~Serum Bone-specific alkaline phosphatase (BALP)~Markers of Bone Resorption:~- Serum C-telopeptides of collagen cross-links (CTX)" (NCT01387672)
Timeframe: 3 months

,,,,,
InterventionPercent change from baseline (Mean)
P1NPOCBALPCTX
0.3 Sublingual (Nitrostat 1) - Treatment Arm 4-6.1261.046-7.000-0.666
0.6 Sublingual (Nitrostat 2) - Treatment Arm 52.9411.033-3.686-1.380
ISMO - Treatment Arm 1-4.627-3.244-5.023-5.844
Ointment (Nitrol) - Treatment Arm 3-4.297-4.481-7.426-9.699
Patch (Nitro-Dur) - Treatment Arm 2-0.4053.796-0.541-1.025
Placebo Ointment - Treatment Arm 6-1.6354.247-1.648-1.783

[back to top]

Headache

"Severity of headaches. Subjects recorded the severity of headaches upon awakening every day during the run-in phase using a visual analogue scale (VAS). The scale is represented by a line (continuum) 10 cm long. Subjects were asked to make a vertical line along the continuum to indicate the severity of their headache each morning upon awakening. The score is recorded in cm from 0 to 10. A vertical line marked at 0 means no headache (score recorded = 0), a vertical line marked at 10 means a terrible headache (score recorded = 10)." (NCT01387672)
Timeframe: Run-in phase - 2 days

Interventionscore on a scale (Mean)
ISMOPatchOintment0.3 Sublingual0.6 Sublingual
Run-in Phase2.13.11.50.360.6

[back to top]

Number of Participants With a Pathological Complete Response (pCR)

"pathological complete response (pCR) at time of surgery following the completion of neoadjuvant therapy. This will be compared to the institutional historical pCR rate.~Pathologic complete response indicates a complete absence of cancer at the time of surgical resection." (NCT01407107)
Timeframe: Time of surgery (~ 6-9 wks) following the completion of neoadjuvant therapy

InterventionParticipants (Count of Participants)
Cohort 11
Cohort 20
Cohort 31

[back to top]

The Number of Participants Experiencing Dose Limiting Toxicities (DLT)

DLT was defined as greater or equal to two instances of grade 3 toxicity, or a single event of grade 4-5 toxicity deemed probably or definitely related to the addition of transdermal neoadjuvant chemoradiation to the standard neoadjuvant chemoradiation (NCT01407107)
Timeframe: Up to 4-6 weeks for each dosing cohort

InterventionParticipants (Count of Participants)
Cohort 10
Cohort 20
Cohort 30

[back to top]

Provider Ease With Intrauterine Device Insertion Measured on a 100 mm VAS

Provider ease with intrauterine device insertion measured on a 100 mm VAS. VAS (visual analog scale) anchors: 0 indicates easiest insertion imaginable, 100 indicates most difficult insertion imaginable (NCT01490073)
Timeframe: 30-45 minutes after insertion of nitroglycerin ointment

Interventionmm (Mean)
Active Nitroglycerin Ointment29.4
Placebo Ointment22.8

[back to top]

Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS

Patient-reported pain at passage of insertion device through cervix, as measured on a 100 mm VAS. VAS anchors: 0 indicates no pain, and 100 indicates worst pain imaginable. (NCT01490073)
Timeframe: 30-45 minutes after insertion of nitroglycerin ointment

Interventionmm (Mean)
Active Nitroglycerin Ointment55.8
Placebo Ointment53.9

[back to top]

Participants Exhibiting Neurological Deterioration as Indicated by a Two-point or Greater Worsening in the Glasgow Coma Scale

The Glasgow Coma Scale (GCS) score measures level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. (NCT01811693)
Timeframe: Baseline, One hour after enrollment

InterventionParticipants (Count of Participants)
Dose Tier 11

[back to top]

Participants With Systolic Blood Pressure Change of 8mmHg or More

The mean change in blood pressure was measured in the Emergency Department approximately 15 minutes after application of the treatment (NCT01811693)
Timeframe: Baseline, 15 minutes after treatment

InterventionParticipants (Count of Participants)
Dose Tier 11

[back to top]

Participants With Systolic Blood Pressure Less Than 120 mm/Hg

(NCT01811693)
Timeframe: 24 hours after enrollment

InterventionParticipants (Count of Participants)
Dose Tier 10

[back to top]

Plasma Lactate Level, After Protamine Administration

Plasma Lactate Level, mmol/L, After Cessation of CPB and Protamine Administration (NCT01901419)
Timeframe: After Protamine Administration

Interventionmmol/L (Mean)
High-dose NTG3.3
Low-dose NTG3.0

[back to top]

Cardiac Index, After Protamine Administration

Cardiac Index, L/min/m2, After Protamine Administration (NCT01901419)
Timeframe: After Protamine Administration

InterventionL/min/m2 (Mean)
High-dose NTG3.2
Low-dose NTG3.1

[back to top]

Activated Coagulation Time, Before Start of CPB

Activated Coagulation Time, sec, Before Start of CPB (NCT01901419)
Timeframe: Before Start of CPB

Interventionsecond (Mean)
High-dose NTG158.9
Low-dose NTG153.1

[back to top]

Activated Coagulation Time, After Protamine Administration

Activated Coagulation Time, sec, After Cessation of CPB and Protamine Administration (NCT01901419)
Timeframe: After Protamine Administration

Interventionsecond (Mean)
High-dose NTG144.2
Low-dose NTG138.2

[back to top]

Cerebral Oximetry, Before Start of CPB, Right Forehead

Absolute Value of Cerebral Oximetry, %, Before Start of CPB, Right Forehead (NCT01901419)
Timeframe: Before Start of CPB

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG74.9
Low-dose NTG77.9

[back to top]

Plasma Glucose Level, After Protamine Administration

Plasma Glucose Level, mg/dL, After Cessation of CPB and Protamine Administration (NCT01901419)
Timeframe: After Protamine Administration

Interventionmg/dL (Mean)
High-dose NTG196.9
Low-dose NTG205.7

[back to top]

Mean Arterial Blood Pressure ≤ 40 mmHg After Initiation of NTG Infusion

Mean Arterial Blood Pressure ≤ 40 mmHg After Initiation of NTG Infusion During Rewarming of Cardiopulmonary Bypass (NCT01901419)
Timeframe: After Initiation of NTG infusion During Rewarming

InterventionParticipants (Count of Participants)
High-dose NTG6
Low-dose NTG0

[back to top]

Length of ICU Stay

Time from Arrival at ICU to Leaving ICU, day (NCT01901419)
Timeframe: Arrival at ICU and Leaving ICU

Interventionday (Mean)
High-dose NTG4.1
Low-dose NTG4.0

[back to top]

Cerebral Oximetry, Release of Aortic Clamp, Right Forehead

Absolute Value of Cerebral Oximetry, %, Release of Aortic Clamp, Right Forehead (NCT01901419)
Timeframe: Release of Aortic Clamp

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG68.2
Low-dose NTG67.9

[back to top]

Cerebral Oximetry, Release of Aortic Clamp, Left Forehead

Absolute Value of Cerebral Oximetry, %, Release of Aortic Clamp, Left Forehead (NCT01901419)
Timeframe: Release of Aortic Clamp

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG67.4
Low-dose NTG66.8

[back to top]

Cerebral Oximetry, Cessation of CPB, Right Forehead

Absolute Value of Cerebral Oximetry, %, Cessation of CPB, Right Forehead (NCT01901419)
Timeframe: Cessation of CPB

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG71.4
Low-dose NTG70.0

[back to top]

Cerebral Oximetry, Cessation of CPB, Left Forehead

Absolute Value of Cerebral Oximetry, %, Cessation of CPB, Left Forehead (NCT01901419)
Timeframe: Cessation of CPB

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG71.1
Low-dose NTG69.8

[back to top]

Cerebral Oximetry, Beginning Rewarming, Right Forehead

Absolute Value of Cerebral Oximetry, %, Beginning Rewarming, Right Forehead (NCT01901419)
Timeframe: Beginning Rewarming

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG67.9
Low-dose NTG69.5

[back to top]

Cerebral Oximetry, Beginning Rewarming, Left Forehead

Absolute Value of Cerebral Oximetry, %, Beginning Rewarming, Left Forehead (NCT01901419)
Timeframe: Beginning Rewarming

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG68.0
Low-dose NTG68.4

[back to top]

Cerebral Oximetry, Before Start of CPB, Left Forehead

Absolute Value of Cerebral Oximetry, %, Before Start of CPB, Left Forehead (NCT01901419)
Timeframe: Before Start of CPB

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG74.4
Low-dose NTG76.8

[back to top]

Cerebral Oximetry, After Protamine Administration, Right Forehead

Absolute Value of Cerebral Oximetry, %, After Protamine Administration, Right Forehead (NCT01901419)
Timeframe: After Protamine Administration

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG75.0
Low-dose NTG74.3

[back to top]

Cerebral Oximetry, After Protamine Administration, Left Forehead

Absolute Value of Cerebral Oximetry, %, After Protamine Administration, Left Forehead (NCT01901419)
Timeframe: After Protamine Administration

Intervention% of Cerebral Oximetry (Mean)
High-dose NTG74.9
Low-dose NTG72.1

[back to top]

Cardiac Index, Upon Arrival at ICU

Cardiac Index, L/min/m2, Upon Arrival at ICU (NCT01901419)
Timeframe: Upon Arrival at ICU

InterventionL/min/m2 (Mean)
High-dose NTG3.3
Low-dose NTG3.3

[back to top]

Cardiac Index, Cessation of CPB

Cardiac Index, L/min/m2, Cessation of CPB (NCT01901419)
Timeframe: Cessation of CPB

InterventionL/min/m2 (Mean)
High-dose NTG2.6
Low-dose NTG2.7

[back to top]

Cardiac Index, Before Start of CPB

Cardiac Index, L/min/m2, Before Start of CPB (NCT01901419)
Timeframe: Before Start of CPB

InterventionL/min/m2 (Mean)
High-dose NTG3.0
Low-dose NTG2.8

[back to top]

Plasma Glucose Level, Before Incision

Plasma Glucose Level, mg/dL, Before Incision (NCT01901419)
Timeframe: Before Incision

Interventionmg/dL (Mean)
High-dose NTG139.4
Low-dose NTG124.2

[back to top]

Plasma Glucose Level, Before Start of CPB

Plasma Glucose Level, mg/dL, Before Start of CPB (NCT01901419)
Timeframe: Before Start of CPB

Interventionmg/dL (Mean)
High-dose NTG179.2
Low-dose NTG165.7

[back to top]

Plasma Glucose Level, Release of Aortic Clamp

Plasma Glucose Level, mg/dL, Release of Aortic Clamp (NCT01901419)
Timeframe: Release of Aortic Clamp

Interventionmg/dL (Mean)
High-dose NTG174.5
Low-dose NTG165.0

[back to top]

Plasma Glucose Level, Upon Arrival at ICU

Plasma Glucose Level, mg/dL, Upon Arrival at ICU (NCT01901419)
Timeframe: Upon Arrival at ICU

Interventionmg/dL (Mean)
High-dose NTG206.4
Low-dose NTG214.8

[back to top]

Plasma Lactate Level, Before Incision

Plasma Lactate Level, mmol/L, Before Incision (NCT01901419)
Timeframe: Before Incision

Interventionmmol/L (Mean)
High-dose NTG1.1
Low-dose NTG1.0

[back to top]

Plasma Lactate Level, Before Start of CPB

Plasma Lactate Level, mmol/L, Before Start of CPB (NCT01901419)
Timeframe: Before Start of CPB

Interventionmmol/L (Mean)
High-dose NTG1.4
Low-dose NTG1.6

[back to top]

Plasma Lactate Level, Release of Aortic Clamp

Plasma Lactate Level, mmol/L, Release of Aortic Clamp (NCT01901419)
Timeframe: Release of Aortic Clamp

Interventionmmol/L (Mean)
High-dose NTG3.1
Low-dose NTG2.6

[back to top]

Plasma Lactate Level, Upon Arrival at ICU

Plasma Lactate Level, mmol/L, Upon Arrival at ICU (NCT01901419)
Timeframe: Upon Arrival at ICU

Interventionmmol/L (Mean)
High-dose NTG3.4
Low-dose NTG3.2

[back to top]

Post-op Dopamine Infusion

Infusion Rate of Dopamine, mcg/kg/min, Upon Arrival at ICU (NCT01901419)
Timeframe: Upon Arrival at ICU

Interventionmcg/kg/min (Mean)
High-dose NTG3.7
Low-dose NTG4.7

[back to top]

Time to Extubation

Time from Arrival at ICU to Extubation, hour (NCT01901419)
Timeframe: Arrival at ICU and Extubation

Interventionhour (Mean)
High-dose NTG43.6
Low-dose NTG45.8

[back to top]

Change in GFR

The primary endpoint for this trial will be to determine the change in glomerular filtration rate after exposure to contrast media. We will compare the change in GFR before and after PCI of the group that received intravenous nitroglycerin with the change in GFR before and after PCI of the group that did not receive intravenous nitroglycerin. (NCT01999517)
Timeframe: Baseline and 48 to 72 hours post-PCI

InterventionmL/min (Median)
Intravenous Nitroglycerin1.8
Placebo-4.1

[back to top]

Successful Version of the Fetus Into the Vertex Position

Number of participants that had successful version of the fetus into the vertex position. (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline3
Intravenous Nitroglycerine0

[back to top]

Tachycardia

Number of participants that had tachycardia (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline2
Intravenous Nitroglycerine0

[back to top]

Hypotension

Number of participants with hypotension (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline2
Intravenous Nitroglycerine1

[back to top]

Need for Cesarean Delivery

Number of participants that needed a cesarean delivery (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline0
Intravenous Nitroglycerine0

[back to top]

Phosphorus Balance Sub-study (COMIRB 15-0384)

Balance is defined as oral intake minus urine output minus stool output. (NCT02209636)
Timeframe: 9 days from the start of the sub-study, approximately 13 weeks and 2 days from the start of the Main/Parent Study

Interventionmg/d (Mean)
Lanthanum Carbonate-131
Placebo320

[back to top]

Aortic Pulse-wave Velocity

"The speed that blood travels from the carotid artery to the femoral artery, expressed as cm/s (centimeters/second). It is a measure of arterial stiffness.~Aortic pulse-wave velocity will be measured at baseline and at 12 weeks (end-of-study) in the treatment and placebo groups to determine if there is a change aortic pulse wave velocity from baseline to 12 weeks and if this change is significantly different between the treatment and placebo groups." (NCT02209636)
Timeframe: baseline and 12 weeks

,
Interventionchange in aPWV, cm/s (Mean)
baselineweek 12
Lanthanum Carbonate12141216
Placebo993977

[back to top]

Brachial Artery Flow-mediated Dilation

"Measurement of how well the brachial artery dilates in response to shear stress. It is a measure of endothelial function. It is reported as percent change, which represents the change in dilation of the artery before and after occlusion.~Brachial artery flow-mediated dilation will be measured at baseline and at 12 weeks (end-of-study) in the treatment and placebo groups to determine if there is a change brachial artery flow mediated dilation from baseline to 12 weeks and if this change is significantly different between the treatment and placebo groups." (NCT02209636)
Timeframe: baseline and 12 weeks

,
Interventionpercent change FMD (Mean)
baselineweek 12
Lanthanum Carbonate3.132.73
Placebo3.743.09

[back to top]

C-reactive Protein to Measure Systemic Inflammation

This is a blood test. C-reactive protein will be measured at baseline and at 12 weeks (end-of-study) in the treatment and placebo groups to determine if there is a change in C-reactive protein from baseline to 12 weeks and if this change is significantly different between the treatment and placebo groups. (NCT02209636)
Timeframe: baseline and 12 weeks

,
Interventionmg/ml (Median)
C-reactive protein, baselineC-reactive protein, week 12
Lanthanum Carbonate2.923.06
Placebo2.722.24

[back to top]

Interleukin-6 to Measure Systemic Inflammation

This is a blood test. Interleukin-6 and C-reactive protein will be measured at baseline and at 12 weeks (end-of-study) in the treatment and placebo groups to determine if there is a change in interleukin-6 and C-reactive protein from baseline to 12 weeks and if this change is significantly different between the treatment and placebo groups. (NCT02209636)
Timeframe: baseline and 12 weeks

,
Interventionpg/ml (Median)
Interleukin-6, baselineInterleukin-6, week 12
Lanthanum Carbonate1.581.61
Placebo1.281.34

[back to top]

Oxidative Stress-associated Suppression of EDD

The influence of oxidative stress on FMD will be determined by infusing a supraphysiologic dose of ascorbic acid or isovolemic saline. The difference in FMD, expressed as percentage change in FMD, which represents the change in dilation of the artery before and after occlusion, during ascorbic acid vs. saline infusion will be taken as a measure of the modulation of EDD/stiffness by oxidative stress. (NCT02209636)
Timeframe: baseline and 12 weeks

,
Interventionpercent change in FMD (Mean)
baseline FMDbaseline FMD after ascorbic acidweek 12 FMDweek 12 FMD w/ ascorbic acid
Lanthanum Carbonate2.913.242.483.44
Placebo3.543.442.953.69

[back to top]

Oxidized Low-density Lipoprotein (Ox-LDL) to Measure Systemic Oxidized Stress

This is a blood test art. Oxidized low-density lipoprotein (ox-LDL) will be measured at baseline and at 12 weeks (end-of-study) in the treatment and placebo groups to determine if there is a change in ox-LDL from baseline to 12 weeks and if this change is significantly different between the treatment and placebo groups. (NCT02209636)
Timeframe: baseline and 12 weeks

,
InterventionmU/ml (Median)
baselineweek 12
Lanthanum Carbonate6183759725
Placebo6292768057

[back to top]

Vascular Endothelial Cell Protein Expression

Measures of different protein markers on endothelial cells. Will help understand the underlying pathophysiology of vascular dysfunction in chronic kidney disease. Vascular endothelial cell protein expression will be measured at baseline and at 12 weeks (end-of-study) in the treatment and placebo groups to determine if there is a change vascular endothelial cell protein expression from baseline to 12 weeks and if this change is significantly different between the treatment and placebo groups. The expression of endothelial cells collected from patients will be compared to the expression in HUVEC (human umbilical vein endothelial cell) controls and this ratio will be reported as the outcomes measure. (NCT02209636)
Timeframe: baseline and 12 weeks

,
Interventionratio (Mean)
baselineweek 12
Lanthanum Carbonate1.541.44
Placebo1.411.40

[back to top]

Angina Episode Frequnecy

One month after treatment, patients were asked to determine the frequency of angina episodes in the preceding week. (NCT02254252)
Timeframe: 1 month

Interventionepisodes per week (Mean)
Nitroglycerin2.28
Nicorandil1.68

[back to top]

Angina Episode Intensity

One month after treatment, patients were asked to determine the average intensity of chest pain in experienced episodes using a Likert-type scale of 0 to 10, where 0 indicated lowest intensity/no pain and 10 indicated the highest possible pain experienced. (NCT02254252)
Timeframe: 1 month

Interventionunits on a scale (Mean)
Nitroglycerin3.89
Nicorandil3.03

[back to top]

Canadian Cardiovascular Society (CCS) Grading of Angina Pectoris

One month after treatment, patients were asked to describe the angina episode and based on their descriptions, the CCS class of chest pain was determined. Based on patient's description of the anginal episodes, angina severity was classified into one of CCS class I (angina only with prolonged demanding physical activity), Class II (Slight limitation, with angina only during vigorous physical activity), Class III (Symptoms with everyday living activities), or class IV (angina at rest). (NCT02254252)
Timeframe: 1 month

,
Interventionparticipants (Number)
CCS Class ICCS Class IICCS Class III
Nicorandil1942
Nitroglycerin8115

[back to top]

Surgical Blood Loss

Total blood loss will be measured (NCT02265965)
Timeframe: During and after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Interventionml (Mean)
Intravenous Nitroglycerin935.7
Intravenous Saline1036.4

[back to top]

Total Operative Time in Minutes

Time from uterine incision to out of room (NCT02265965)
Timeframe: After cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Interventionminutes (Mean)
Intravenous Nitroglycerin68.3
Intravenous Saline74.2

[back to top]

Umbilical Artery Blood pH

Measure of umbilical artery blood pH (NCT02265965)
Timeframe: At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

InterventionpH (Mean)
Intravenous Nitroglycerin7.3
Intravenous Saline7.3

[back to top]

APGAR at 5 Minutes

The APGAR scale is determined by evaluating the newborn baby on five simple criteria -- Appearance, Pulse, Grimace, Activity, Respiration -- on a scale from zero to two, then summing up the five values thus obtained. The resulting APGAR score ranges from zero to 10. Zero is the worst possible score and 10 is the highest possible score. (NCT02265965)
Timeframe: Immediately after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Interventionscore on a scale (Median)
Intravenous Nitroglycerin9
Intravenous Saline9

[back to top]

Fetal Extraction Time in Seconds

Time from uterine incision to delivery (body of neonate fully extracted from uterus) (NCT02265965)
Timeframe: At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Interventionseconds (Mean)
Intravenous Nitroglycerin104.9
Intravenous Saline131

[back to top]

Number of Participants With Deliveries After Which Neonate is Admitted to NICU

(NCT02265965)
Timeframe: After cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

InterventionParticipants (Count of Participants)
Intravenous Nitroglycerin1
Intravenous Saline2

[back to top]

Number of Participants With Deliveries in Which Cord Blood Base Deficit is More Negative Than or Equal to Negative 12

A cord blood base deficit more negative than negative 12 is abnormal and a sign of metabolic acidosis. (NCT02265965)
Timeframe: At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

InterventionParticipants (Count of Participants)
Intravenous Nitroglycerin7
Intravenous Saline11

[back to top]

Number of Participants With Uterine Extension of Hysterotomy

Obstetrician determined whether the subject had an uterine extension. (NCT02265965)
Timeframe: During cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

InterventionParticipants (Count of Participants)
Intravenous Nitroglycerin3
Intravenous Saline4

[back to top]

Pain Assessment Using Visual Analogue Scale

the patients' feeling of pain in the forearm, and it was measured using a visual analogue scale (VAS), applied at the end of the procedure by an interventional nurse. The VAS consists of a single line measuring 100 mm, anchored by verbal descriptors, saying 'no pain' and 'worst possible pain'. Higher values mean a worse pain. (NCT02343276)
Timeframe: Five minutes after sheath removal

Interventionscore on a scale (Mean)
Placebo24.75
Intervention24.74

[back to top]

Radiation Exposure

Total radiation required to complete the procedure. (NCT02343276)
Timeframe: Immediate

InterventionmGy (Mean)
Placebo660.92
Intervention655.61

[back to top]

Procedure Duration

Procedure duration, from artery catheterization up to removal of sheath. (NCT02343276)
Timeframe: Immediate

Interventionminutes (Mean)
Placebo22.24
Intervention21.36

[back to top]

Sexual Desire Domain Score of the International Index of Erectile Function (IIEF)

Sexual desire domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome. (NCT02495467)
Timeframe: 4 Weeks

Interventionscore on a scale (Mean)
MED Placebo7.1
MED20057.5

[back to top]

Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 5

"SEP Question 5: Were you satisfied overall with this sexual experience?. Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period." (NCT02495467)
Timeframe: 4 Weeks

Interventionpercentage of yes responses (Mean)
MED Placebo36.88
MED200548.23

[back to top]

Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 4

"SEP Question 4: Were you satisfied with the hardness of your erection?. Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period." (NCT02495467)
Timeframe: 4 Weeks

Interventionpercentage of yes responses (Mean)
MED Placebo28.97
MED200542.91

[back to top]

Orgasmic Function Domain Score of the International Index of Erectile (IIEF)

Orgasmic function domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-10, a lower score is regarded as having a worse outcome. (NCT02495467)
Timeframe: 4 Weeks

Interventionscore on a scale (Mean)
MED Placebo6.6
MED20057.0

[back to top]

Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2

"SEP Question 2: Were you able to insert your penis into your partner's vagina?. Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period." (NCT02495467)
Timeframe: 4 Weeks

Interventionpercentage of yes responses (Mean)
MED Placebo75.37
MED200575.53

[back to top]

Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2

"GAQ Question 2: Has the treatment improved your ability to engage in sexual activity?. Answered yes/no after each treatment period of 4 weeks (+/- 1 week)." (NCT02495467)
Timeframe: 4 Weeks

InterventionParticipants (Count of Participants)
MED Placebo54
MED200585

[back to top]

Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1

"GAQ Question 1: Has the treatment you have been taking improved your erectile function?. Answered yes/no after each treatment period of 4 weeks (+/- 1 week)." (NCT02495467)
Timeframe: 4 Weeks

InterventionParticipants (Count of Participants)
MED Placebo56
MED200594

[back to top]

Intercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF)

Intercourse satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 0-15, a lower score is regarded as having a worse outcome. (NCT02495467)
Timeframe: 4 Weeks

Interventionscore on a scale (Mean)
MED Placebo8.6
MED20059.0

[back to top]

Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF)

Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of the treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-30, a lower score is regarded as more severe. (NCT02495467)
Timeframe: 4 Weeks

Interventionscore on a scale (Mean)
MED Placebo18.5
MED200519.6

[back to top]

Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 3

"SEP Question 3: Did your erection last long enough for you to have successful intercourse?. Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period." (NCT02495467)
Timeframe: 4 Weeks

Interventionpercentage of yes responses (Mean)
MED Placebo52.64
MED200557.32

[back to top]

Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 1

"SEP Question 1: Were you able to achieve at least some erection (some enlargement of the penis)?. Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period." (NCT02495467)
Timeframe: 4 Weeks

Interventionpercentage of yes responses (Mean)
MED Placebo86.93
MED200587.24

[back to top]

Overall Satisfaction Domain Score of the International Index of Erectile Function (IIEF)

Overall satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome. (NCT02495467)
Timeframe: 4 weeks

Interventionscore on a scale (Mean)
MED Placebo6.6
MED20057.1

[back to top] [back to top]

Incidence of Catheter-Associated Infections

Catheter-Associated Infections will be measured by microbiological culture defined as either Catheter-Related Bloodstream Infection (CRBSI) as defined by the Infectious Diseases Society of America (IDSA), particularly in neutropenic patients, or Central Line-Associated Bloodstream Infection (CLABSI) as defined by the Centers for Disease Control and Prevention (CDC), particularly in non-neutropenic patients (NCT02577718)
Timeframe: 60 Days

Interventioninfections per 1000 catheter days (Number)
NiCE Lock0
Off NiCE Lock1.6

[back to top]

Raynaud's Symptom Severity (Percentage of Responders)

(NCT02688270)
Timeframe: 6 weeks

InterventionParticipants (Count of Participants)
Vascana37
Vehicle Cream29

[back to top]

Raynaud's Symptom Severity (Change From Baseline)

Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom. (NCT02688270)
Timeframe: 6 weeks

Interventionscore on a scale (Least Squares Mean)
Vascana-20.19
Vehicle Cream-18.63

[back to top]

Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score

Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life (NCT02714205)
Timeframe: Repeated change from baseline to 5 and 12 weeks

Interventionscore on a scale (Least Squares Mean)
Transdermal Nitroglycerin-1.27
Placebo-1.18

[back to top] [back to top]

Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score

Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life (NCT02714205)
Timeframe: Repeated change from baseline to 5 and 12 weeks

Interventionunits on a scale (Least Squares Mean)
Transdermal Nitroglycerin-0.15
Placebo-0.57

[back to top]

Change From Baseline Center for Epidemiologic Studies Depression (CES-D) Score

Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-60, a higher score indicates a lower quality of life. (NCT02714205)
Timeframe: Repeated change from baseline to 5 and 12 weeks

Interventionunits on a scale (Least Squares Mean)
Transdermal Nitroglycerin-1.39
Placebo-1.79

[back to top]

Change From Baseline Hot Flash Frequency

Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. (NCT02714205)
Timeframe: Repeated change from baseline to 5 and 12 weeks

InterventionHot flashes per day (Least Squares Mean)
Transdermal Nitroglycerin-4.56
Placebo-4.02

[back to top]

Change in Baseline Frequency of Moderate-to-severe Hot Flashes

Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points (NCT02714205)
Timeframe: Repeated change from baseline to 5 and 12 weeks

InterventionHot flashes per day (Least Squares Mean)
Transdermal Nitroglycerin-3.27
Placebo-2.44

[back to top]

Change in Baseline Total Hot Flash Severity Score

"Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. The hot flash severity score is calculated as the sum of severity ratings for all hot flashes recorded on the symptom over a 7-day period (mild=1, moderate=2, severe=3), and then divided by 7 for the daily average score.~Range 12-60, higher score indicates lower quality of life." (NCT02714205)
Timeframe: Repeated change from baseline to 5 and 12 weeks

Interventionunits on a scale (Least Squares Mean)
Transdermal Nitroglycerin-8.33
Placebo-6.92

[back to top]

Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score

"Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points.~Range 1-8, Higher score indicates lower quality of life" (NCT02714205)
Timeframe: Repeated change from baseline to 5 and 12 weeks

Interventionunits on a scale (Least Squares Mean)
Transdermal Nitroglycerin-1.53
Placebo-1.33

[back to top] [back to top]

Change in Radial Artery Dimension Measured in mm^2.

Change in Radial artery cross sectional area in mm^2 - Before application of topical nitroglycerine / placebo (Pre dilation) vs Prior to arterial puncture after application of topical nitroglycerine / placebo (Post-dilation) (NCT02832115)
Timeframe: Application of nitroglycerine / placebo until prior to arterial puncture. Approximate 60 to 120 minutes

Interventionmm^2 (Mean)
Study2.5
Control-0.2

[back to top]

Radial Pulse at End of Procedure

Radial pulse at end of procedure 0- 4+, 0 indicating no palpable pulse (worst); 1 + indicating a faint, but detectable pulse; 2 + suggesting a slightly more diminished pulse than normal; 3 + is a normal pulse; and 4 + indicating a bounding pulse (best). (NCT02832115)
Timeframe: At the end of transradial cardiac catheterization after sheath removal

Interventionscore on a scale (Mean)
Study2.208333333
Control2.166666667

[back to top]

Radial Artery Spasm

"Incidence of radial artery spasm indicated by a Radial artery spasm score of 1 or more. Radial artery spasm score is sum of:~Intraprocedural pain in the forearm aggravated by movement of the catheter/sheath - Absent :0; Present:1~Difficulty in manipulating the catheter- Absence :0; Present:1~Difficulty with sheath removal: Absent: 0; Present:1~Additional use of intraarterial nitroglycerine or verapamil after the initial vasodilator cocktail- No:0; Yes:1" (NCT02832115)
Timeframe: Intraprocedural: From procedure start to application of radial band. Approximate time 30 to 90 minutes.

InterventionParticipants (Count of Participants)
Study8
Control15

[back to top]

Patient Discomfort or Pain During Procedure (Visual Analog Scale 0-10)

Patient discomfort or pain during procedure measured using Visual analog scale 0-10, 0 being no discomfort or pain (best) and 10 being worst discomfort or pain (worst) (NCT02832115)
Timeframe: Intraprocedural: From procedure start to application of radial band. Approximate time 30 to 90 minutes.

Interventionscore on a scale (Mean)
Study0.792
Control0.875

[back to top]

Number of Patients With Procedural Failure

Need to abort procedure or convert to transfemoral access (NCT02832115)
Timeframe: Intraprocedural: From procedure start to application of radial band. Approximate time 30 to 90 minutes.

InterventionParticipants (Count of Participants)
Study0
Control4

[back to top]

Coronary Artery Diameter Change

Average diameter of coronary arteries at 7 predefined locations in the proximal, mid, and distal segments of the left main, left anterior descending, left circumflex and right coronary artery. Measurements avoid areas of coronary non-calcified and calcified plaques and measured twice for each location. Proximal and distal deviation from original measurements is possible in case of plaque. (NCT02961946)
Timeframe: obtained on the same day (day 0) of nitroglycerine administration (nitroglycerine is administered during the cCTA exam appointment).

InterventionFold change (Mean)
Sublingual Nitroglycerin Spray1.14
Sublingual Nitroglycerin Tablet1.13
Nitroglycerin Skin Patch1.15

[back to top]

Medications/Procedures Performed During Visit

Total number of other medications or procedures used to relieve the esophageal food impaction (NCT03305848)
Timeframe: Length of Emergency Department stay (Time Frame: up to 12 hours)]

InterventionParticipants (Count of Participants)
Received additional medicationUnderwent endoscopy
Oral Nitroglycerin Solution715

[back to top]

Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG

The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG. (NCT03357731)
Timeframe: at the end of the 5-hour infusion

InterventionmL/m^2 (Mean)
BMS-98623128.721
Nitroglycerin (NTG)27.811

[back to top]

Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~Diastolic function" (NCT03357731)
Timeframe: at the end of the 5-hour infusion

,,
InterventionRatio (Mean)
E/A ratioE/e' ratio
BMS-9862310.737.00
Nitroglycerin (NTG)0.717.81
Placebo (PBO)0.809.42

[back to top]

Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~LV global longitudinal strain" (NCT03357731)
Timeframe: at the end of the 5-hour infusion

InterventionPercentage of blood pumped from the LV (Mean)
Placebo (PBO)-11.98
BMS-986231-11.94
Nitroglycerin (NTG)-11.36

[back to top]

Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~Diastolic function" (NCT03357731)
Timeframe: at the end of the 5-hour infusion

Interventioncm/sec (Mean)
Placebo (PBO)7.18
BMS-9862318.07
Nitroglycerin (NTG)7.18

[back to top]

Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~LV ejection fraction" (NCT03357731)
Timeframe: at the end of the 5-hour infusion

InterventionPercentage of blood pumped from the LV (Mean)
Placebo (PBO)31.9
BMS-98623132.8
Nitroglycerin (NTG)33.5

[back to top]

Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~Mean LV power index" (NCT03357731)
Timeframe: at the end of the 5-hour infusion

Interventionwatts per square meter (W/m^2) (Mean)
Placebo (PBO)0.4122
BMS-9862310.3427
Nitroglycerin (NTG)0.3568

[back to top]

Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo

The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo. (NCT03357731)
Timeframe: at the end of the 5-hour infusion

InterventionmL/m^2 (Mean)
Placebo (PBO)29.545
BMS-98623128.721

[back to top]

Number of Participants Requiring Wound Care Management Modalities for Treatment of Delayed Wound Healing Complications

(NCT03716050)
Timeframe: up to 30 days

InterventionParticipants (Count of Participants)
Group 10
Group 20
Group 30
Group 40
Group 50
Group 70
Group 80

[back to top]

Number of Participants Requiring Outpatient Prescription for Antibiotics or Requiring Hospital Admission for IV Antibiotics

(NCT03716050)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Group 10
Group 20
Group 30
Group 40
Group 50
Group 70
Group 80

[back to top]

Number of Participants With Delayed Wound Healing

manifesting as suture dehiscence and opening of an incisional wound (NCT03716050)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Group 10
Group 20
Group 30
Group 40
Group 50
Group 70
Group 80

[back to top] [back to top]

Number of Participants With Surgical Site Infection

Number of Participants with soft tissue cellulitis or abscess identified postoperatively either clinically or with wound culture (NCT03716050)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Group 10
Group 20
Group 30
Group 40
Group 50
Group 70
Group 80

[back to top]

Number of Soft Tissue Ischemia/Loss

Number of partial and full thickness soft tissue defects identified postoperatively in clinic follow up (NCT03716050)
Timeframe: Up to 30 days

Interventionnumber of defects (Number)
Group 10
Group 20
Group 30
Group 40
Group 50
Group 70
Group 80

[back to top]